Note: Descriptions are shown in the official language in which they were submitted.
I
ANTIVIRAL AGENTS AND USES THEREOF
FIELD OF THE INVENTION
[0001] The invention relates to the field of medical treatment.
More
particularly, this invention relates to novel antiviral agents and their use
in
treating a disease or condition caused by a viral infection.
BACKGROUND TO THE INVENTION
[0002] Any reference to background art herein is not to be
construed as an
admission that such art constitutes common general knowledge in Australia or
elsewhere.
[0003] Viruses are responsible for a wide range of mammalian
disease
which represents a great cost to society. The effects of viral infection can
range
from common flu symptoms to serious respiratory problems and can result in
death, particularly amongst the young, elderly and immunocompromised
members of the community.
[0004] Viruses of the family Orthomyxoviridae, including influenza
virus
types A, B and C, and the family Paramyxoviridae are the pathogenic organisms
responsible for a significant number of human infections annually.
[0005] Taking the family Paramyxoviridae as one example, human
parainfluenza viruses types 1 to 3 (hPIV-1, 2 and 3) are the leading cause of
upper and lower respiratory tract disease in infants and young children and
also
impact the elderly and immunocom promised. Significantly, it is estimated that
in
the United States alone up to five million lower respiratory tract infections
occur
each year in children under 5 years old, and hPIV has been isolated in
approximately one third of these cases. There are currently neither vaccines
nor
specific antiviral therapy to prevent or treat hPIV infections respectively,
despite
continuing efforts. Some of the more recent approaches have focussed on an
entry blockade and the triggering of premature virus fusion by a small
molecule.
Date recue/ date received 2022-02-18
2
[0006] An initial interaction of the parainfluenza virus with the
host cell is
through its surface glycoprotein, haemagglutinin-neuraminidase (HN) and
involves recognition of N-acetylneuraminic acid-containing glycoconjugates.
The
parainfluenza virus HN is a multifunctional protein that encompasses the
functions of receptor binding (for cell adhesion) and receptor destruction
(facilitating virus release), not only within the one protein, but apparently
in a
single binding site. In addition, the HN is involved in activation of the
viral
surface fusion (F) protein necessary to initiate infection of the target host
cell.
Inhibition of haemagglutinin and/or neuraminidase enzymes may therefore
provide a target for antivirals.
SUMMARY OF INVENTION
[0007] According to a first aspect of the invention, there is
provided a
compound of formula (I), or a pharmaceutically acceptable salt thereof:
R8 R6
R7
R4
R3
Formula (I)
wherein, R1 is selected from the group consisting of COOH, or a salt
thereof, C(0)NR9Rio, C(0)0Rii wherein Rg, Rig and Rii are independently
selected from the group consisting of hydrogen and optionally substituted Cu-
C6
alkyl;
R3 is selected from the group consisting of N-linked triazole substituted at
one or both ring carbon atoms, optionally substituted N-linked tetrazole,
optionally substituted N-linked indole, optionally substituted N-linked
isoindole,
and optionally substituted N-linked benzotriazole;
Date recue/ date received 2022-02-18
3
R4 is NHC(0)R17 wherein R17 is selected from the group consisting of
C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl ;
R6, R7 and R8 are independently selected from the group consisting of
OH, NH2, Ci-C6 alkyl, NIR181R18', Ci-C6 alkoxy, ¨0C(0)1R18, ¨NH(C=0)1R18, and
S(0)nRi8, wherein n = 0 ¨ 2 and each Ri8 and Ri8' are independently hydrogen
or optionally substituted Ci-C6 alkyl.
[0008] In one embodiment of the first aspect, the compound of
formula (I) is
a compound of formula (II):
R8 R6
Ri
1
R7
R4
=
P3
Formula (II)
wherein, R1, R3, R4, R6, R7 and R8 are as described above.
[0009] According to a second aspect of the invention there is
provided a
pharmaceutical composition comprising an effective amount of a compound of
the first aspect, or a pharmaceutically acceptable salt thereof, and a
pharmaceutically acceptable carrier, diluent and/or excipient.
[0010] Suitably, the pharmaceutical composition is for the
treatment or
prophylaxis of a disease, disorder or condition caused by viral infection.
[0011] A third aspect of the invention resides in a method of
treating a
disease, disorder or condition caused by viral infection in a patient
including the
step of administering an effective amount of a compound of the first aspect,
or a
pharmaceutically effective salt thereof, or the pharmaceutical composition of
the
second aspect to the patient.
Date recue/ date received 2022-02-18
4
[0012] A fourth aspect of the invention provides for a compound of
the first aspect, or a pharmaceutically effective salt thereof, or the
pharmaceutical composition of the second aspect for use in the treatment of a
disease, disorder or condition caused by viral infection in a patient.
[0013] A fifth aspect of the invention provides for use of a
compound of the
first aspect, or a pharmaceutically effective salt thereof, in the manufacture
of a
medicament for the treatment of a disease, disorder or condition caused by
viral
infection.
[0014] In one embodiment of the third, fourth or fifth aspects, the
disease,
disorder or condition is influenza.
[0015] The influenza may be influenza A, B or C or parainfluenza.
[0016] In one embodiment, the parainfluenza is an hPIV-1, -2 or -3
virus.
[0017] Preferably, the patient is a domestic or livestock animal or
a human.
[0018] A sixth aspect of the invention provides fora method of
modulating
the activity of a viral haemagglutinin and/or neuraminidase enzyme including
the
step of contacting the enzyme with a compound of the first aspect.
[0019] The various features and embodiments of the present
invention,
referred to in individual sections above apply, as appropriate, to other
sections,
mutatis mutandis. Consequently features specified in one section may be
combined with features specified in other sections as appropriate.
[0020] Further features and advantages of the present invention
will become
apparent from the following detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order that the invention may be readily understood and
put into
practical effect, preferred embodiments will now be described by way of
example with reference to the accompanying figures wherein:
Date recue/ date received 2022-02-18
5
[0022] FIG 1 is a comparison of HI IC50 values for inhibitors 6 and
10,
using guinea pig red blood cells (gp RBC, solid bar) and human red blood cells
(h RBC, dashed bar);
[0023] FIG 2 is a graphical representation of NI (solid) and HI
(dashed) IC50
values for the Neu5Ac2en derivatives 2, 3, 5-10. Inhibitors 2, 3, 7, 8 with a
C5
acetamido group (left panel, group 1) and inhibitors 5, 6, 9, 10 with a C5
isobutyramido group (right panel, group 2). Values are the means of
determinations from 3 independent experiments and error bars correspond to
calculated standard deviations;
[0024] FIG 3A-C is a graphical comparison of NI (solid bar) and HI
(dashed
bar) IC5ovaluesfor selected inhibitors. (A) Comparison of NI and HI IC5ovalues
for compounds 3, 6-10 and their C-4 hydroxyl analogues (2 and 5). (B)
Comparison of NI and HI IC50 values for compounds 7-10 and their C-4 azido
analogues (3 and 6). (C) Comparison of NI and HI IC50 values for compounds 6,
9 and 10 and their C-5 acetamido analogues (3, 7 and 8 respectively);
[0025] FIG 4 is (A) Titration (focus forming assay) of progeny
virus after a
48 h virus growth inhibition assay. Representative results of a progeny virus
titration. Virus was harvested after 48 h amplification in the presence of 2
pM of
compounds 8, 10 or 6. Collected virus-culture supernatants were diluted at
least
1:1000 to make sure the remaining compound has no effect on foci formation.
(B) Virus growth inhibition of the reference inhibitor 6 and inhibitor 10.
Virus
growth inhibition was determined by titration of progeny from a low MOI
infected
confluent LLC-MK2 monolayer in the presence of 2 pM inhibitor. At this
inhibitor
concentration, 10 showed 94% inhibition compared with 14% inhibition for 6.
These results are representative of 2 independent experiments performed in
duplicate and error bars correspond to the calculated standard deviation;
[0026] FIG 5 shows Virus growth inhibition of the reference
inhibitor 6 (0
and inhibitor 10 (A) in various cell lines. Virus growth IC50 values of
compounds
6 (.) and 10 (A) were determined by an in situ ELISA technique against both
Date recue/ date received 2022-02-18
6
human cell lines (A549 and NHBE) and a monkey kidney cell line (LLC-MK2).
IC50 values of 54.6 3.8 pM and 2.1 0.6 pM (LLC-MK2); 130.6 13.0 pM and
10.3 0.3 pM (A549); 79.3 1.0 pM and 13.9 0.7 pM (NHBE) were
determined for 6 and 10 respectively. These values were determined from at
least 2 independent experiments performed in triplicate and error bars
correspond to the calculated standard deviation;
[0027] FIG 61H and STD NMR spectra of 8 in complex with hPIV-3 HN.
(a)
1H NMR spectrum of 8 and (b) STD NMR spectrum of 8 in the presence of 20
M hPIV-3 HN at a protein-ligand ratio of 1:100 (2 mM 8). (C) 1H NMR spectrum
of the H7, H8, H9 and H9" region. Signals from residual glycerol are marked as
*. (d) STD NMR spectrum of the H7, H8, H9 and H9" region;
[0028] FIG 7 is a 1H and STD NMR spectra and epitope map of 10 in
complex with hPIV-3 HN. (a) 1H NMR spectrum of 10. (b) STD NMR spectrum
of 10 in the presence of 20 M hPIV-3 HN at a protein-ligand ratio of 1:100(2
mM of 10). (c) 1H NMR spectrum of the H7, H8, H9 and H9" region. (d) STD
NMR spectrum of the H7, H8, H9 and H9" region;
[0029] FIG 8 is an STD NMR spectra comparison of 10 in complex with
intact hPIV-3 virus or recombinant HN. (a) 1H NMR spectrum of 10 in the
presence of hPIV-3 HN, (b) STD NMR spectrum of 10 in the presence of intact
hPIV-3 virus and (c) STD NMR spectrum of 10 in the presence of hPIV-3 HN;
[0030] FIG 9 is a superimposition of the phenyl protons from 10 in
complex
with intact virus or recombinant HN. (Lower image) 1H NMR spectrum of 10
(Upper image) Superimpositions of STD NMR spectra from 10 in the presence
of hPIV-3 virus or recombinant hPIV-3 HN;
[0031] FIG 10 is a graphical representation of the results of cell
cytotoxicity
tests against A549 cells; and
[0032] FIG 11 indicates the results of Neu2 inhibition assays for
select
fluorinated and non-fluorinated compounds.
Date recue/ date received 2022-02-18
7
DETAILED DESCRIPTION
[0033] The present invention is predicated, at least in part, on
the finding
that certain neuraminic acid derivatives display useful efficacy in the
treatment
of diseases caused by viral infection. Particularly, the compounds of the
invention are useful in the inhibition of parainfluenza haemagglutinin and/or
neuraminidase enzymes.
Definitions
[0034] In this patent specification, the terms 'comprises',
'comprising',
'includes', 'including', or similar terms are intended to mean a non-exclusive
inclusion, such that a method or composition that comprises a list of elements
does not include those elements solely, but may well include other elements
not
listed.
[0035] Unless defined otherwise, all technical and scientific terms
used
herein have the same meaning as would be commonly understood by those of
ordinary skill in the art to which this invention belongs.
[0036] As used herein, "effective amount" refers to the
administration of an
amount of the relevant active agent sufficient to prevent the occurrence of
symptoms of the condition being treated, or to bring about a halt in the
worsening of symptoms or to treat and alleviate or at least reduce the
severity of
the symptoms. The effective amount will vary in a manner which would be
understood by a person of skill in the art with patient age, sex, weight etc.
An
appropriate dosage or dosage regime can be ascertained through routine trial.
[0037] The term "pharmaceutically acceptable salt", as used herein,
refers
to salts which are toxicologically safe for systemic or localised
administration
such as salts prepared from pharmaceutically acceptable non-toxic bases or
acids including inorganic or organic bases and inorganic or organic acids. The
pharmaceutically acceptable salts may be selected from the group including
alkali and alkali earth, ammonium, aluminium, iron, amine, glucosamine,
chloride, sulphate, sulphonate, bisulphate, nitrate, citrate, tartrate,
bitarate,
Date recue/ date received 2022-02-18
8
phosphate, carbonate, bicarbonate, malate, maleate, napsylate, fumarate,
succinate, acetate, benzoate, terephthalate, palmoate, piperazine, pectinate
and S-methyl methionine salts and the like.
[0038] The terms "substituted" and "optionally substituted" in each
incidence
of its use herein, and in the absence of an explicit listing for any
particular
moiety, refers to substitution of the relevant moiety, for example an alkyl
chain
or ring structure, with one or more groups selected from Ci-C6 alkyl, Ci-C6
haloalkyl, C1-C6 alkoxy, CN, OH, oxo, NH2, Cl, F, Br, I, aryl and heterocyclyl
which latter two may themselves be optionally substituted. When the term is
used before the recitation of a number of functional groups then it is
intended to
apply to all of the listed functionalities unless otherwise apparent. For
example,
"optionally substituted amino, heterocyclic, aryl" means all of the amino,
heterocyclic and aryl groups may be optionally substituted.
[0039] The term "alkyl" refers to a straight-chain or branched
alkyl
substituent containing from, for example, Ito about 12 carbon atoms,
preferably
1 to about 8 carbon atoms, more preferably 1 to about 6 carbon atoms, even
more preferably from Ito about 4 carbon atoms, still yet more preferably from
1
to 2 carbon atoms. Examples of such substituents include methyl, ethyl,
propyl,
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, isoamyl, 2-
methylbutyl,
3-methylbutyl, hexyl, heptyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl,
2-
ethylbutyl, 3-ethylbutyl, octyl, nonyl, decyl, undecyl, dodecyl and the like.
The
number of carbons referred to relates to the carbon backbone and carbon
branching but does not include carbon atoms belonging to any substituents, for
example the carbon atoms of an alkoxy substituent branching off the main
carbon chain.
[0040] The term "cycloalkyl" refers to optionally substituted
saturated mono-
cyclic, bicyclic or tricyclic carbon groups. Where appropriate, the cycloalkyl
group may have a specified number of carbon atoms, for example, C3-C6
cycloalkyl is a carbocyclic group having 3, 4, 5 or 6 carbon atoms. Non-
limiting
Date recue/ date received 2022-02-18
9
examples may include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl,
cyclohexyl, cyclohexenyl, cyclohexadienyl and the like.
[0041] The term "aryl" refers to an unsubstituted or substituted
aromatic
carbocyclic substituent, as commonly understood in the art. It is understood
that
the term aryl applies to cyclic substituents that are planar and comprise 4n+2
7C
electrons, according to Hackers Rule. C-6 aryl is preferred.
[0042] The terms "heterocyclic" and "heterocycly1" as used herein
specifically in relation to certain 'R' groups refers to a non-aromatic ring
having
to 7 atoms in the ring and of those atoms 1 to 4 are heteroatoms, said ring
being isolated or fused to a second ring wherein said heteroatoms are
independently selected from 0, N and S. Heterocyclic includes partially and
fully
saturated heterocyclic groups. Heterocyclic systems may be attached to another
moiety via any number of carbon atoms or heteroatoms of the radical and may
be both saturated and unsaturated. Non-limiting examples of heterocyclic may
be selected from pyrazole, imidazole, indole, isoindole, triazole,
benzotriazole,
tetrazole, pyrimidine, pyridine, pyrazine, diazine, triazine, tetrazine,
pyrrolidinyl,
pyrrolinyl, pyranyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl,
tetrahydrothiophenyl, pyrazolinyl, dithiolyl, oxathiolyl, dioxanyl, dioxinyl,
oxazinyl, azepinyl, diazepinyl, thiazepinyl, oxepinyl and thiapinyl,
imidazolinyl,
thiomorpholinyl, and the like.
[0043] The term "protected OH" or "protected hydroxy" refers to a
hydroxyl
group which is protected with a common protecting group such as an acyl
group, ether group or ester group including Ci-C3 acyl, Ci-C4 alkyl groups to
form the ether or aryl, such as benzyl, forming the ether or Ci-C4 ester.
[0044] The term "N-linked" as used herein with reference to
compounds of
the first aspect including compounds of formula (1) and (II), for example "N-
linked triazole" or "N-linked heterocycle", refers to the moiety attached at
the C-
4 position of the neuraminic acid core (R3 in formula (I) and alp and limits
that
attachment to involving a direct attachment between ring carbon and nitrogen
Date recue/ date received 2022-02-18
10
atom. Preferably, it refers to the R3 moiety being linked to the neuraminic
acid core via a nitrogen atom which itself forms part of the appropriate
heterocycle, such as one of the nitrogens of a triazole ring, tetrazole,
indole etc.
For the "dilfuoro" compounds of formula (111) and (111a) the term N-linked
refers to
the R3 moiety either being linked to the core via an intermediate nitrogen
atom
or, in the case of a heterocyclic moiety, it may be via a nitrogen atom which
forms part of the heterocycle itself, such as one of the nitrogens of a
triazole
ring
[0045] Whenever a range of the number of atoms in a structure is
indicated
(e.g., a C1-C12, C1-C10, C1-C9, C1-C6, Ci-C4, alkyl, etc.), it is specifically
contemplated that any sub-range or individual number of carbon atoms falling
within the indicated range also can be used. Thus, for instance, the
recitation of
a range of 1-12 carbon atoms (e.g., Ci-C12), 1-9 carbon atoms (e.g., Ci-C9), 1-
6
carbon atoms (e.g., Ci-C6), 1-4 carbon atoms (e.g., Ci-C4), 1-3 carbon atoms
(e.g., Ci-C3), or 2-8 carbon atoms (e.g., C2-C8) as used with respect to any
chemical group (e.g., alkyl, etc.) referenced herein encompasses and
specifically describes 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, and/or 12 carbon
atoms, as
appropriate, as well as any sub-range thereof (e.g., 1-2 carbon atoms, 1-3
carbon atoms, 1-4 carbon atoms, 1-5 carbon atoms, 1-6 carbon atoms, 1-7
carbon atoms, 1-8 carbon atoms, 1-9 carbon atoms, 1-10 carbon atoms, 1-11
carbon atoms, 1-12 carbon atoms, 2-3 carbon atoms, 2-4 carbon atoms, 2-5
carbon atoms, 2-6 carbon atoms, 2-7 carbon atoms, 2-8 carbon atoms, 2-9
carbon atoms, 2-10 carbon atoms, 2-11 carbon atoms, 2-12 carbon atoms, 3-4
carbon atoms, 3-5 carbon atoms, 3-6 carbon atoms, 3-7 carbon atoms, 3-8
carbon atoms, 3-9 carbon atoms, 3-10 carbon atoms, 3-11 carbon atoms, 3-12
carbon atoms, 4-5 carbon atoms, 4-6 carbon atoms, 4-7 carbon atoms, 4-8
carbon atoms, 4-9 carbon atoms, 4-10 carbon atoms, 4-11 carbon atoms,
and/or 4-12 carbon atoms, etc., as appropriate).
[0046] As used herein, the terms "subject" or "individual" or
"patient" may
refer to any subject, particularly a vertebrate subject, and even more
particularly
Date recue/ date received 2022-02-18
11
a mammalian subject, for whom therapy is desired. Suitable vertebrate
animals include, but are not restricted to, primates, avians, livestock
animals
(e.g., sheep, cows, horses, donkeys, pigs), laboratory test animals (e.g.,
rabbits,
mice, rats, guinea pigs, hamsters), companion animals (e.g., cats, dogs) and
captive wild animals (e.g., foxes, deer, dingoes). A preferred subject is a
human
in need of treatment for a disease or condition caused by viral infection.
However, it will be understood that the aforementioned terms do not imply that
symptoms are necessarily present.
[0047] According to a first aspect of the invention, there is
provided a
compound of formula (I), or a pharmaceutically acceptable salt thereof:
R8 R6
0
R7
R4
R3
Formula (I)
wherein, Ri is selected from the group consisting of COOH, or a salt
thereof, C(0)NR6Rio, C(0)0Rii wherein R9, Rio and Rii are independently
selected from the group consisting of hydrogen and optionally substituted Ci-
C6
alkyl;
R3 is selected from the group consisting of N-linked triazole substituted at
one or both ring carbon atoms, optionally substituted N-linked tetrazole,
optionally substituted N-linked indole, optionally substituted N-linked
isoindole,
and optionally substituted N-linked benzotriazole;
R4 is NHC(0)Ri7 wherein Ri7 is selected from the group consisting of C--
C6 alkyl, Ci-C6 haloalkyl and C3-C6 cycloalkyl ; and
Date recue/ date received 2022-02-18
12
R6, R7 and R8 are
independently selected from the group
consisting of OH, NH2, C1-C6 alkyl, NR18R18', C1-C6 alkoxy, ¨0C(0)R18, ¨
NH(C=0)R18, and S(0)nR18, wherein n = 0 ¨ 2 and each R18 and R18' are
independently hydrogen or optionally substituted Ci-C6 alkyl.
[0048] In
one embodiment of the first aspect, the compound of formula (I) is
a compound of formula (II):
R8 R6
0 R 1
1
R7 ====,
R4
=
=
R3
Formula (II)
wherein, R1, R3, R4, R6, R7 and R8 are as previously described.
[0049]
Preferably, the triazole is a 1,2,3-triazole ring connected directly to
the neuraminic acid ring carbon at the N-1 position.
[0050] In
one embodiment wherein the tetrazole is substituted, it is
substituted at the ring carbon only.
[0051] In
one embodiment of the compound of formula (I) or (II) R1 is
COOH, or a salt thereof, or C(0)0Ri I wherein Rii is selected from methyl,
ethyl
and propyl.
[0052] In
certain specific embodiments R1 is selected from the group
consisting of COOH, COONa and C(0)0Me.
[0053] In
one embodiment of the compound of formula (I) or (II) R3 is
selected from the group consisting of:
Date recue/ date received 2022-02-18
13
Jw .fln..1"V"`
..11.1-Vtr
N, N
R20 N R22 Z R23 R24
N-N
R21
wherein, R20 and R21 are independently selected from the group
consisting of hydrogen, hydroxyl, cyano, halo, Ci-C6 alkyl, Ci-C6 haloalkyl,
C1-
C6 alkylether, optionally substituted pyridyl and optionally substituted
phenyl,
and wherein at least one of R20 and R21 is not hydrogen;
R22 is selected from the group consisting of hydrogen, Ci-C6 alkyl and
optionally substituted phenyl; and
R23 and R24 are independently selected from the group consisting of
hydrogen, hydroxyl, cyano, halo, Ci-C6 alkyl and Ci-C6 haloalkyl.
[0054] In certain preferred embodiments, R20 and R21 are selected from Ci-
C6 alkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, optionally substituted pyridyl and
optionally substituted phenyl.
[0055] In one embodiment, wherein when R20, R21 or R22 are optionally
substituted pyridyl or optionally substituted phenyl, as appropriate, then the
substitution may be with a moiety selected from the group consisting of Ci-C6
alkyl, Ci-C6 haloalkyl, Ci-C6 alkylhydroxy, Ci-C6 alkoxy, halo, -C(0)0Me and ¨
CH2OCH3.
Date recue/ date received 2022-02-18
14
[0056] In certain embodiments, R3 may be selected from the group
consisting of:
T
N3, T N
TN N \ // N N
N N N \ µ4\1 \ *.'4N
HO \ //
r_PI 111 N
0 N
/ =\O lip
\ /
T
N,
N l'" iv ify I" ify
\,, N
N N 3,N N 3,N N,N N õN N,N 'N
lik--0 \ CI \ if Br \ il \ Tj F3C \ if
HOOC \
¨0 111 111 li * 111 *
; ; ; ; ; ; ,
N N N
Na00 C ' ig H3C 00C ' if
N 1 . 7
N N * N,
. IP N; / No' j rN OCH3
N N /0 IN /1 \I
N¨N
T
N
CN
õN \/
,N NH N
N¨N and li .
[0057] The specific moieties listed above may be combined with any
disclosure of an Ri , R4, R6, R7 or R8 group as described herein.
[0058] In any of the aforedescribed embodiments, R4 may be selected
from
the group consisting of:
HN;11- ;11- %IL HN;t1-
IIN HN HN FIN;61- IIN ;It.
Ac HO
0 0 CIO CI----
Hls?-t- /"--- ----- CI CI I
HN21- HN
HN;It
HNI)71-
HN HN )tt=
FIN)1/4
HN IIN;t4- eo
/......õ,0
.,0 0 ,
0
F,C F3C....../.0 ..._._x_..0 -
'
HN;11-
F3C ..../0
and F F .
Date recue/ date received 2022-02-18
15
[0059] In certain
embodiments, R4 is selected from the group consisting
of ¨NHAc, -NHC(0)CH2(CH3)2, -NHC(0)CF3 and ¨NHC(0)CH2CH3.
[0060] In any embodiment of
the compounds of formula (I) or (II), R6, R7 and
Rg may be independently selected from the group consisting of OH, C1-C3
alkoxy and ¨0C(0)R18 wherein Rig is optionally substituted Ci-C3 alkyl.
[0061] In any one or more
of the preceding embodiments, R6, R7 and Rg
may be independently selected from OH and OAc.
[0062] In embodiments of
formula (I) and formula (II) the compound may be
selected from the group consisting of:
OH OH
OH OH
OH OH 1 0 COONa OH OHH
1."zi 0 COONa
L..I,0 COONa 1 )j:) COONa
OH 1
OH 1 AcHN _ OH 1 OH
1------'
.0"--------" AcHN
AcHN N AcHN_
k 'N N,
N, \ 0 ,N N
N il N \ ,,
05rV N
\c)
/
HO
OH OH
OH OH OH OH
OH OH 1,..õ...)Nis.,,,- ,-I ,
L.õ,õ,0, ,COONa 0 COONa 0
COONa
OCOONa _ F OH 1
I\/ 1
OH 1 OH I\./ AcHN
AcHN OH
o"\---"
I\/
AcHN AcHN N,
N, \ õ
N N.N
)\¨NN
110
/ \ / 11104
N 0
\
OH OH OH OH OH OH
L-3-1,0 COONa H 0 COONa OH OH
L,y0 00N
1-..,...1
.,__,1 0 COONa
OH 1 OH 1 ,_4
OH 1
HN OH
AcHN _ I\/I
HN
HN
b N,N
,N 0 N = m \ õ \
N N
111 0
\ 11111, /0
Date recue/ date received 2022-02-18
16
OH OH OH OH OH OH OH OH
rz-1 0 COONa 0 COONa H)."zi 0 IROON
lyi"z1 0 COONa
I
OH OH ,'I OHI OH
HN AcHN AcHN AcHN
N 'NI
\ 'N \ N 'N
\ ,, CI \ rj H3C \ F30 \ I,N N
. 1111 IIP
O
OH OH H OH
H
OH OH OH OH 1.1 1 000ONa UJNOCOONa
y.-zi
0 COONa
L.õ1õ,1 0:.COONa I
OH OH
I I AcHN AcHN I
OH ,õõ-
AcHN _ AcHN _ N ' \ N
, N ,N
N Br \ r4
N
µN N
111
OH OH OAc OAF.
OH OH
1,..õ-kt-1,,0 COONa n 0 C0001-13 OH OH
0 COONa
OH
I
OAc I ly.1 0 COONa I
AcHN HN _ I
HN
OH AcHN
N
N
\N CN
Na00C \ // \A") N \ / ¨ss' =-jsj
11104 ip CI N¨N *
OH OH OH OH
Lj.7"1 0 COONa
L.õõõ,..)-1,,0 C001 I OH OH
OH I I .",1 0 GOONa
OH
HN HN _ OH
cw NF3 n C ¨ AcHN
N CN
\ i \ / N ,N
* N¨N
and all C-2 analogues thereof wherein the C-2 carboxy group is in the
protonated form, sodium salt form or Ci-C3 ester prod rug form and wherein
each compound may be considered to have close analogues disclosed wherein
the R4 position is explicitly replaced with any ¨NHC(0)R group wherein R is Ci-
C4 alkyl or haloalkyl.
[0063] It will be appreciated by a person of skill in the art of
synthetic
chemistry that the COOH group is easily interchanged with a salt form or an
ester protecting group, for example a methyl ester group, and so all such
forms
Date recue/ date received 2022-02-18
17
are considered to be disclosed herein with reference to the compounds listed
above.
[0064] In one specific embodiment of formula (I) or formula (II),
wherein R4
is NHAc and R3 is a substituted triazole then the triazole is not substituted
with a
carboxyl group.
[0065] In a further specific embodiment of formula (I) or formula
(II), wherein
R4 is NHAc and R3 is a triazole substituted only at the 4-position of the
triazole
ring (the 1-position being the ring nitrogen attached to the neuraminic acid
core)
then the triazole is not substituted with propyl, substituted propyl,
substituted
tert-butyl or diethoxyalkyl.
[0066] In one embodiment, the compound of the first aspect is a
haemagglutinin and/or neuraminidase modulator. Preferably, a haemagluttinin
and/or neuraminidase inhibitor.
[0067] In one embodiment, it may be preferred that the
haemagluttinin
and/or neuraminidase inhibitor is an influenza or parainfluenza haemagluttinin
and/or neuraminidase inhibitor.
[0068] In one alternative aspect, referred to herein as the
"difluoro" aspect,
the invention resides in a compound of formula (III) or (111a), or a
pharmaceutically acceptable salt thereof:
R8 R6 R8 R5
R
Ri a Ria
R7 R7
R4 R2 R4 R2
R3 R3
Formula (III) Formula (111a)
Date recue/ date received 2022-02-18
18
wherein, Ri is selected from the group consisting of COOH, or a salt
thereof, C(0)NR9R10, C(0)01R11, P(0)(OH)2 and P(0)(01R11)2;
Ria and R2 are fluorine;
R3 is selected from the group consisting of optionally substituted N-linked
heterocyclic, -NHC(0)NHIR12, -NHC(0)1R13 and -NHS(0)2R14,
R4 is selected from the group consisting of NR151R16 and NHC(0)1R17; and
R6, R7 and R8 are independently selected from the group consisting of
OH, NH2, Ci-C6 alkyl, NR181R18', Ci-C6 alkoxy, ¨0C(0)R18, ¨NH(C=0)R18, and
S(0)nRi8, wherein n = 0 ¨ 2 and each R18 and R18' are independently hydrogen
or optionally substituted Ci-C6 alkyl.
[0069] In one embodiment of formula (III) or formula (111a) R1 is
selected
from the group consisting of COOH, or a salt thereof, and COORii wherein Rii
is optionally substituted Ci-C6 alkyl.
[0070] In one embodiment of formula (III) or formula (111a) R11 is
selected
from methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-
butyl and
pentyl.
[0071] In one embodiment of formula (III) or formula (111a) R12,
R13 and R14
are independently selected from the group consisting of optionally substituted
benzyl and phenyl.
[0072] In one embodiment of formula (III) or formula (111a) R3 is
selected
from the group consisting of pyrazole, imidazole, indole, isoindole, triazole,
benzotriazole, tetrazole, pyrimidine, pyridine, pyrazine, diazine, triazine
and
tetrazine, all of which may be optionally substituted, and which are linked to
the
core via a ring nitrogen.
[0073] In one embodiment of formula (III) or formula (111a) R3 is
selected
from the group consisting of:
Date recue/ date received 2022-02-18
19
i
N,
T' iv , N Iv
1'4,, N, \ 0 N,
I- N % N
.N.,,, .N. N \ i' \ \ 0
) j- le j- If r j- le 111 \O lip N
/o
IP N \ / HO
' ' ; ; ;
i
N
'N 4i- iv vv -I-
\ õ N N N N
--0 \
, 'N 'IV
111 if a \ T;f \ // , \ ii
N . 3`-' N
_. ,
= = IP
= i;,- lw 0- j---NocH3
N N
i i I
I- 0,NH ONH 0H
N 1 IA' 1 1
NH O H3C0
NH 0 NH NH
j14,,T up-AL"=-
IP
N
0 NH
113C0
, OCH3 0\ _0
; /0 OCH3
'Iv
ONH
I- I IA' HN 0 HN 0
I
0,NH ,
1 NH 1 ONI-1
1 0 NH I
0 NH
I
; HN 0
0 0
io NH diNi NH 0
IW 10 0
H3C0 CI , OCH3 , OCH3 0CF3 0
0CH3 I
;
1 0 HN,, ) 1 0
HNõ. 0 ,,r,
HN 0 --- '""' S...,-.0 1
"S. 'S-
..,--.0 --0 1 0 =
HN ,0
HN 0
I
S. `s,-_-0 0
HN 1
(NT NI,N 1\TH2 N
I 0 OCH 3 IW OCH3 N-N N-II
1 0 ---1 ___ r
, , '
I
N
1 CN
N \/
N; N iik
W- and
[0074] In one embodiment of formula (III) or formula (111a) R4 is
selected
from the group consisting of NIR15R16 and NHC(0)R17 and wherein R15, Ri6 and
Ri7 are independently selected from the group consisting of optionally
substituted Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 alkenyl and C3-C6 cycloalkyl.
Date recue/ date received 2022-02-18
20
[0075] In one embodiment of formula (III) or formula (111a) R4 is
NFIC(0)R17 and wherein R17 is selected from the group consisting of optionally
substituted Ci-C6 alkyl, Ci-C6 haloalkyl and C3-C6 cycloalkyl.
[0076] In one embodiment of formula (III) or formula (111a) R4 is
selected
from the group consisting of:
7
HN
HN HN71-
HN HNZ-
HN;It H1\1 HNI>1.
Aci .(1) 1:(C)
Thrlµ I CI
HN;11- HN HN;11-
HN HN?1-
11N)It
F,C/La HN,
HNP2-
F3C-.70
and F F .
[0077] In one embodiment of formula (III) or formula (111a) R4 is
selected
from ¨NHC(0)-methyl, ¨NHC(0)-ethyl, ¨NHC(0)-propyl, ¨NHC(0)-isopropyl, ¨
NHC(0)-n-butyl,¨NHC(0)-sec-butyl, ¨NHC(0)-isobutyl, ¨NHC(0)-tert-butyl and
¨NHC(0)-pentyl.
[0078] In one embodiment of formula (III) or formula (111a) R5 is
C1-C6 alkyl
or Cl-C6 alkenyl each of which may be optionally substituted.
[0079] In one embodiment of formula (III) or formula (111a) R5 is
C1-C6 alkyl
substituted with hydroxy or protected hydroxy.
[0080] In one embodiment of formula (III) or formula (111a) R6, R7
and R8 are
independently selected from OH, C1-C10 alkoxy and ¨0C(0)R18 wherein R18 is
C1-C10 alkyl.
[0081] In one embodiment of formula (III) orformula (111a) R6, R7
and R8 are
independently selected from OH and OAc.
Date recue/ date received 2022-02-18
21
[0082] In one embodiment of the difluoro aspect, the compound of
formula (III) or formula (111a), or a pharmaceutically acceptable salt
thereof, is
selected from the group consisting of:
OH OH
)Nivi 0OONa
z F
OH
AcHNF
_
ICI,
N
,
OH OH
OH OH OH OH
(:) /COONa
14,0 COONa L3,1,1 0 COONa i F
F OH
z z AcHNF
,\.-N / I\/-
c N,
AcHN - F AcHN - ,
N
\ 0
5/171 ry,./1/1
N
N N
0
/ , , ,
OH OH
OH OH
'Izi 0 COONa OH OH
L,,1 c, COONa ....F
L,)20, zCOONa
-.__F z
OH
OH AcHN - F
AcHN _ F k AcHN - .
E
N \ 0
N ICI,
\ 0 \ 0
N N
\
N , 0
\ / , HO
OH OH
(:) /COONa OH OH OH OH
(:) /COONa 'izi (:) /COONa
OH
AcHNF -`"--F F
OFI oFI
ICI
AcHN - F AcHNF
'N
_
\ 0 ICI, Fi,
N \ N N
\ ii a \
¨0 N N
Date recue/ date received 2022-02-18
22
OH OH OH OH
c) /COONa .,"1 0 COONa
-"--F Z__F
OH _ _ 6H OH OH
AcHNF i\/
AcHN - F /COONa
F
\
"N
0
F3C \
N AcHN -- F
_ICI
N /
" /
N
OH OH
.Xy'l (D /COONa OH OH
COO Na
OH OH
.Xlizcy /COONa AcHN/F z
OH I\/
.
N'
, -"-F HN -
OH N / _
AcHN- F N )()'N
_
N
j¨
N'FC1
µµ j---- \OC H3
N /o
OH OH OH OH OH OH
..)N,Filyc, /COONa .)FlN.,0z.._COONa ,7-1 (:)__
COONa
-`""-F F z F
oH oH OH
HNF HNF I\/
_
O\
ICLN \/---O ICLN
lµI
0 \ 0
N N N
0
\
, , ,
Date recue/ date received 2022-02-18
23
OH OH
OH OH .71 c) zCOONa
L'izi 0 COONa , -`"-F OH OH
X COONa
F/
6H AcHNF
HNF -
OICIH OH
_
\r"-0 F1'N 1 AcHNF
_
* NH OiCiH
\ I/
1 N
CI
* NH
, OCH3
OH OH OH OH
1,_,"1 cc zCOONa .y'l 0 COONa OH OH
0 COONa
OH OH Z__F
I\/ z
AcHNF AcHN - F OH _
OH OH
1 AcHNF
O. NH
H3C0 H3C0 0 NH * NH
* NH
0
OCH3 \--0 , H3C0
, ,
OH OH
H 0 COONa
F i
OH
OH OH OH OH
AcHN - F
/COONa
)Nyzo COONa -
0 ICI H
1
z
OH
../\õ.. NH AcHNiF
AcHN - F -
OyICIH OICIH
1
* N
0 * NH
H
CI OCH3 OCH3
, , ,
Date recue/ date received 2022-02-18
24
OH OH
OH OH
.),"1 (:) /COON
OH OH
COONa -.zi 0 COOH
OH
AcHNF
OH -
I\ OH
AcHN -./ F /\/ HII 0
AcHN - F
_
0y1C1H HICI 0
0 NH
0
OC F3 0 OC H 3
OH OH
/COOH
OH
AcHN-F
41 0
Cl
OH OH OH OH
/COONa L NI-1,101-
),N)
z
OH COONa
F OH OH
H 0 COONa
AcHN AcHN - F
HIC1, // HIC1,
S------0 S-_,---0 AcHN - F
- 0
H11,/,
0 0 S---0
CH3 ' , CI *
,
,
Date recue/ date received 2022-02-18
25
OH OH OH OH OH OH
L,),NyzoOONa L,),1 c,,,, /COONa c),,,;1 (:),COONa
OH OH OH
AcHNF HNF HNF
,- ID - 0
HINI, // H iL F1- 0
ollICID
s_.--.0 o
0 0 0
ocH3 , ocH3 , ocH3 ,
OH OH
0 COONa
F
61-1 OH OH OH OH
HNF
.)Nyzo COOH ilzo COONa
_
ic 6H 6H
'''F
HN * HN -
IAcHN - F
i= k CI,
0 /171 IN
OCH3 , N¨N N¨I4
OH OH OH OH OH OH
y'zi c) /COONa OH NE11,140- COONa
F
(5H oH
HNF HN : F I\/p
HN - .
C1-õ(Y1'N CI,,AA el'IN
F3C70 il'/!NI
Ii CI "4 , CI ci N¨N N¨N
OH OH OH OH OH OH
c) /COONa H 0 COONa IcH.,0 COONa
= -`"-F
OH I\/ OH OH
AcHN - F AcHN - F I\/p
- _ _
ICI ICI zICI
Nµ r NH2
RI¨N 1 ir
Date recue/ date received 2022-02-18
26
OH OH
OH OH OH OH
)NFI.zo /COONa
.)Nyzo COONa c) .)NH., COONa
....F ....F OH
, z
OH OH AcHN- F
-
-/
AcHNIF
- HN1\ - F ICI
- CN
Nfi
o *
N N *
OH OH OH OH OH OH
-1, 1 0 COONa INIF17 0 COONa 1,1 cs COONa
Z__FF
6H OH OH
HNF HNF HNF
_
yo N CN &O ICI CN CN
OH OH OH OH OH OH
)NFilzo/COONa izFl 0 /COONa -1,1z oOONa
OH OH OH
HNF HN , - 1
_
N
F3C0 ICI ON &O ICI _
CN
a,
, ,
OH OH OH OH OH OH
L,)NNFilvo COONa H c, COONa
Liyi 0 COONa
F
z z
OH OH OH
HNF HN i F HN - i
_ _
N N-
7---X0 N- CN õ.z-,,..A) CN
,
Date recue/ date received 2022-02-18
27
OH OH OH OH OH OH
NFilyoz_COONa .)!N.õ1-1 () /COONa 1OOOH
(5H (5H OH
HNF HNF 1\./
HN - F
Cl CNC>VIZOCN CN
ci
OH OH
HO
OH
/COOH COOH
OH
OH H 0 F
FN
N¨N
F3CID CN
F F
and 0cH3
wherein each incidence of
COOH may be read interchangeably with COONa, and vice versa.
[0083] In
any of the above embodiments of formula (III) or formula (111a) it
may be that R3 is not N-linked aryl, that is, an aryl ring linked to the core
via an
intermediate nitrogen atom.
[0084] It is
postulated that compounds such as those represented by
formula (III) and (111a), wherein there is a C-2 and 3 fluoro substitution
pattern,
may be particularly efficacious against influenza strains. While not wishing
to be
bound by any particular theory it is believed such compounds are active by
virtue of being effective inhibitors of the viral neuraminidase.
[0085] A
number of synthetic pathways can be employed to access the
compounds of the invention. Scheme 1, below, shows one pathway by which
certain known neuraminidase inhibitors were synthesised to use as reference
Date recue/ date received 2022-02-18
28
compounds. Relevant synthetic techniques, which may also
be applied
to synthesis of compounds of the first aspect, are disclosed in Carbohydr.
Res.
244, 181-185 (1993); Carbohydr. Res. 342, 1636-1650 (2007); Bioorg. Med.
Chem. Lett. 16, 5009-5013 (2006); and PCT application W02002076971.
OAc OAc OAc OAcH OAc OAc OAc OAc
.000OCH3
iv
OAc OAc OAc OAc
AcHN" Ac BocHN.
I -
R Boc R
17: R = OAc 18: R = OAc 20: R = OAc 22: R = OAc
11: R =N3 19: R = N3 21: R = N3 23: R = N3
OAc OAc OH OH
vi
OAc OH
HN
R R
24: R = OAc 5: R = OH
12: R = N3 6: R = N3
Scheme 1: i) (Boc)20, DMAP, THF, 60 C, o/n, (18, 71%; 19, 96%) (ii)
NaOCH3/CH3OH, rt, 1h; (iii) Ac20, pyridine, rt, o/n, (20, 81%; 21, 63% over 2
steps) (iv) TFA, DCM, rt, o/n, (22, 90%; 23, 85%) (v) Isobutyryl chloride,
Et3N,
DCM, rt, 4h, (24,84%; 12, 91%) (vi) NaOH, Me0H/H20 (1:1), rt, o/n, (5,94%; 6,
82%).
[0086] Scheme 2, below, shows a synthetic route used to access
compounds 7-10 which are preferred compounds of the first aspect.
Date recue/ date received 2022-02-18
29
OAc OAc OAc OAcH OH OH
.0 COOCH3 COOCH3 0 COONa
HN- R2 __
R0 N3
N N
\ // \
R2 R2
Methyl
13: Ri = Methyl, R2 = CH2OCH3 7: R1 = Methyl, R2 = CH2OCH3
12: R= Isopropyl
14: Ri = Methyl, R2 = Ph 8: R1 = Methyl, R2 = Ph
15: R1 = Isopropyl, R2 = CH2OCH3 9: R1 = Isopropyl, R2 = CH2OCH3
16: R1 = Isopropyl, R2 = Ph 10: R1 = Isopropyl, R2 = Ph
Scheme 2: (i) CuSO4, Na-ascorbate, tert-butanol/H20 (1:1), 45 C, 6 h (13,
78%; 14,82%; 15, 71%; 16, 84%); (ii) NaOH, Me0H/H20 (1:1), rt, o/n (7, 85%;
8, 96%; 9, 92%; 10, 89%).
[0087] In brief, the synthesis of the triazoles 7-10 was achieved
using the
known 4-azido-4-deoxy-Neu5Ac2en based intermediates 11 and 12. Each of
the two intermediates was exposed to either methylpropargyl ether or
ethynylbenzene under typical click azide-alkyne coupling conditions (heating a
mixture of the 4-azido-4-deoxy-Neu5Ac2en derivative, alkyne, CuSO4 and
sodium ascorbate in a (1:1) mixture of water and tert-butanol for 6 h) to
afford
the triazole derivative (see below). Triazoles 13 and 14 (starting from 11)
and
the triazole derivatives 15 and 16 (starting from 12) were isolated in yields
of
78%, 82%, 71% and 84%, respectively. The resulting per-O-acetylated triazole
derivatives 13-16 were then deprotected by treatment with aqueous methanol
(50%) adjusted to pH 13-14 at RT for 24 h to yield the final products 7-10 as
sodium salts in 85%, 96%, 92% and 89% yields, respectively.
Date recue/ date received 2022-02-18
30
OH OH OH OHH OH OH
Lko,c00H y."0 COONa y.,""1 0 COONa
'4-0H
OH OH OH
AcHN - AcHN
HN
15H R
o
R = OH Neu5Ac2en
3: R = N3 5: R = OH
1. N-Acetylneuraminic acid
4: R = NHC(NH)NH2 6: R = N3 BCX 2798
Zanamivir
OH OH OH OH
LL,0 COONa0 COONa
OH OH
AcHN - HN
7: R = CH200H3 9: R = CH200H3
8: R = Ph 10: R = Ph
The above illustrates the structures of N-acetylneuraminic acid (1), the
sialidase
inhibitor Neu5Ac2en (2), 4-azido-4-deoxy-Neu5Ac2en (3) zanam ivir (4), the C-5
isobutyramido analogue of Neu5Ac2en (5), the reference hPIV inhibitor BCX
2798 (6), and the novel inhibitors 7-10.
[0088] The synthetic targets were, in part, driven by information gleaned
from molecular modelling of the hPIV-3 HN crystal structure. Particularly, the
216 loop of the hPIV-3 HN indicates significant flexibility and so it was
postulated that Neu5Ac2en derivatives with somewhat bulky C4 substituents
Date recue/ date received 2022-02-18
31
could be accommodated in and lock open the 216 cavity within the active
site. Molecular Dynamics (MD) simulations were employed to design and
assess Neu5Ac2en derivatives that incorporate C4 functionalised triazoles, as
a
base from which to test the theory. From the initial study of 216 loop
flexibility
and the resultant 216 cavity dimensions, it was felt that relatively bulky C4
substituents on the unsaturated neuraminic acid-based template (compounds
7-10 shown above) could be well tolerated within the open 216 cavity.
Furthermore, modelling of these C4 triazole substituted inhibitors in complex
with hPIV-3 HN indicated that both an acetamido (7, 8) and an isobutyramido
(9,
10) moiety at C5 on the template could also be well accommodated
simultaneously within the C5 binding domain. It was assessed, using MD
simulations, the capacity of the bulkier triazole compounds (8 and 10) to
efficiently lock open the 216 loop in hPIV-3 HN. The relative interaction
energies of 8 and 10 in complex with hPIV-3 HN were determined to predict if
the bulkier C5 acylamino moiety, in combination with the bulky C4 substituent,
would be expected to improve inhibitor affinity.
[0089] The
methodology of the modelling and biological evaluation are
discussed in detail in the experimental section but, briefly, led to a number
of
conclusions concerning the influence of C4/C5 substituents on inhibitor
potency.
Within each of the two screened groups, that is Group 1 (C5 acetamido) and
Group 2 (C5 isobutyramido), the order of potency based on the substituent at
04 was found to be as follows: hydroxyl < azido 4-methoxymethyltriazole < 4-
phenyltriazole. The weakest inhibition in both groups was observed for the 4-
hydroxy derivatives 2 and 5. This outcome supports the notion that the C4
binding domain, which accommodates the C4 hydroxyl group on Neu5Ac2en
(2), has significant hydrophobic character and consequently does not favour
the
interaction with a polar, hydrophilic group including a hydroxyl group. The
hydrophobic nature of the pocket, combined with the large 216 cavity size
created by the opening of the 216 loop, does favour inhibitors, including
Date recue/ date received 2022-02-18
32
inhibitors 8 and 10, that have the C4 hydroxyl group replaced with bulky
hydrophobic substituents.
[0090] Comparison of both group's IC50 values revealed that
replacement of
the C5 acetamido group with an isobutyramido group in all of the prepared
inhibitors led to overall enhanced potency. Typically, close to an order of
magnitude improvement was observed, except for the most potent inhibitor 10.
Furthermore, analysis of the IC50 values supports the notion that the potency
enhancement in the best inhibitors, 8 and 10, results predominantly from the
introduction of the C4 substituent, with the C5 substituent contributing to a
much
lesser extent. This notion is also substantiated by STD NMR data analysis that
led to an epitope map of inhibitor 10 in which the protons of the 4-
phenyltriazole
moiety showed the strongest contribution to the binding event of 10 in complex
with hPIV-3 HN, while the relative interactions observed for the isobutyramido
group were less (-50%).
[0091] The potent inhibition of both HN functions (NI and HI) by
inhibitor 10
demonstrates that the compound exerts its antiviral effect against hPIV-3 by
action on the virus' key HN protein. These findings are further supported by
STD NMR experiments of 10 in complex with either intact virus or recombinant
HN protein, that clearly show identical STD NMR signal intensities for the
inhibitor's C4 triazole aromatic moiety. Moreover, the calculated binding
epitope
for 10 in complex with hPIV-3 HN is in excellent agreement with the MD
simulations that clearly predict the close contact of the Neu5Ac2en
derivative's
H3 and the C4 triazolo moiety's phenyl protons to the protein surface.
[0092] Furthermore, the in situ ELISA results are in good agreement
with the
NI and HI assay data. The LLC-MK2 cell-based assays demonstrate that 10 is
even more potent at the cellular level compared to NI and HI protein-based
assays. In this cell-based assay 10 was found to be ¨ 26 times more potent
than 6, whereas protein inhibition assays showed only ¨ 8 and 11 fold
improvement in NI and HI assays, respectively. This strongly suggests 10 is a
potent dual acting inhibitor that derives efficient synergism from the
inhibition of
Date recue/ date received 2022-02-18
33
both the protein's neuraminidase and haemagglutinin activities. This is in
contrast to the known inhibitor 6, which derives less synergistic effect as a
result
of it's significantly poorer inhibition of the haemagglutinin activity.
Finally, the
extent of virus growth inhibition in both human cell lines for inhibitor 10
compared with 6 clearly demonstrates the superiority of the designer ligand
10.
[0093] It will be appreciated that the compounds of the first
aspect have
efficacy at more than just the hPIV-3 HN. It has been found, as indicated in
the
experimental section, that variations in the structure of the compound can
tailor
the activity to different hPIV or influenza neuraminidases generally. For
example, the difluoro derivatives disclosed herein may be preferentially
active
against certain influenza neuraminidases.
[0094] Particularly, the results indicate that not only is compound
10 a much
better inhibitor than prior art compound BCX-2798 (reference compound 6) in
an inhibition assay to compare their capacity to inhibit hPIV-3 virus
infection and
propagation in LLC-MK2 cells by a reduction of 94% versus 14%, respectively,
but other compounds of the first aspect have been shown to have even greater
potency than 10 or 6. For example, the inventors have designed, synthesised
and biologically evaluated compounds 1E1398-33 and 1E927-99. These
compounds have IC50 values for hPIV-3 HN of 1.97 micromolar and 0.27
micromolar, respectively. This represents a 1 to 2 order of magnitude
improvement over the prior art reference compound BCX-2798. These results
demonstrate the surprising level of efficacy of the present compounds and
hence the value of the present structure-guided inhibitor design.
[0095] According to a second aspect of the invention there is
provided a
pharmaceutical composition comprising an effective amount of a compound of
formula (I), (II), (III) or (111a), or a pharmaceutically acceptable salt
thereof, and a
pharmaceutically acceptable carrier, diluent and/or excipient.
[0096] Suitably, the pharmaceutical composition is for the
treatment or
prophylaxis of a disease, disorder or condition caused by viral infection.
Date recue/ date received 2022-02-18
34
[0097] The pharmaceutical composition may include more than
one compound of formula (I), (II), (III) or (111a). When the composition
includes
more than one compound then the compounds may be in any ratio. The
composition may further comprise known co-actives, delivery vehicles or
adjuvants.
[0098] The compound of formula (I), (II), (III) or (111a) is
present in the
pharmaceutical composition in an amount sufficient to inhibit or ameliorate
the
disease, disorder or condition which is the subject of treatment. Suitable
dosage
forms and rates of the compounds and the pharmaceutical compositions
containing such may be readily determined by those skilled in the art.
[0099] Dosage forms may include tablets, dispersions, suspensions,
injections, solutions, syrups, troches, capsules and the like. These dosage
forms may also include injecting or implanting devices designed specifically
for,
or modified to, ensure placement at the site of connective tissue degradation.
A
hydrogel is a preferred delivery form.
[00100] A third aspect of the invention resides in a method of treating a
disease, disorder or condition caused by viral infection in a patient
including the
step of administering an effective amount of a compound of formula (I), (II),
(III)
or (111a), or a pharmaceutically effective salt thereof, or the pharmaceutical
composition of the second aspect to the patient.
[00101] A fourth aspect of the invention provides fora compound of formula
(I), (II), (III) or (111a), or a pharmaceutically effective salt thereof, or
the
pharmaceutical composition of the second aspect for use in the treatment of a
disease, disorder or condition caused by viral infection in a patient.
[00102] A fifth aspect of the invention provides for use of a compound of
formula (I), (II), (III) or (111a), or a pharmaceutically effective salt
thereof, in the
manufacture of a medicament for the treatment of a disease, disorder or
condition caused by viral infection.
Date recue/ date received 2022-02-18
35
[00103] In one embodiment of the third, fourth or fifth aspects, the
disease, disorder or condition is an infection caused by influenza or
parainfluenza virus.
[00104] The infection may be caused by the influenza A, B or C or
parainfluenza virus.
[00105] In one embodiment, the parainfluenza is an hPIV-1, 2, 3 or 4
virus.
[00106] Preferably, the patient is a domestic or livestock animal or
a human.
[00107] A sixth aspect of the invention provides fora method of modulating
the activity of a viral haemagglutinin and/or neuraminidase enzyme including
the
step of contacting the enzyme with a compound of formula (I), (II), (III) or
(111a).
[00108] Preferably, the modulating involves inhibiting the viral
haemagglutinin
and/or neuraminidase enzyme.
[00109] The following experimental section describes in more detail the
characterisation of certain of the compounds of the invention and their
antiviral
activity. The intention is to illustrate certain specific embodiments of the
compounds of the invention and their efficacy without limiting the invention
in
any way.
EXPERIMENTAL
Computational Chemistry
[00110] Molecular Dynamics simulations were performed with GROMOS
software using the force-field parameter set 54A4 (ref 39). Initial
coordinates
were taken from the X-ray structure (PDB accession code 1V3E) of hPIV-3 HN
in complex with 4. Compound 8 was superimposed on zanamivir (4) ring atoms
from the crystal structure. Parameters for 8 were generated in an analogous
manner to existing parameters in the GROMOS force-field. The number of
atoms in the final composite system for 1V3E-4 and IV3E-8 was 78253 and
78084, respectively. Ionization states of amino acid residues were assigned at
pH 7Ø The histidine side chains were protonated at the N,-atom. Water
Date recue/ date received 2022-02-18
36
molecules associated with the X-ray structure were removed, and replaced
by explicit solvation using the simple-point-charge (SPC) water model and
periodic boundary conditions, consistent with previously published
methodology.
In the simulations, water molecules were added around the protein within a
truncated octahedron with a minimum distance of 1 A nm between the protein
atoms and the square walls of the periodic box. All bonds were constrained
with
a geometric tolerance of 10-4 using the SHAKE algorithm.
[00111] A steepest-descent energy minimization of the system was
performed to relax the solute-solvent contacts, while positionally restraining
the
solute atoms using a harmonic interaction with a force constant of 2.5 x 104
kJ
m01-1 nm-2. Next, steepest-descent energy minimization of the system without
any restraints was performed to eliminate any residual strain. The energy
minimizations were terminated when the energy change per step became
smaller than 0.1 kJ mo1-1. For non-bonded interactions, a triple-range method
with cut-off radii of 0.8/1.4 nm was used. Short-range van der Waals and
electrostatic interactions were evaluated at each time step, based on a charge-
group pair-list. Medium-range van der Waals and electrostatic interactions,
between (charge group) pairs at a distance longer than 0.8 nm and shorter than
1.4 nm, were evaluated every fifth time step, at which point the pair list was
updated. Outside the longer cut-off radius a reaction-field approximation was
used with a relative dielectric permittivity of 78.5. The centre of mass
motion of
the whole system was removed every 1000 time steps. Solvent and solute were
independently, weakly coupled to a temperature bath of 295 K with a relaxation
time of 0.1 ps.
[00112] The systems were also weakly coupled to a pressure bath of 1 atm
with a relaxation time of 0.5 ps and an isothermal compressibility of 0.7513 x
10-3 (kJ mol-lnm-3)-1. MD simulations of 20 ps periods with harmonic position
restraining of the solute atoms and force constants of 2.5 x 104 kJ mo1-1 nm-
2,
2.5 x 103 kJ mo1-1 nm-2, 2.5 x 102 kJ mo1-1 nm-2, 2.5 x 101 kJ m01-1 nm-2 were
performed to further equilibrate the systems at 50 K, 120 K, 1800 K, 240 K and
Date recue/ date received 2022-02-18
37
300 K, respectively. The simulations were each carried out for 30 ns. The
trajectory coordinates and energies were saved every 0.5 ps for analysis.
Simulation trajectories for hPIV-3 HN in complex with 4 were produced in an
analogous manner to that described above and were used for analysis and
comparison to results obtained for hPIV-3 HN in complex with 8.
[00113] Analyses were done with the analysis software GROMOS++. Atom-
positional root-mean-square differences (RMSDs) between structures were
calculated for the residues comprising the 216-loop (residues 210-221) by
performing a rotational and translational atom-positional least-squares fit of
one
structure on the second (reference) structure using a given set of atoms (N,
Ca,
C). Atom-positional root-mean-square fluctuations (RMSFs) were calculated as
an average from a 30 ns period of simulation by performing a rotational and
translational atom-positional least- squares fit of the Ca-atoms of the
trajectory
structures on the reference. RMSFs were calculated for all residues including
the 216-loop (residues 210-221). To obtain reduced, representative structural
ensembles for the simulations, RMSD-based conformational clustering was
performed.
[00114] Structures extracted every 10 ps from simulations were
superimposed on backbone-Ca atoms to remove overall rotation and translation.
Clustering of all atoms of residues that line the binding site (residues 190-
198,
210-221, 251-259, 274-280, 320-326, 334-339, 369- 377, 407-413, 474-480,
529-533) was performed to compare relative structural populations of hPIV-3
HN protein from the different simulation trajectories. The similarity
criterion
applied was the RMSD of all atoms of these residues with a cut-off of 0.13 nm.
Final structures resulting from the 30 ns of MD simulations were extracted.
Interaction energies between hPIV-3 HN and inhibitors 8 and 10 were
calculated using GROMOS generated energies, free-energy A-derivatives and
block averages as separate trajectory files, referred to as the energy
trajectory.
The program ene ana was used to extract individual interaction energy values
such as non-bonded contributions, i.e. van der Waals and Coulomb interactions
Date recue/ date received 2022-02-18
38
from these files. Thus, these contributions between the ligand and
the protein were extracted from the energy trajectory resulting from the
simulation and interaction energies calculated. The error estimate was
calculated from block averages of growing sizes extrapolating to infinite
block
size. Hydrophobic interactions were analysed and a map of interactions
between inhibitor 10 and hPIV-3 HN was created using LIGPLOT. To measure
the extent of cavity opening for selected structures, the pocket volume was
analysed using POVME. Importantly, extended simulation times, up to 80 ns
provided outcomes entirely consistent with the data presented.
Compound 8 as a model of a Neu5Ac2en-based hPIV-3 HN inhibitor with a
bulky C4 substituent
[00115] The simulation of the available hPIV-3 HN crystal structure (PDB
accession code 1V3E) in complex with 8 allowed an analysis of the dynamic
behaviour of the protein relative to the zanamivir (4) bound structure. Atom-
positional root-mean-square deviations (RMSDs) of the hPIV-3 HN backbone
atoms (C,, N, C) for the 216-loop from the simulations of the hPIV-3 HN-4 and
-8 complexes showed that the 216-loop undergoes more significant deviations
from the crystal structure in the case of the hPIV-3 HN-8 complex. RMSD-
values of larger than 0.5 nm are observed for the simulation of the hPIV-3 HN-
8
complex, whereas the structure deviates less (0.4 nm) for the hPIV-3 HN-4
complex. This notion is further supported by the root-mean-square fluctuations
(RMSFs) observed for the C,-atoms of the backbone for residues associated
with the 216-loop (residues 205-225). Increased RMS fluctuations are observed
for the residues of the second half of the 216-loop (215-220), where values of
-
0.3 nm are reached, indicating a substantial conformational rearrangement
within that domain compared with the starting hPIV-3 HN reference X-ray
structure (PDB accession code IV3E). Table 1 shows a selection of RMSF
values of residues comprised in the 216-loop.
Residue Reference X-ray 1V3E-4 1V3E-8
Date recue/ date received 2022-02-18
39
structure (IV3E)
210 0.036 0.059 0.056
212 0.046 0.104 0.141
214 0.048 0.093 0.109
216 0.057 0.111 0.162
218 0.060 0.134 0.289
220 0.041 0.070 0.079
Table 1: Root-Mean-Square Fluctuations (RMSF) of selected residues comprised
in
the 216-loop for the 1V3E-4 and 1V3E-8 simulated systems, in nanometres,
compared
with the reference X-ray structure IV3E
[00116] The data suggests that loop flexibility, present under physiological
simulation conditions, has been significantly underestimated in crystal
structures
and provides an opportunity for anti-parainfluenza virus drug discovery.
Comparison of the hPIV-3 HN-4 complex and the hPIV-3 HN-8 complex
simulations demonstrates that the C4 substituent on 8 induces significant
movement in the hPIV-3 HN 216-loop. The induced loop opening could be seen
from the solvent-accessible surface plots of the final structures obtained
from 10
ns simulations of hPIV-3 HN-4 complex and 8.
[00117] The most populated conformational clusters from the MD simulations
of hPIV-3 HN in complex with 4 and 8 were identified and the superposition of
the final conformations from the simulations of hPIV-3 HN in complex with 4
and
8 were generated. The difference in 216-loop conformation could clearly be
seen. The 216-loop cavity adopts a more open conformation when in complex
with the more sterically-encumbered inhibitor 8. Generally, a wider cavity is
observed for the simulation of hPIV-3 HN-8 complex. The most populated
cluster from the simulation of the hPIV-3 HN-4 complex has a slightly smaller
cavity volume (654 M) compared to the simulated hP1V-3-8 complex (717 M).
[00118] To evaluate if a bulkier C5 acylamino moiety would be
accommodated in the presence of the C4 functionalised triazole an identical
analysis of 10 in complex with hPIV-3 HN was undertaken. This analysis
Date recue/ date received 2022-02-18
40
indicated that a C5 isobutyramido moiety is well accommodated within
the C5 binding domain in the presence of the C4 functionalised triazole.
Relative interaction energies of 8 and 10 in complex with hPIV-3 HN
[00119] To quantify the extent of inhibitor engagement with hPIV-3 HN an MD
simulations approach was used to determine theoretical averaged interaction
energies for the known inhibitor 2, as well as the novel C5 acetamido and C5
isobutyramido inhibitors, 8 and 10 respectively. Average interaction energy
(Eavi) values of -609.38 10.92 kJ mo1-1, -733.96 15.49 kJ mo1-1and -821.88
10.93 kJ mo1-1 for 2, 8 and 10 respectively in complex with hPIV-3 HN (1V3E)25
were determined. These calculations support the notion that the replacement of
the acetamido moiety in 8 with an isobutyramido moiety in 10 significantly
improves the absolute Eavi value of the inhibitor in complex with the protein.
Consequently, 10 is predicted to be a more potent hPIV-3 HN inhibitor than 8.
Further analysis of the MD simulation and extraction of the lowest (-1,078.13
kJ
mo1-1) interaction energy structure of 10 in complex with hPIV-3 HN (1V3E)
revealed that 10 makes several key interactions within the binding pocket.
Noteworthy is the electrostatic interaction between the ligand's carboxylate
and
the triarginyl cluster (Arg192, Arg424, Arg502), hydrogen bond interactions
between the C7 hydroxyl group and Glu276 and the C5 isobutyramido NH and
Tyr337 and Glu409. Furthermore, additional hydrophobic interactions are
observed for both the C4 aromatic and C5 isobutyl functionalities,
particularly
with the peptide backbone, within the C4 and C5 binding domains respectively.
Chemistry
General Methods
[00120]
Reagents and dry solvents were purchased from commercial
sources and used without further purification. Anhydrous reactions were
carried
out under an atmosphere of argon in oven-dried glassware. Reactions were
monitored using thin layer chromatography (TLC) on aluminium plates pre-
coated with Silica Gel 60 F254 (E. Merck). Developed plates were observed
Date recue/ date received 2022-02-18
41
under UV light at 254 nm and then visualized after application of a
solution of H2SO4 in Et0H (5% v/v) followed by charring. Flash chromatography
was performed on Silica Gel 60 (0.040 - 0.063 mm) using distilled solvents. 1H
and 13C NMR spectra were recorded at 300 and 75.5 MHz respectively on a
BrukerAvance 300 MHz spectrometer. Chemical shifts (6) are reported in parts
per million, relative to the residual solvent peak as internal reference
[CDCI3:
7.26 (s) for 1H, 77.0 (t) for 13C; DMSO: 2.50 (pent) for 1H, 39.51 (hept) for
13C;
D20: 4.79 (s) for 1H]. 2D COSY and HSQC experiments were run to support
assignments. Low-resolution mass spectra (LRMS) were recorded, in
electrospray ionization mode, on a BrukerDaltonics Esquire 3000 ESI
spectrometer, using positive mode. High-resolution mass spectrometry (HRMS)
were recorded for either the protected or deprotected final derivatives, and
were
carried out by the University of Queensland FTMS Facility on a BrukerDaltonics
Apex III 4.7e Fourier Transform micrOTOF-Q70 MS or by the Griffith University
FTMS Facility on a BrukerDaltonics Apex III 4.7e Fourier Transform MS, fitted
with an Apollo ESI source.
[00121] Final deprotected sialic acid derivatives were purified on a
GracePureTM SPE C18-Aq (5000 mg/20 mL) column using 2% acetonitrile/H20
as a solvent. The purity of all synthetic intermediates after chromatographic
purification was determined to be >90% by 1H and 13C NMR spectroscopy and
the purity of reference compounds synthesised for screening purposes (2, 3, 5,
6), as well as the novel final products 7-10, was determined to be 95`)/o.
Synthesis
[00122] The synthesis of intermediates 11, 12 and 17-24 and reference
inhibitors 2, 3, 5, and 6 was achieved by the literature procedures. General
methods are set out in Schemes 1 and 2 which allow access to all of the
compounds described and synthesised herein.
[00123] General procedure for the synthesis of 18 & /9: A mixture of 17 or 11
(0.42 mmol), Boc20 (275 mg, 1.27 mmol) and DMAP (50 mg, 0.42 mmol) in
Date recue/ date received 2022-02-18
42
anhydrous THF (5 mL) was stirred under argon atmosphere at 60 C o/n.
After cooling to rt, the solvent was evaporated under vacuum, and the residue
was taken up in dichloromethane (DCM) for chromatographic separation on a
silica gel column using ethyl acetate:hexane (1:2) as solvent to yield pure 18
(170 mg, 71%) or 19 (225 mg, 96%).
[00124] General procedure for the synthesis of 20 & 2: To a methanolic
solution of Na0Me, freshly prepared by dissolving sodium metal (0.39 mmol, 9
mg) in anhydrous Me0H (5 mL), was added compound 18 or 19 (0.26 mmol).
The mixture was stirred at it for lh and then quenched with Am berlite IR-120
(H+) resin (to pH = 5). The resin was filtered off, washed with Me0H (5 mL ><
3)
and the combined filtrate and washings were evaporated under vacuum. The
residue was re-dissolved in pyridine (2 mL), and acetic anhydride (0.5 mL)
added. The reaction mixture was stirred at it under argon atmosphere o/n and
the solvent and excess Ac20 were then removed under vacuum. Finally, the
residue was taken up in DCM for chromatographic separation on a silica gel
column using ethyl acetate:hexane (1:2) as solvent to yield pure 20 (112 mg,
81%) or 21(84 mg, 63%).
[00125] General procedure for the synthesis of 22 & 23:To a solution of 20 or
21(0.15 mmol) in anhydrous DCM (2 mL) was added TFA (230 pL, 3.0 mmol)
and the mixture was stirred at it under argon o/n. The reaction was diluted
with
DCM (20 mL) and quenched with sat. aq. NaHCO3 solution (20 mL). The DCM
layer was washed with water, brine then dried over anhydrous Na2SO4. The
dried organic solvent was concentrated under vacuum, and purified by silica
gel
chromatography using the suitable solvent system to yield pure 22 (58 mg,
90%) or 23 (53 mg, 85%).
[00126] General procedure for the synthesis of 24 & 12:To a solution of 22 or
23 (0.116 mmol) in DCM (2 mL) under argon was added Et3N (82 pL, 0.58
mmol) and isobutyryl chloride (18 pL, 0.17 mmol). The mixture was stirred at
it
for 4 h and then loaded on a silica gel column for chromatographic separation
using ethyl acetate:hexane (1:1) as solvent to yield pure 24 (50 mg, 84%) or
12
Date recue/ date received 2022-02-18
43
(51 mg, 91%).
[00127] General procedure for the synthesis of 5 & 6: To a suspension of
compound 24 or 12 (0.08 mmol) in a 1:1 mixture of MeOH:H20 (2 mL) at 0 C
was added dropwise a NaOH solution (1.0 M) until pH - 14. The temperature
was raised gradually to it and the mixture was stirred at it overnight. The
solution was then acidified with Amberlite IR-120 (H+) resin (to pH = 5),
filtered
and washed with Me0H (10 mL) and H20 (10 mL). The combined filtrate and
washings were then concentrated under vacuum and the residue was diluted
with distilled water (5 mL) and adjusted to pH = 8.0 using 0.05 M NaOH to
convert the compound to its sodium salt. The compounds were then purified on
a C18-GracePureTm cartridge using 2% acetonitrile/water as solvent to yield
pure 5 (26 mg, 94%) or 6 (24 mg, 82%) as fluffy white powders.
[00128] General procedure for the synthesis of 13-16: The appropriate 4-
azido-4-deoxy-Neu5Ac2en derivative (11 or 12, 0.22 mmol) and the
corresponding ethynyl derivative (0.33 mmol) were dissolved in a 1:1 mixture
of
tert-butanol:H20 (4 mL). Copper(II) sulfate pentahydrate (4 mg, 0.015 mmol)
was added to the mixture followed by sodium ascorbate (0.1 mL of freshly
prepared 1 M solution in H20). The mixture was stirred at 45 C for 6 h and
then
left to cool to it. The mixture was then diluted with DCM (100 mL), washed
with
10% NH4OH (50 mL), followed by brine (50 mL). The organic layer was dried
over anhydrous Na2SO4 and concentrated under vacuum to give the crude
products 13-16, which were purified by silica gel chromatography using an
appropriate solvent system.
[00129] General procedure for the synthesis of 7-10: To a suspension of the
protected triazole derivative 13-16 in a 1:1 mixture of MeOH:H20 (2 mL) at 0
C
was added dropwise a NaOH solution (1.0 M) until pH -14. The temperature
was gradually raised to it and the mixture was stirred at it overnight. The
solution was then acidified with Amberlite IR-120 (H+) resin (to pH = 5),
filtered
and washed with Me0H (10 mL) and H20 (10 mL). The combined filtrate and
washings were then concentrated under vacuum, then diluted with distilled
Date recue/ date received 2022-02-18
44
water (5 mL) and adjusted to pH = 8.0 using 0.05 M NaOH to convert the
compound to its sodium salt. Finally, the compound was purified on a C18-
GracePureTM cartridge using 2% acetonitrile/water as solvent to yield the pure
products 7-10.
Characterisation of Synthesised Compounds
Methyl 5-
acetamido-7,8,9-tri-O-acetyl-2,6-anhydro-3,4,5-trideoxy-4-(4-
methoxymethyl-[1,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate (13)
OAc OAc
L141.õ.000OCH3
OAc
AcHNI
0
13
Purification by silica gel chromatography using ethyl acetate:acetone (6:1)
yielded (90 mg, 78%) of pure 13. 1H NMR (300 MHz, CDCI3): 6 1.81 (s, 3H,
NAc), 2.05 (s, 6H, 20Ac), 2.06 (s, 3H, OAc), 3.36 (s, 3H, OCH3), 3.80 (s, 3H,
COOCH3), 4.17 (dd, J= 12.5, 7.2 Hz, 1H, H-9), 4.29 (m, 1H, H-5), 4.50 (s, 2H,
OCH2), 4.68-4,79 (m, 2H, H-9", H-6), 5.40 (ddd, J= 7.4, 4.9, 2.5 Hz, 1H, H-8),
5.53 (dd, J= 5.1, 1.8 Hz, 1H, H-7), 5.78 (dd, J= 10.0, 2.5 Hz, 1H, H-4), 6.00
(d,
J= 2.3 Hz, 1H, H-3), 7.05 (d, J= 9.1 Hz, 1H, NH), 7.64 (s, 1H, triazole-CH);
13C
NMR (75 MHz, CDCI3) El 20.71, 20.79, 20.91 (3 0000H3), 22.80 (NHCOCH3),
48.39 (C-5), 52.71 (COOCH3), 58.16 (OCH3), 58.38 (C-4), 62.21 (C-9), 65.68
(OCH2), 67.73 (C-7), 70.90 (C-8), 76.71 (C-6), 107.18 (C-3), 121.50 (triazole-
C-
5), 145.24 (triazole-C-4), 145.92 (C-2), 161.27 (COOCH3), 170.06, 170.27,
170.81, 170.88 (NHCOCH3, 3 OCOCH3). LRMS [C22H301\14011] (m/z): (+ve ion
mode) 549.1 [M+Na]; HRMS (API) (m/z): [M+Na] calcd for C22H301\14Na011
[M+Na] 549.1803; found, 549.1805.
Methyl 7,8,9-tri-O-acetyl-2,6-anhydro-3,4,5-trideoxy-5-isobutyramido-4-(4-
methoxymethy141,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate
(15).
Date recue/ date received 2022-02-18
45
OAc OAc
0 COOC H3
OAc
H N
N
0
Purification by silica gel chromatography using ethyl acetate:acetone (9:1)
yielded (65 mg, 71%) of pure 15. 1H NMR (300 MHz, CDCI3): 60.97 (d, J= 6.9
Hz, 3H, isobut-CH3), 1.01 (d, J = 6.8 Hz, 3H, isobut-CH3), 2.05 (s, 3H, OAc),
2.08 (s, 6H, 20Ac), 2.24 (m, 1H, isobut-CH), 3.37 (s, 3H, OCH3), 3.81 (s, 3H,
COOCH3), 4.14-4.29 (m, 2H, H-9, H-5), 4.51 (s, 2H, OCH2), 4.68 (dd, J= 12.5,
2.6 Hz, 1H, H-9"), 4.84 (dd, J= 10.5, 1.7 Hz, 1H, H-6), 5.38 (ddd, J= 6.6,
5.5,
2.5 Hz, 1H, H-8), 5.48 (dd, J= 5.5, 1.7 Hz, 1H, H-7), 5.91 (dd, J=10.0,2.4 Hz,
1H, H-4), 6.02 (d, J = 2.4 Hz, 1H, H-3), 6.44 (d, J= 8.7 Hz, 1H, NH), 7.59 (s,
1H, triazole-CH); 13C NMR (75 MHz, CDCI3): El 18.81, 19.30 (isobut-20H3),
20.74, 20.90 (3 OCOCH3), 35.51 (isobut-CH), 48.79 (C-5), 52.69 (COOCH3),
57.59 (C-4), 58.38 (OCH3), 62.08 (C-9), 65.73 (OCH2), 67.66 (C-7), 70.79 (C-
8),
76.24 (C-6), 107.07 (C-3), 121.54 (triazole-C-5), 145.39 (triazole-C-4),
145.82
(C-2), 161.30 (COOCH3), 170.15, 170.23, 170.69 (3 OCOCH3), 177.87 (isobut-
CO). LRMS [C24H34N4011] (m/z): (+ve ion mode) 577.2 [M+Na].
Methyl 7,8,9-tri-O-acetyl-2,6-anhydro-3,4,5-trideoxy-5-isobutyramido-4-(4-
phenyl-[1,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate (16).
OAc OAc
0 COOCH3
0Ac
HNI)
16
Purification by silica gel chromatography using ethyl acetate:hexane (4:1)
Date recue/ date received 2022-02-18
46
yielded (82 mg, 84%) of pure 16. 1H NMR (300 MHz, CDCI3): 6 0.95 (d, J=
6.8 Hz, 3H, isobut-CH3), 0.99 (d, J= 6.9 Hz, 3H, isobut-CH3), 2.06 (s, 3H,
OAc),
2.09 (s, 6H, 20Ac), 2.20-2.27 (m, 1H, isobut-CH), 3.83 (s, 3H, COOCH3), 4.16-
4.39 (m, 2H, H-9, H-5), 4.70 (dd, J= 12.5, 2.6 Hz, 1H, H-9"), 4.88 (dd, J=
10.5,
1.7 Hz, 1H, H-6), 5.40 (m, 1H, H-8), 5.52 (dd, J= 5.4, 1.7 Hz, 1H, H-7), 5.99
(dd, J= 10.0, 2.4 Hz, 1H, H-4), 6.08 (d, J=2.4 Hz, 1H, H-3), 6.51 (d, J=8.7
Hz,
1H, NH), 7.26-7.43 (m, 3H, Ph-H-3", Ph-H-4", Ph-H-5"), 7.74 (d, J= 7.2 Hz, 2H,
Ph-H-2", Ph-H-6"), 7.81 (s, 1H, triazole-CH); 13C NMR (75 MHz, CDCI3):
18.83, 19.31 (isobut-2CH3), 20.76, 20.92 (3 OCOCH3), 35.55 (isobut-CH), 48.74
(C-5), 52.72 (COOCH3), 57.67 (C-4), 62.12 (C-9), 67.72 (C-7), 70.84 (C-8),
76.39 (C-6), 107.25 (C-3), 118.84 (triazole-C-5), 125.83 (Ph), 128.47 (Ph),
128.89 (Ph), 129.97 (Ph q carbon), 145.81 (C-2), 148.19 (triazole-C-4), 161.35
(COOCH3), 170.18, 170.26, 170.71 (3 OCOCH3), 178.00 (isobut-CO). LRMS
[C281-134N4010] (m/z): (+ve ion mode) 608.9 [M+Na].
Sodium 5-
acetamido-2,6-anhydro-3,4,5-trideoxy-4-(4-methoxymethyl-
[1,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate (7).
OH OH
OCOONa
OH
oe\/
AcHN
N,
5/IN
0
7
Yield = 85%. 1H NMR (300 MHz, D20): 6 1.84 (s, 3H, NAc), 3.31 (s, 3H, OCH3),
3.52-3.71 (m, 2H, H-9 & H-7), 3.85 (dd, J= 11.9, 2.6 Hz, 1H, H-9"), 3.95 (ddd,
J
= 9.3, 6.2, 2.5 Hz, 1H, H-8), 4.33 (m, 1H, H-5), 4.51 (dd, J= 10.9, 1.2 Hz,
1H,
H-6), 4.56 (s, 2H, OCH2), 5.48 (dd, J= 9.6, 2.3 Hz, 1H, H-4), 5.80 (d, J= 2.2
Hz, 1H, H-3), 8.08 (s, 1H, triazole-CH); 13C NMR (75 MHz, D20): 8 21.65
(NHCOCH3), 48.68 (C-5), 57.15 (OCH3), 59.94 (C-4), 63.06 (C-9), 64.22
(OCH2), 68.05 (C-7), 69.71 (C-8), 75.34 (C-6), 101.80 (C-3), 123.54 (triazole-
C-
Date recue/ date received 2022-02-18
47
5), 144.08 (triazole-C-4), 150.43 (C-2), 168.75 (COONa), 173.57 (NHCOCH3);
LRMS [Ci5H2iN4Na08] (m/z): (+ve ion mode) 432.1 [M+Na].
Sodium 5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-(4-phenyl-[1,2,3,]triazol-
1-y1)-D-Wycero-D-ga/acto-non-2-enonate (8).
OH OH
Na
AcHN
JN
OH
N,
8
Yield = 96%. 1H NMR (300 MHz, D20): 6 1.87 (s, 3H, NAG), 3.64 (dd, J= 12.1,
6.4 Hz, 1H, H-9), 3.69 (dd, J= 9.6, 1.4 Hz, 1H, H-7), 3.89 (dd, J= 11.9, 2.7
Hz,
1H, H-9"), 4.00 (ddd, J= 9.3, 6.3, 2.7 Hz, 1H, H-8), 4.39 (m, 1H, H-5), 4.56
(dd,
J= 10.8, 1.4 Hz, 1H, H-6), 5.49 (dd, J= 9.7, 2.3 Hz, 1H, H-4), 5.83 (d, J= 2.2
Hz, 1H, H-3), 7.40 (m, 1H, Ph-H4"), 7.46 (dd, J= 8.4, 6.9 Hz, 2H, Ph-H-3", Ph-
H-5"), 7.71 (d, J= 7.1 Hz, 2H, Ph-H-2", Ph-H-6"), 8.28 (s, 1H, triazole-CH);
13C
NMR (75 MHz, D20): 6 21.63 (NHCOCH3), 48.70 (C-5), 59.96 (C-4), 63.05 (C-
9), 68.03 (C-7), 69.69 (C-8), 75.31 (C-6), 101.75 (C-3), 120.41 (Ph), 125.61
(Ph), 128.77 (triazole-C-5), 129.10 (Ph), 129.28 (Ph q carbon), 147.74
(triazole-
C-4), 150.48 (C-2), 168.75 (COONa), 173.58 (NHCOCH3). LRMS
[Ci9H21N4Na07] (m/z): (+ve ion mode) 463.1 [M+Na]; HRMS (API) (m/z):
[M+1] calcd for Ci9H22N4Na07 [M+H] 441.138070; found, 441.140189.
Sodium 2,6-anhydro-3,4,5-trideoxy-5-isobutyramido-4-(4-methoxymethyl-
[1,2,3,]triazol-1-y1)-D-Wycero-D-gaiacto-non-2-enonate (9).
Date recue/ date received 2022-02-18
48
OH OH
OCOONa
OH
HN
N
:52N
0
9
Yield = 92%. 1H NMR (300 MHz, D20): 8 0.98 (d, J = 7.0 Hz, 3H, isobut-CH3),
1.03 (d, J = 6.9 Hz, 3H, isobut-CH3), 2.46 (m, 1H, isobut-CH), 3.39 (s,
3H2OCH3), 3.65-3.76 (m, 2H, H-9, H-7), 3.94 (dd, J= 11.9, 2.7 Hz, 1H, H-9"),
4.04 (ddd, J= 9.3, 6.3, 2.6 Hz, 1H, H-8), 4.49 (m, 1H, H-5), 4.60-4.65 (m, 3H,
H-6, OCH2), 5.61 (dd, J= 9.7, 2.3 Hz, 1H, H-4), 5.87 (d, J= 2.2 Hz, 1H, H-3),
8.18 (s, 1H, triazole-CH); 13C NMR (75 MHz, D20): 8 18.43 (isobut-CH3), 18.64
(isobut-CH3), 35.10 (isobut-CH), 48.19 (C-5), 57.24 (OCH3), 59.86 (C-4), 63.07
(C-9), 64.24 (OCH2), 68.13 (C-7), 69.82 (C-8), 75.43 (C-6), 102.02 (C-3),
123.65 (triazole-C-5), 144.07 (triazole-C-4), 150.30 (C-2), 168.81 (COONa),
180.66 (isobut-CO). LRMS [C17H25N4Na08] (m/z): (+ve ion mode) 459.0
[M+Na]; HRMS (API) (m/z): [M+Na] calcd for C17H25N4Na208 [M+Na]
459.1462; found, 459.1458.
Sodium 2,6-
anhydro-3,4,5-trideoxy-5-isobutyramido-4-(4-phenyl-
[1,2,3,]triazol-1-y1)-D-g/ycero-D-ga/acto-non-2-enonate (10).
OH OH
HN
OH
0
Yield = 89%. 1H NMR (300 MHz, D20): 8 0.94 (d, J = 6.9 Hz, 3H, isobut-CH3),
0.99 (d, J= 6.9 Hz, 3H, isobut-CH3), 2.43 (m, 1H, isobut-CH), 3.60-3.76(m, 2H,
H-9, H-7), 3.93 (dd, J= 12.0,2.7 Hz, 1H, H-9"), 4.04 (ddd, J= 9.2,6.3, 2.6 Hz,
Date recue/ date received 2022-02-18
49
1H, H-8), 4.51 (m, 1H, H-5), 4.62 (d, J = 11.0 Hz, 1H, H6), 5.58 (dd, J = 9.7,
2.3 Hz, 1H, H-4), 5.88 (d, J = 2.2 Hz, 1H, H-3), 7.42-7.54 (m, 3H, Ph-H-3", Ph-
H-4", Ph-H-5"), 7.78 (d, J= 7.1 Hz, 2H, Ph-H-2", Ph-H-6"), 8.36 (s, 1H,
triazole-
CH); 13C NMR (75 MHz, D20): 6 18.38 (isobut-CH3), 18.65 (isobut-CH3), 35.10
(isobut-CH), 48.23 (C-5), 59.91 (C-4), 63.07 (C-9), 68.15 (C-7), 69.76 (C-8),
75.41 (C-6), 101.96 (C-3), 120.66 (Ph), 125.67 (Ph), 128.81 (triazole-C-5),
129.16 (Ph), 129.36 (Ph q carbon), 147.71 (triazole-C-4), 150.32 (C-2), 168.80
(COONa), 180.67 (isobut-CO). LRMS [C211-125N4Na07] (m/z): (+ve ion mode)
491.2 [M+Na]; HRMS (API) (m/z): [M+Na]calcd for C21H25N4Na207 [M+Na]
491.1513; found, 491.1515.
Methyl 5-
acetamido-7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-4-(4-
isobuty141,2,3,]triazol-1-y1)-D-glycero-o-galacto-non-2-enonate (1E832-6).
OAc OAc
N"000OCH3
OAc
AcHN
N,
>i_11\iN
1E832-6
Purification by silica gel chromatography using ethylacetate yielded (93 mg,
66%) of pure 1E832-6. 1H NMR (300 MHz, CDCI3): 8 0.89 (d, J = 6.6 Hz, 6H,
isobuty1-2CH3), 1.81 (s, 3H, NAc), 1.93 (m, 1H, isobutyl-CH), 2.06 (s, 6H,
20Ac), 2.09 (s, 3H, OAc), 2.58 (d, J = 6.9 Hz, 2H, isobutyl-CH2), 3.82 (s, 3H,
COOCH3), 4.17 (dd, J= 12.5, 6.7 Hz, 1H, H-9), 4.38 (m, 1H, H-5), 4.67 (dd, J=
12.4, 2.3 Hz, 1H, H-9'), 4.77 (d, J= 10.5 Hz, 1H, H-6), 5.40 (m, 1H, H-8),
5.55
(d, J= 5.4 Hz, 1H, H-7), 5.88 (d, J= 9.9 Hz, 1H, H-4), 6.03 (s, 1H, H-3), 7.07
(brs, 1H, NH), 7.49 (s, 1H, triazole-CH); 13H NMR (75 MHz, CDCI3): 8 20.74,
20.81, 20.93 (3 OCOCH3), 22.12, 22.84 (2 isobutyl-CH3 + NHCOCH3), 28.60
(isobutyl-CH), 34.17 (isobutyl-CH2), 48.04 (C-5), 52.76 (COOCH3), 58.62 (C-4),
Date recue/ date received 2022-02-18
50
62.06 (C-9), 67.56 (C-7), 70.55 (C-8), 76.57 (C-6), 106.82 (C-3), 120.94
(triazole-C-5), 146.03 (C-2), 146.83 (triazole-C-4), 161.30 (COOCH3), 169.99,
170.00 170.13, 170.78 (NHCOCH3, 3 OCOCH3). LRMS [C24H34N4010] (m/z):
(+ve ion mode) 561.2 [M+Na].
Sodium 5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-(4-isobutyl-
[1,2,3,]triazol-1-y1)-b-glycero-b-galacto-non-2-enonate (1E832-8).
OH OH
1,-1 OCOONa
OH I
I\/
AcHN
N,
> j_11,4N
1E832-8
Yield = 79%. IH NMR (300 MHz, D20): 8 0.82 (d, J = 6.6 Hz, 6H, isobuty1-
2CH3), 1.81-1.86 (m, 4H, NAc & isobutyl-CH), 2.53(d, J = 6.9 Hz, 2H, isobutyl-
CH2), 3.54-3.68 (m, 2H, H-9 & H-7), 3.85 (dd, J= 11.9, 2.6 Hz, 1H, H9'), 3.94
(ddd, J= 9.3, 6.3, 2.5 Hz, 1H, H-8), 4.33 (m, 1H, H-5), 4.49 (dd, J= 10.9, 1.2
Hz, 1H, H-6), 5.40 (dd, J= 9.7, 2.2 Hz, 1H, H-4), 5.78 (d, J= 2.2 Hz, 1H, H-
3),
7.80 (s, 1H, triazole-CH); 13C NMR (75 MHz, D20): 8 21.15 (isobuty1-2CH3),
21.54 (NHCOCH3), 28.09 (isobutyl-CH), 33.42 (isobutyl-CH2), 48.53 (C-5),
59.65 (C-4), 62.99 (C-9), 67.98 (C-7), 69.63 (C-8), 75.29 (C-6), 102.06 (C-3),
122.01 (triazole-C-5), 147.74 (triazole-C-4), 150.12 (C-2), 168.81 (COONa),
173.28 (NHCOCH3). LRMS [C17H25N4Na07] (m/z): (+ve ion mode) 443.1
[M+Na]; HRMS (API) (m/z): [M+1] calcd for C17F126N4Na07[M+1] 421.169370;
found, 421.170091.
Methyl 5-acetamido-7,8,9-tri-0-acety1-2,6-anhydro-3,4,5-trideoxy-4-(4-(4-
hydroxymethylpheny1)41,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-
enonate (1E932-10).
Date recue/ date received 2022-02-18
51
OAc OAc
oCOOCH3
OAc
AcHN _
N
HO
1E932-10
1H NMR (300 MHz, CDCI3): 51H NMR (300 MHz, Chloroform-d) El 1.86 (s, 3H,
NAc), 2.07 (s, 3H, OAc), 2.09 (s, 3H, OAc), 2.10 (s, 3H, OAc), 3.84 (s, 3H,
COOCH3), 4.19 (dd, J= 12.5, 6.6 Hz, 1H, H-9), 4.31 (m, 1H, H-5), 4.60-4.74 (m,
3H, H-9', CH2), 4.80 (d, J= 10.4 Hz, 1H, H-6), 5.40 (m, 1H, H-8), 5.54 (dd, J=
5.8, 1.7 Hz, 1H, H-7), 5.93 (d, J= 10.1 Hz, 1H, H-4), 6.07 (d, J= 2.2 Hz, 1H,
H-
3), 6.74 (brs, 1H, NH), 7.38 (d, J= 7.9 Hz, 2H, Ph-H-3', Ph-H-5'), 7.74 (d, J=
7.7 Hz, 2H, Ph-H-2', Ph-H-6'), 7.96 (s, 1H, triazole-CH); 13H NMR (75 MHz,
CDCI3): 8 20.74, 20.85, 20.98 (3 OCOCH3), 22.90 (NHCOCH3), 48.31 (C-5),
52.83 (COOCH3), 58.49 (C-4), 62.19 (C-9), 64.66 (CH2), 67.72 (C-7), 70.93 (C-
8), 76.78 (C-6), 107.12 (C-3), 119.00 (triazole-C-5), 125.91 (Ph), 127.47
(Ph),
128.61 (Ph q carbon), 141.59 (Ph q carbon), 146.01 (C-2), 147.65 (triazole-C-
4), 161.37 (COOCH3), 170.13, 170.41, 170.92, 171.26 (NHCOCH3, 3 OCOCH3).
LRMS [C27H32N4011] (m/z): (4-ye ion mode) 611.2 [M+Na].
Sodium 5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-(4-(4-
hydroxymethylpheny1)-(1 ,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-
enonate (1E832-12).
Date recue/ date received 2022-02-18
52
OH OH
OH
AcHN -
N,N
\
HO
1E832-12
1H NMR (300 MHz, D20): 8 1.85 (s, 3H, NAc), 3.54-3.71 (m, 2H, H-9, H-7), 3.86
(dd, J= 11.9, 2.5 Hz, 1H, H-9'), 3.96 (ddd, J= 9.3, 6.3, 2.4 Hz, 1H, H-8),
4.37
(m, 1H, H-5), 4.54 (d, J= 10.9 Hz, 1H, H-6), 4.62 (s, 2H, CH2), 5.50 (dd, J=
9.6,
2.1 Hz, 1H, H-4), 5.83 (d, J= 2.1 Hz, 1H, H-3), 7.44 (d, J= 8.2 Hz, 2H, Ph-H-
3',
Ph-H-5'), 7.75 (d, J= 8.2 Hz, 2H, Ph-H-2', Ph-H-6'), 8.38 (s, 1H, triazole-
CH);
13C NMR (75 MHz, D20): 8 21.70 (NHCOCH3), 48.78 (C-5), 60.04 (C-4), 63.12
(C-9), 63.55 (CH2), 68.11 (C-7), 69.77 (C-8), 75.39 (C-6), 101.78 (C-3),
120.53
(triazole-C-5), 125.90 (Ph), 128.06 (Ph), 128.77 (Ph q carbon), 140.80 (Ph q
carbon), 147.60 (C-2), 150.57 (triazole-C-4), 168.77 (COONa), 173.66
(NHCOCH3). LRMS [C201-123N4Na08] (m/z): (-'-ye ion mode) 493.1 [M-'-Na];
HRMS (API) (m/z): [M+1] calcd for C201-124N4Na08[M+1] 471.148635; found,
471.147973.
Methyl 5-acetamido-7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-4-
(4-
methoxymethy141,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate
(1E832-13).
OAc OAc
yN,000OCH3
OAc,)
AcHN
N,
jr/4N
0
1E832-13
Purification by silica gel chromatography using ethylacetate : acetone (6:1)
Date recue/ date received 2022-02-18
53
yielded (67 mg, 58%) of pure 1E832- 13.1H NMR (300 MHz, CDCI3): 8 1.81
(s, 3H, NAG), 2.05 (s, 6H, 20Ac), 2.06 (s, 3H, OAc), 3.36 (s, 3H, OCH3), 3.80
(s,
3H, COOCH3), 4.17 (dd, J= 12.5, 7.2 Hz, 1H, H-9), 4.29 (m, 1H, H-5), 4.50 (s,
2H, OCH2), 4.68-4.79 (m, 2H, H-9', H-6), 5.40 (ddd, J= 7.4, 4.9, 2.5 Hz, 1H, H-
8), 5.53 (dd, J= 5.1, 1.8 Hz, 1H, H-7), 5.78 (dd, J= 10.0, 2.5 Hz, 1H, H-4),
6.00
(d, J= 2.3 Hz, 1H, H-3), 7.05 (d, J= 9.1 Hz, 1H, NH), 7.64 (s, 1H, triazole-
CH);
13C NMR (75 MHz, CDCI3) El 20.71, 20.79, 20.91 (3 00001-13), 22.80
(NHCOCH3), 48.39 (C-5), 52.71 (COOCH3), 58.16 (OCH3), 58.38 (C-4), 62.21
(C-9), 65.68 (OCH2), 67.73 (C-7), 70.90 (C-8), 76.71 (C-6), 107.18 (C-3),
121.50 (triazole-C-5), 145.24 (triazole-C-4), 145.92 (C-2), 161.27 (COOCH3),
170.06, 170.27, 170.81, 170.88 (NHCOCH3, 3 OCOCH3). LRMS [C22H301\14011]
(m/z): (+ve ion mode) 549.1[M+Na]. HRMS (API) (m/z): [M+Na] calcd for
C22H301\14Na011 [M+Na] 549.1803; found, 549.1805.
Sodium 5-
acetamido-2,6-anhydro-3,4,5-trideoxy-4-(4-methoxymethyl-
[1,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate (1E832-17).
JN.--111,
0,COONa
OH
AcHN
0
1E832-17
Yield = 85%. 1H NMR (300 MHz, D20): 6 1.84 (s, 3H, NAc), 3.31 (s, 3H, OCH3),
3.52-3.71 (m, 2H, H-9 & H-7), 3.85 (dd, J= 11.9, 2.6 Hz, 1H, H-9'), 3.95 (ddd,
J
= 9.3, 6.2, 2.5 Hz, 1H, H-8), 4.33 (m, 1H, H-5), 4.51 (dd, J= 10.9, 1.2 Hz,
1H,
H-6), 4.56 (s, 2H, OCH2), 5.48 (dd, J= 9.6, 2.3 Hz, 1H, H-4), 5.80 (d, J= 2.2
Hz, 1H, H-3), 8.08 (s, 1H, triazole-CH); 13C NMR (75 MHz, D20): 6
21.65(NHCOCH3), 48.68 (C-5), 57.15 (OCH3), 59.94 (C-4), 63.06 (C-9), 64.22
(OCH2), 68.05 (C-7), 69.71 (C-8), 75.34 (C-6), 101.80 (C-3), 123.54 (triazole-
C-
5), 144.08 (C-2), 150.43 (triazole-C-4), 168.75 (COONa), 173.57 (NHCOCH3);
Date recue/ date received 2022-02-18
54
LRMS [C-15H2iN4Na08] (m/z): (+ve ion mode) 432.1 [M+Na].
Methyl 5-acetamido-7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-4-(4-(3-
methoxypheny1)41,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate
(1E832-18).
OAc OAc
LJN0 COOCH3
0Ac
AcHN
N,
0
1E832-18
1H NMR (300 MHz, CDCI3): 6 1.84 (s, 3H, NAG), 2.05 (s, 3H, OAc), 2.06 (s, 3H,
OAc), 2.08 (s, 3H, OAc), 3.83 (s, 3H, COOCH3), 3.84 (s, 3H, OCH3), 4.20 (dd, J
= 12.5, 7.0 Hz, 1H, H-9), 4.32 (m, 1H, H-5), 4.71 (dd, J= 12.5, 2.7 Hz, 1H,
H9'),
4.83 (dd, J= 10.5, 1.9 Hz, 1H, H-6), 5.43 (ddd, J= 6.9, 5.4, 2.6 Hz, 1H, H-8),
5.57 (dd, J= 5.4, 1.9 Hz, 1H, H-7), 5.87 (dd, J= 10.0, 2.5 Hz, 1H, H-4), 6.05
(d,
J= 2.4 Hz, 1H, H-3), 6.79-6.92 (m, 2H, NH, Ph-H-4'), 7.23-7.38 (m, 3H, Ph-H-
2', Ph-H-5', Ph-H-6'), 7.84 (s, 1H, triazole-CH); 13C NMR (75 MHz, CDCI3)
20.73, 20.79, 20.92 (3 OCOCH3), 22.98 (NHCOCH3), 48.79 (C-5), 52.74
(COOCH3), 55.35 (Ar-OCH3), 58.04 (C-4), 62.18 (C-9), 67.74 (C-7), 70.78 (C-8),
76.63 (C-6), 107.19 (C-3), 110.94 (Ph), 114.43 (Ph), 118.20 (Ph), 118.93
(triazole-C-5), 129.97 (Ph), 131.17 (Ph q carbon), 146.02(C2), 148.03
(triazole-
C-4), 160.02 (Ph q carbon), 161.31 (COOCH3), 17012, 170.24, 170.81, 170.99
(NHCOCH3, 3 OCOCH3). LRMS [C27F132N4011] (m/z): (+ve ion mode) 611.2
[M+Na].
Sodium 5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-(4-(3-methoxypheny1)-
[1,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate (1E832-20).
Date recue/ date received 2022-02-18
55
OH OHH
x0;COONa
OH
AcHN
N,
0
1E832-20
NMR (300 MHz, D20): 6 1.86 (s, 3H, NAG), 3.52-3.74 (m, 2H, H-9, H-7),
3.77-3.92 (m, 4H, OCH3, H-9'), 3.97 (m, 1H, H-8), 4.37 (m, 1H, H-5), 4.54 (d,
J
= 10.9 Hz, 1H, H-6), 5.49 (dd, J= 9.6, 2.4 Hz, 1H, H-4), 5.84 (s, 1H, H-3),
6.96
(m, 1H, Ph-H-4'), 7.23-7.48 (m, 3H, Ph-H-2', Ph-H-5', Ph-H-6'), 8.35 (s, 1H,
triazole-CH); 13C NMR (75 MHz, D20): 8 21.71 (NHCOCH3), 48.80 (C-5), 55.39
(OCH3), 60.03 (C-4), 63.12 (C-9), 68.11 (C-7), 69.77 (C-8), 75.39 (C-6),
101.73
(C-3), 110.89 (Ph), 114.54 (Ph), 118.49 (Ph), 120.66 (triazole-C-5), 130.49
(Ph),
130.85 (Ph q carbon), 147.51 (C2), 150.62 (triazole-C-4), 159.29 (Ph q
carbon),
168.77 (COONa), 173.65 (NHCOCH3). LRMS [C201-123N4Na08] (m/z): (+ve ion
mode) 493.0 [M+1]+; HRMS (API) (m/z): [M+1], calcd for C201-124N4Na08[M+1]+
471.148635; found, 471.148177.
Methyl 5-
acetamido-7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-4-(4-
propyl-[1,2,3,]triazol-1-y1)-o-glycero-D-galacto-non-2-enonate (1E832-24).
OAc OAc
COOCH3
OAc
AcHN
N,
1E832-24
1H NMR (300 MHz, CDCI3): 6 0.97 (t, J= 7.3 Hz, 3H, propyl-CH3), 1.73 (m, 2H,
propy1-2'-CH2), 1.83 (s, 3H, NAc), 2.07 (s, 6H, 20Ac), 2.10 (s, 3H, OAc), 2.77
(t,
Date recue/ date received 2022-02-18
56
J= 7.6 Hz, 2H, propy1-1-CH2), 3.83(s, 3H, COOCH3), 4.16 (dd, J = 12.5, 6.0
Hz, 1H, H-9), 4.38 (m, 1H, H-5), 4.58 (dd, J= 12.6, 2.6 Hz, 1H, H-9'), 4.85
(d, J
= 10.6 Hz, 1H, H-6), 5.42 (m, 1H, H-8), 5.56 (d, J = 6.5 Hz, 1H, H-7), 6.01
(s,
1H, H-3), 6.11 (d, J = 10.1 Hz, 1H, H-4), 7.37 (brs, 1H, NH), 7.68 (s, 1H,
triazole-CH); LRMS [C23H32N4010] (m/z): (+ve ion mode) 547.2 [M+Na]
Sodium 5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-(4-propy141,2,3,]triazol-
1-y1)-D-glycero-D-galacto-non-2-enonate (1E832-26).
OH OH
OCOONa
OH
AcHN
N,
ri¨N171
1E832-26
1H NMR (300 MHz, D20): 8 0.92 (t, J = 7.4 Hz, 3H, propyl-CH3), 1.57-1.76 (m,
2H, propy1-2'-CH2), 1.93 (s, 3H, NAG), 2.71 (t, J= 7.3 Hz, 2H, propy1-1-CH2),
3.62-3.77 (m, 2H, H-9, H-7), 3.94 (dd, J= 11.9, 2.7 Hz, 1H, H-9'), 4.04 (ddd,
J=
9.2, 6.3, 2.7 Hz, 1H, H-8), 4.41 (m, 1H, H-5), 4.58 (dd, J= 10.9, 1.3 Hz, 1H,
H-
6), 5.50 (dd, J= 9.7, 2.3 Hz, 1H, H-4), 5.87 (d, J= 2.3 Hz, 1H, H-3), 7.89 (s,
1H,
triazole-CH). LRMS [Ci6H23N4Na07] (m/z): (+ve ion mode) 429.0 [M+Na];
HRMS (API) (m/z): [M+Na] calcd for C16H23N4Na207[M+1]+ 429.1357; found,
429.1361.
Methyl 5-
acetamido-7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-4-(4-
(pyridin-3-y1)41,2,3jtriazol-1-y1)-D-glycero-D-galacto-non-2-enonate (1E832-
25).
Date recue/ date received 2022-02-18
57
OAc OAc
)N!!"-1 0 COOCH3
I
OAc
AcH N :
N ,
N
\ /
N
1E832-25
1H NMR (300 MHz, CDCI3): 6 1.82 (s, 3H, NAG), 2.06 (s, 6H, 20Ac), 2.08 (s, 3H,
OAc), 3.82 (s, 3H, COOCH3), 4.19 (dd, J= 12.5, 7.2 Hz, 1H, H-9), 4.40 (q, J=
9.9 Hz, 1H, H-5), 4.64-4.88 (m, 2H, H-7, H-9'), 5.38 (m, 1H, H-8), 5.57 (dd, J
=
4.8, 1.9 Hz, 1H, H-7), 5.86 (dd, J= 9.9, 2.4 Hz, 1H, H-4), 6.08 (d, J= 2.4 Hz,
1H, H-3), 7.08 (d, J= 9.1 Hz, 1H, NH), 7.36 (dd, J= 7.9, 4.8 Hz, 1H, Pyr-H5'),
8.04 (s, 1H, triazole-CH), 8.14 (d, J= 7.8 Hz, 1H, Pyr-H4'), 8.54 (d, J = 4.8
Hz,
1H, Pyr-H-6'), 8.96 (s, 1H, Pyr-H-2'); 13C NMR (75 MHz, CDCI3) El 20.69,
20.79,
20.94 (3 OCOCH3), 22.89 (NHCOCH3), 48.35 (C-5), 52.81 (COOCH3), 58.57
(C-4), 62.14 (C-9), 67.77 (C-7), 71.17 (C-8), 76.85 (C-6), 106.88 (C-3),
119.07
(triazole-C-5), 123.89 (Pyr), 126.33 (Pyr q carbon), 133.20 (Pyr), 145.13
(triazole-C-4), 146.17 (C2), 146.88 (Pyr), 149.31 (Pyr), 161.25 (COOCH3),
170.16, 170.49, 170.80, 170.95 (NHCOCH3, 3 OCOCH3); LRMS [C25H29N5010]
(m/z): (+ve ion mode) 582.2 [M+Na].
Sodium 5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-(4-(pyridin-3-
y1)-
[1,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate (1E832-27).
Date recue/ date received 2022-02-18
58
OH OH
LJ,OCOONa
OH
AcHN
N,
/
1E832-27
1H NMR (300 MHz, D20): 8 1.92 (s, 3H, NAc), 3.62-3.78 (m, 2H, H-9, H-7), 3.93
(dd, J= 11.9, 2.7 Hz, 1H, H-9'), 4.04 (ddd, J= 9.3, 6.3, 2.6 Hz, 1H, H-8),
4.44
(m, 1H, H-5), 4.61 (dd, J= 10.9, 1.3 Hz, 1H, H-6), 5.59 (dd, J= 9.6, 2.3 Hz,
1H,
H-4), 5.90 (d, J= 2.3 Hz, 1H, H-3), 7.53 (m, 1H, Pyr-H-5'), 8.17 (d, J= 8.0
Hz,
1H, Pyr-H-4'), 8.49-8.60 (m, 2H, triazole-CH, Phyr-H-6'), 8.87 (brs, 1H, Pyr-H-
2'); 13C NMR (75 MHz, D20): 8 21.67 (NHCOCH3), 48.77 (C-5), 60.17 (C-4),
63.08 (C-9), 68.06 (C-7), 69.73 (C-8), 75.36 (C-6), 101.61 (C-3), 121.13
(triazole-C-5), 134.31 (Pyr), 144.68 (C-2), 145.64 (Pyr), 148.42 (Pyr), 150.65
(triazole-C-4), 168.72 (COONa), 173.65 (NHCOCH3). LRMS [C18F120N5Na07]
(m/z): (+ve ion mode) 463.7 [M+1]+; HRMS (API) (m/z): [M+1] calcd for
Ci8H2iN5Na07[M+1]+ 442.133319; found, 442.133358.
Methyl 5-acetamido-7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-4-(4-(4-
methoxypheny1)-[1,2,3,]triazol-1-y1)-o-glycero-o-galacto-non-2-enonate
(1E832-29).
OAc OAc
L.)..7-1 0 COOCH3
OAc
AcHN
¨0
1E832-29
Date recue/ date received 2022-02-18
59
1H NMR (300 MHz, CDCI3): 8 1.88 (s, 3H, NAG), 2.06 (s, 3H, OAc), 2.10 (s,
6H, 20Ac), 3.83 (s, 3H, COOCH3), 3.84 (s, 3H, OCH3), 4.13-4.30 (m, 2H, H-9,
H-5), 4.66 (dd, J= 12.5, 2.6 Hz, 1H, H-9'), 4.83 (dd, J= 10.6, 1.9 Hz, 1H, H-
6),
5.41 (m, 1H, H-8), 5.52 (dd, J= 5.8, 1.8 Hz, 1H, H-7), 5.93 (dd, J= 10.0, 2.5
Hz,
1H, H-4), 6.01-6.16 (m, 2H, H-3, NH), 6.94 (d, J= 8.6 Hz, 2H, Ph-H-3', Ph-H-
5'), 7.61-7.83 (m, 3H, triazole-CH, Ph-H-2', Ph-H-6'); 13C NMR (75 MHz, CDCI3)
El 20.71, 20.78, 20.90 (3 00001-13), 22.90 (NHCOCH3), 48.45 (C-5), 52.70
(COOCH3), 55.31 (Ph-OCH3), 58.17 (C-4), 62.23 (C-9), 67.80 (C-7), 70.92 (C-
8), 76.83 (C-6), 107.40 (C-3), 114.32 (Ph), 117.88 (triazole-C-5), 122.57 (Ph
q
carbon), 127.13 (Ph), 145.93 (C-2), 148.07 (triazole-C-4), 159.87 (Ph q
carbon),
161.33 (COOCH3), 170.10, 170.27, 170.81, 170.99 (NHCOCH3, 3 OCOCH3).
LRMS [C27H32N4011] (m/z): (+ve ion mode) 611.3 [M+Na].
Sodium 5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-(4-(4-methoxypheny1)-
[1,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate (1E832-31).
OH OH
-1-1,000ONa
OH
AcHN -
N,
¨0
1E832-31
1H NMR (300 MHz, D20): 8 1.92 (s, 3H, NAc), 3.63-3.77 (m, 2H, H-9, H-7), 3.85
(s, 3H, OCH3), 3.93 (dd, J= 11.9, 2.7 Hz, 1H, H-9'), 4.03 (ddd, J= 9.6,
6.3,2.6
Hz, 1H, H-8), 4.42 (m, 1H, H-5), 4.59 (dd, J= 10.9, 1.3 Hz, 1H, H-6), 5.52
(dd, J
= 9.6, 2.3 Hz, 1H, H-4), 5.87 (d, J = 2.2 Hz, 1H, H-3), 7.05 (d, J = 9.0 Hz,
2H,
Ph-H-3', Ph-H-5'), 7.68 (d, J = 9.0 Hz, 1H, Ph-H-2', Ph-H-6'), 8.26 (s, 1H,
triazole-CH); 13C NMR (75 MHz, D20): 8 21.65 (NHCOCH3), 48.75 (C-5), 55.39
(OCH3), 60.01 (C-4), 63.08 (C-9), 68.07 (C-7), 69.72 (C-8), 75.35 (C-6),
101.82
(C-3), 114.60 (Ph), 119.78 (triazole-C-5), 122.49 (Ph q carbon), 127.21 (Ph),
Date recue/ date received 2022-02-18
60
147.65 (C-2), 150.49 (triazole-C-4), 159.23 (Ph q carbon), 168.78
(COONa), 173.62 (NHCOCH3). LRMS [C201-123N4Na08] (m/z): (+ve ion mode)
492.6 [M+1]+; HRMS (API) (m/z): [M+1] calcd for C201-124N4Na08 [M+1]
471.148635; found, 471.147452.
Methyl 5-acetamido-7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-4-(4-(2-
methoxypheny1)41 ,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate
(1E832-30).
OAc OAc
LN,0 COOCH3
OAc
AcHN -
N,N
¨0 \
1E832-30
Purification by silica gel chromatography using ethylacetate : hexane (7:1)
yielded (81 mg, 62%) of pure 1E832-30. 1H NMR (300 MHz, CDCI3): 8 1.84 (s,
3H, NAc), 2.05 (s, 3H, OAc), 2.06 (s, 3H, OAc), 2.08 (s, 3H, OAc), 3.83 (s,
3H,
COOCH3), 3.88 (s, 3H, OCH3), 4.20 (dd, J= 12.4, 7.0 Hz, 1H, H-9), 4.37 (m,
1H, H-5), 4.71 (dd, J= 12.4, 2.7 Hz, 1H, H-9'), 4.89 (dd, J=10.5,1.9 Hz, 1H, H-
6), 5.45 (m, 1H, H-8), 5.59 (dd, J= 5.4, 1.9 Hz, 1H, H-7), 5.87 (dd, J= 9.9,
2.5
Hz, 1H, H-4), 6.07 (d, J= 2.4 Hz, 1H, H-3), 6.91 (d, J= 8.3 Hz, 1H, Ph-H-3'),
7.03 (m, 1H, Ph-H-5'), 7.22-7.30 (m, 2H, Ph-H-4', NH), 8.07 (s, 1H, triazole-
CH), 8.17 (dd, J= 7.8, 1.8 Hz, 1H, Ph-H-6'); 13C NMR (75 MHz, CDCI3) El 20.71,
20.76, 20.88 (3 OCOCH3), 22.90 (NHCOCH3), 48.84 (C-5), 52.64 (COOCH3),
55.36 (Ph-OCH3), 57.83 (C-4), 62.24 (C-9), 67.85 (C-7), 70.79 (C-8), 76.75 (C-
6), 107.72 (C-3), 110.87 (Ph), 118.66 (Ph q carbon), 120.88 (Ph), 122.32
(triazole-C-5), 127.37 (Ph), 129.24 (Ph), 143.40 (triazole-C4), 145.82 (C-2),
155.68 (Ph q carbon), 161.44 (COOCH3), 170.06, 170.19, 170.75, 171.04
(NHCOCH3, 3 OCOCH3). LRMS [C27F132N4011] (m/z): (+ve ion mode) 611.2
Date recue/ date received 2022-02-18
61
[M+Na]; HRMS (API) (m/z): [M+Na] calcd for C27F132N4Na0ii [M+Na]
611.195979; found, 611.196049.
Sodium 5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-(4-(2-methoxypheny1)-
[1 ,2,3,]triazol-1-y1)-n-g/ycero-n-ga/acto-non-2-enonate (1E832-37).
OH OH
NI-11,000ONa
OH
AcHN -
N,N
¨0 \
1E832-37
Yield = 91%. 1H NMR (300 MHz, D20): 8 1.91 (s, 3H, NAG), 3.63-3.77 (m, 2H,
H-9, H-7), 3.86-3.97 (m, 4H, H-9', OCH3), 4.04 (ddd, J= 9.3, 6.3, 2.6 Hz, 1H,
H-
8), 4.45 (m, 1H, H-5), 4.60 (dd, J= 10.9, 1.2 Hz, 1H, H-6), 5.53 (dd, J=
9.6,2.3
Hz, 1H, H-4), 5.90 (d, J= 2.2 Hz, 1H, H-3), 7.08-7.14 (m, 2H, Ph-H-3', Ph-H-
5'),
7.34-7.49 (m, 1H, Ph-H-4'), 7.92 (dd, J = 8.0, 1.7 Hz, H-6'), 8.32 (s, 1H,
triazole-CH); 13C NMR (75 MHz, D20): 8 21.67 (NHCOCH3), 48.59 (C-5), 55.38
(OCH3), 59.81 (C-4), 63.09 (C-9), 68.11 (C-7), 69.74 (C-8), 75.40 (C-6),
101.95
(C-3), 111.84 (Ph), 117.87 (Ph q carbon), 121.00 (Ph), 123.12 (triazole-C-5),
127.27 (Ph), 130.05 (Ph), 143.23 (triazole-C-4), 150.33 (C-2), 155.70 (Ph q
carbon), 168.81 (COONa), 173.59 (NHCOCH3). LRMS [C201-123N4Na08] (m/z):
(+ve ion mode) 493.2 [M+1]t
Methyl 7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-5-isobutyramido-4-(4-
(2-methoxypheny1)41,2,3,]triazol-1-y1)-D-Wycero-b-gaiacto-non-2-enonate
(1E889-23).
Date recue/ date received 2022-02-18
62
OAc OAc
LJ,OCOOCH3
OAcI\/
F;1\10
\
o/
1E889-23
1H NMR (300 MHz, CDCI3): 6 1.00-1.04 (m, 6H, isobutyry1-2CH3), 2.08 (s, 6H,
20Ac), 2.10 (s, 3H, OAc), 2.25-2.34 (m, 1H, isobutyryl-CH), 3.84 (s, 3H,
COOCH3), 3.88 (s, 3H, Ph-OCH3), 4.20-4.28 (m, 2H, H-9, H-5), 4.71 (dd, J =
12.5, 2.6 Hz, 1H, H-9), 4.99 (d, J= 10.5 Hz, 1H, H-6), 5.43 (m, 1H, H-8), 5.55
(dd, J= 5.4, 1.6 Hz, 1H, H-7), 6.03 (dd, J= 10.1, 2.4 Hz, 1H, H-4), 6.11 (d,
J=
2.3 Hz, 1H, H-3), 6.79 (d, J= 8.3 Hz, 1H, NH), 6.93 (d, J=8.3 Hz, 1H, Ph-H-
3'),
7.05 (m, 1H, Ph-H-5'), 7.29 (m, 1H, Ph-H-4'), 8.04 (s, 1H, triazole-CH), 8.2
(d, J
= 7.9 Hz, 1H, Ph-H-6'); 13C NMR (75 MHz, CDCI3): El 18.86, 19.34, 20.80, 20.95
(3 OCOCH3, isobutyry1-2CH3), 35.42 (isobutyryl-CH), 49.31 (C-5), 52.68
(COOCH3), 55.29 (Ph-OCH3), 57.12 (C-4), 62.19 (C-9), 67.74 (C-7), 70.75 (C-
8), 76.30 (C-6), 107.73(C-3), 110.71 (Ph), 118.68 (Ph q carbon), 120.89 (Ph),
122.62 (triazole-C-5), 127.51 (Ph), 129.21 (Ph), 143.30 (triazole-C-5), 145.68
(C-2), 155.68 (Ph q carbon), 161.56 (COOCH3), 170.10, 170.20, 170.68 (3
OCOCH3), 178.05(isobutyryl-00). LRMS [C29H36N4011] (m/z): (+ve ion mode)
639.1 [M+Na]; HRMS (API) (m/z): [M+Na] calcd for C29H36N4Na011 [M+Na]
639.227279; found, 639.225897.
Sodium 2,6-
anhydro-3,4,5-trideoxy-5-isobutyramido-4-(4-(2-
methoxypheny1)-[1,2,3,]triazol-1-y1)-b-glycero-b-galacto-non-2-enonate
(1E889-34).
Date recue/ date received 2022-02-18
63
OH OH
LJ,OCOONa
OH
-11to
0
1E889-34
1H NMR (300 MHz, D20): 8 0.90 (d, J= 6.9 Hz, 3H, isobutyryl-CH3), 0.97 (d, J=
6.9 Hz, 3H, isobutyryl-CH3), 2.31 (m, 1H, isobutyryl-CH), 3.53 (d, J= 9.4 Hz,
1H, H-7), 3.60 (dd, J= 11.5, 5.4 Hz, 1H, H-9), 3.79 (dd, J= 11.4, 3.0 Hz, 1H,
H-
9'), 3.85-3.91 (m, 4H, H-8, Ph-OCH3), 4.39-4.55 (m, 2H, H-5, H-6), 5.61 (dd,
J=
9.7, 2.2 Hz, 1H, H-4), 5.72 (d, J= 2.2 Hz, 1H, H-3), 6.89-7.10 (m, 2H, Ph-H-
3',
Ph-H-5'), 7.27 (ddd, J= 8.7,7.4, 1.7 Hz, 1H, H-4'), 8.02 (dd, J= 7.7, 1.7 Hz,
1H,
Ph-H-6'), 8.23 (s, 1H, triazole-CH); 13C NMR (75 MHz, D20): 6 18.38, 18.53
(isobutyry1-2CH3), 35.09 (isobutyryl-CH), 48.18 (C-5), 55.34 (OCH3), 59.66 (C-
4), 63.08 (C-9), 68.18 (C-7), 69.76 (C-8), 75.44 (C-6), 102.15 (C-3), 111.80
(Ph), 117.86 (Ph q carbon), 121.00 (Ph), 123.47 (triazole-C-5), 127.21 (Ph),
130.05 (Ph) , 143.12 (triazole-C-4), 150.16 (C-2), 155.70 (Ph q carbon),
168.84
(COONa), 180.64 (NHCOCH3); LRMS [C22H28N408] (m/z): (+ve ion mode)499.1
[M+Na]; HRMS (API) (m/z): [M+Na] calcd for C22H28N4Na08 [M+Na]
499.179935; found, 499.179943.
Methyl 5-
acetamido-7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-4-(4-
pheny141,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate (1E889-45).
Date recue/ date received 2022-02-18
64
OAc OAc
111,1 OCOOCH3
OAc,
AcHN
N,
1E889-45
Purification by silica gel chromatography using ethylacetate : hexane (5:1)
yielded (88 mg, 70%) of pure 1E889-45. 1H NMR (300 MHz, CDCI3): 8 1.79 (s,
3H, NAc), 2.04 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.06 (s, 3H, OAc), 3.81 (s,
3H,
COOCH3), 4.18 (dd, J= 12.4, 7.2 Hz, 1H, H-9), 4.42 (m, 1H, H-5), 4.72 (dd, J=
12.6, 2.7 Hz, 1H, H-9'), 4.79 (dd, J= 10.5, 1.6 Hz, 1H, H-6), 5.42 (m, 1H, H-
8),
5.58 (dd, J= 5.1, 1.8 Hz, 1H, H-7), 5.83 (dd, J= 10.0, 2.4 Hz, 1H, H-4), 6.04
(d,
J= 2.3 Hz, 1H, H-3), 7.20-7.42 (m, 4H, NH, Ph-H-3', Ph-H-4', Ph-H-5'), 7.72
(dd, J= 8.2, 1.3 Hz, 2H, Ph-H-2', Ph-H-6'), 7.88 (s, 1H, triazole-CH); 13C NMR
(75 MHz, CDCI3) El 20.70, 20.80, 20.90 (3 00001-13), 22.85 (NHCOCH3), 48.26
(C-5), 52.71 (COOCH3), 58.41 (C-4), 62.26 (C-9), 67.80 (C-7), 70.97 (C-8),
76.95 (C-6), 107.37 (C-3), 118.76 (triazole-C-5), 125.77 (Ph), 128.51 (Ph),
128.91 (Ph), 129.85 (Ph, q carbon), 145.95 (C-2), 148.13 (triazole-C-4),
161.32
(COOCH3), 170.04, 170.30, 170.84, 170.99 (NHCOCH3, 3 OCOCH3). LRMS
[C26H301\14010] (m/z): (+ve ion mode) 581.0 [M+Na]; HRMS (API) (m/z): [M+Na]
calcd for C26H301\14Na010[M+Na] 581.185414; found, 581.184724.
Sodium 5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-(4-pheny141,2,3,priazol-
1-y1)-D-glycero-D-galacto-non-2-enonate (1E889-52).
Date recue/ date received 2022-02-18
65
OH OH
LJ,OCOONa
OH
AcHN-
N,N
1E889-52
Yield = 96%. 1H NMR (300 MHz, D20): 51.87 (s, 3H, NAc), 3.64 (dd, J= 12.1,
6.4 Hz, 1H, H-9), 3.69 (dd, J= 9.6, 1.4 Hz, 1H, H-7), 3.89 (dd, J= 11.9, 2.7
Hz,
1H, H-9'), 4.00 (ddd, J= 9.3, 6.3, 2.7 Hz, 1H, H-8), 4.39 (m, 1H, H-5), 4.56
(dd,
J= 10.8, 1.4 Hz, 1H, H-6), 5.49 (dd, J= 9.7, 2.3 Hz, 1H, H-4), 5.83 (d, J= 2.2
Hz, 1H, H-3), 7.40 (m, 1H, Ph-H4'), 7.46 (dd, J= 8.4, 6.9 Hz, 2H, Ph-H-3', Ph-
H-
5'), 7.71 (d, J= 7.1 Hz, 2H, Ph-H-2', Ph-H-6'), 8.28 (s, 1H, triazole-CH); 13C
NMR (75 MHz, D20): 6 21.63 (NHCOCH3), 48.70 (C-5), 59.96 (C-4), 63.05 (C-
9), 68.03 (C-7), 69.69 (C-8), 75.31 (C-6), 101.75 (C-3), 120.41 (Ph), 125.61
(Ph), 128.77 (triazole-C-5), 129.10 (Ph), 129.28 (Ph q carbon), 147.74
(triazole-
C-4), 150.48 (C-2), 168.75 (COONa), 173.58 (NHCOCH3). LRMS
[Ci9H21N4Na07] (m/z): (+ve ion mode) 463.1 [M+Na]; HRMS (API) (m/z):
[M+1] calcd for C19H22N4Na07[M+H] 441.138070; found, 441.140189.
Methyl 7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-5-isobutyramido-4-(4-
methoxymethy141,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate
(1E927-57).
OAc OAc
COOCH3
OAc
HN
N`r\I
o
1E927-57
Purification by silica gel chromatography using ethylacetate : acetone (9:1)
Date recue/ date received 2022-02-18
66
yielded (60 mg, 66%) of pure 1E927- 57. 1H NMR (300 MHz, CDCI3): 8 0.97
(d, J = 6.9 Hz, 3H, isobut-CH3), 1.01 (d, J = 6.8 Hz, 3H, isobut-CH3), 2.05
(s,
3H, OAc), 2.08 (s, 6H, 20Ac), 2.24 (m, 1H, isobut-CH), 3.37 (s, 3H, OCH3),
3.81 (s, 3H, COOCH3), 4.14-4.29 (m, 2H, H-9, H-5), 4.51 (s, 2H, OCH2), 4.68
(dd, J= 12.5, 2.6 Hz, 1H, H-9'), 4.84 (dd, J= 10.5, 1.7 Hz, 1H, H-6), 5.38
(ddd,
J = 6.6, 5.5, 2.5 Hz, 1H, H-8), 5.48 (dd, J = 5.5, 1.7 Hz, 1H, H-7), 5.91 (dd,
J =
10.0, 2.4 Hz, 1H, H-4), 6.02 (d, J = 2.4 Hz, 1H, H-3), 6.44 (d, J = 8.7 Hz,
1H,
NH), 7.59 (s, 1H, triazole-CH); 13C NMR (75 MHz, CDCI3): El 18.81, 19.30,
20.74, 20.90 (3 OCOCH3, isobut-2CH3), 35.51 (isobut-CH), 48.79 (C-5), 52.69
(COOCH3), 57.59 (C-4), 58.38 (OCH3), 62.08 (C-9), 65.73 (OCH2), 67.66 (C-7),
70.79 (C-8), 76.24 (C-6), 107.07 (C-3), 121.54 (triazole-C-5), 145.39
(triazole-C-
4), 145.82 (C-2), 161.30 (COOCH3), 170.15, 170.23, 170.69 (3 OCOCH3),
177.87 (isobut-CO). LRMS [C24H34N4011] (m/z): (+ve ion mode) 577.2 [M+Na].
Sodium 2,6-anhydro-3,4,5-trideoxy-5-isobutyramido-4-(4-methoxymethyl-
[1,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate (1E927-60).
OH OH
L=11-1,000ONa
OH
IN110
51/4N
0
1E927-60
Yield = 92%. 1H NMR (300 MHz, D20): 8 0.98 (d, J = 7.0 Hz, 3H, isobut-CH3),
1.03 (d, J = 6.9 Hz, 3H, isobut-CH3), 2.46 (m, 1H, isobut-CH), 3.39 (s,
3H2OCH3), 3.65-3.76 (m, 2H, H-9, H-7), 3.94 (dd, J= 11.9, 2.7 Hz, 1H, H-9'),
4.04 (ddd, J= 9.3, 6.3, 2.6 Hz, 1H, H-8), 4.49 (m, 1H, H-5), 4.60-4.65 (m, 3H,
H-
6, OCH2), 5.61 (dd, J= 9.7, 2.3 Hz, 1H, H-4), 5.87(d, J = 2.2 Hz, 1H, H-3),
8.18
(s, 1H, triazole-CH); 13C NMR (75 MHz, D20): 8 18.43 (isobut-CH3), 18.64
(isobut-CH3), 35.10 (isobut-CH), 48.19 (C-5), 57.24 (OCH3), 59.86 (C-4), 63.07
(C-9), 64.24 (OCH2), 68.13 (C-7), 69.82 (C-8), 75.43 (C-6), 102.02 (C-3),
Date recue/ date received 2022-02-18
67
123.65 (triazole-C-5), 144.07 (triazole- C-4), 150.30 (C-2), 168.81 (COONa),
180.66 (isobut-CO). LRMS [Ci7H25N4Na08] (m/z): (+ve ion mode) 459.0
[M+Na]; HRMS (API) (m/z): [M+Na] calcd for Ci7H25N4Na208 [M+Na]
459.1462; found, 459.1458.
Methyl 7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-4-(4-
isobutyl-
[1,2,3,]triazol-1-y1)-5-isobutyramido-D-glycero-D-galacto-non-2-enonate
(1E927-58).
OAc OAc
NI-1_,OCOOCH3
OAc I
1E927-58
1H NMR (300 MHz, CDC13): 8 0.90 (d, J= 6.6 Hz, 6H, isobuty1-2CH3), 0.96 (d, J
= 6.9 Hz, 3H, isobutyryl-CH3), 1.00 (d, J= 6.8 Hz, 3H, isobutyryl-CH3), 1.90
(m,
1H, isobutyl-CH), 2.05 (s, 3H, OAc), 2.08 (s, 6H, 20Ac), 2.22 (m, 1H,
isobutyryl-
CH), 2.53 (d, J= 7.0 Hz, 2H, isobutyl-CH2), 3.82 (s, 3H, COOCH3), 4.13-4.36
(m, 2H, H-9, H-5), 4.70 (dd, J= 12.5, 2.6 Hz, 1H, H-9'), 4.81 (dd, J= 10.5,
1.7
Hz, 1H, H-6), 5.38 (ddd, J = 6.6, 5.4, 2.5 Hz, 1H, H-8), 5.49 (dd, J = 5.5,
1.7 Hz,
1H, H-7), 5.87 (dd, J= 10.1, 2.4 Hz, 1H, H-4), 6.02 (d, J = 2.4 Hz, 1H, H-3),
6.41 (d, J = 8.8 Hz, 1H, NH), 7.32 (s, 1H, triazole-CH); 13C NMR (75 MHz,
CDC13): 6 18.83, 19.29, 20.76, 20.92 (3 OCOCH3 + isobutyry1-2CH3), 22.23
(isobuty1-2CH3), 28.70 (isobutyl-CH), 34.68 (isobutyl-CH2), 35.55 (isobutyryl-
CH), 48.48 (C-5), 52.68 (COOCH3), 57.47 (C-4), 62.11 (C-9), 67.69 (C-7), 70.89
(C-8), 76.44 (C-6), 107.53 (C-3), 120.36 (triazole-C-5), 145.56 (C-2), 147.53
(triazole-C-4), 161.40 (COOCH3), 170.15, 170.24, 170.70 (3 OCOCH3), 177.74
(isobutyryl-CO). LRMS [C26H38N4010] (m/z): (+ve ion mode) 589.3 [M+Na].
Date recue/ date received 2022-02-18
68
Sodium 2,6-anhydro-3,4,5-trideoxy- 4-(4-isobuty1-[1,2,3,]triazol-1-y1)-5-
isobutyramido-n-g/ycero-o-ga/acto-non-2-enonate.
OH OH
LJN,OCOONa
OH
r_\LN
1E927-67
1H NMR (300 MHz, D20): 8 0.90 (d, J= 6.6 Hz, 6H, isobuty1-2CH3), 0.97 (d, J=
6.9 Hz, 3H, isobutyryl-CH3), 1.02 (d, J= 6.9 Hz, 3H, isobutyryl-CH3), 1.92 (m,
1H, isobutyl-CH), 2.43 (m, 1H, isobutyryl-CH), 2.60(d, J=6.9 Hz, 2H, isobutyl-
CH2), 3.62-3.74 (m, 2H, H-9, H-7), 3.93 (dd, J= 11.9, 2.7 Hz, 1H, H-9'), 4.02
(ddd, J= 9.3, 6.3, 2.6 Hz, 1H, H-8), 4.47 (m, 1H, H-5), 4.56 (d, J= 11.1 Hz,
1H,
H-6), 5.53 (dd, J= 9.7, 2.2 Hz, 1H, H-4), 5.84 (d, J= 2.2 Hz, 1H, H-3), 7.88
(s,
1H, triazole-CH); 13C NMR (75 MHz, D20): 6 18.45 (isobutyryl-CH3), 18.61
(isobutyryl-CH3), 21.31 (isobuty1-2CH3), 28.17 (isobutyl-CH), 33.54 (isobutyl-
CH2), 35.12 (isobutyryl-CH), 48.09 (C-5), 59.53 (C-4), 63.07 (C-9), 68.14 (C-
7),
69.78 (C-8), 75.47 (C-6), 102.30 (C-3), 121.99 (triazole-C-5), 147.82
(triazole-C-
4), 150.05 (C-2), 168.88 (COONa), 180.46 (isobutyryl-CO). LRMS
[C19H29N4Na07] (m/z): (+ve ion mode) 471.2 [M+Na], 449.2; HRMS (API) (m/z):
[M+Na] calcd for Ci9H29N4Na207[M+Na] 471.1826; found, 471.1823.
Methyl 7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-5-isobutyramido-4-(4-
phenyl-[1 ,2,3,]triazol-1-y1)-D-Wycero-D-gaiacto-non-2-enonate (1E984-4).
Date recue/ date received 2022-02-18
69
OAc OAc
LJ,OCOOCH3
-11to 1:\LN
1E984-4
Purification by silica gel chromatography using ethylacetate : hexane (4:1)
yielded (72 mg, 74%) of purelE984-4. 1H NMR (300 MHz, CDCI3): 6 0.95 (d, J=
6.8 Hz, 3H, isobut-CH3), 0.99 (d, J= 6.9 Hz, 3H, isobut-CH3), 2.06 (s, 3H,
OAc),
2.09 (s, 6H, 20Ac), 2.20-2.27 (m, 1H, isobut-CH), 3.83 (s, 3H, COOCH3), 4.16-
4.39 (m, 2H, H-9, H-5), 4.70 (dd, J= 12.5, 2.6 Hz, 1H, H-9'), 4.88 (dd, J=
10.5,
1.7 Hz, 1H, H-6), 5.40 (m, 1H, H-8), 5.52 (dd, J= 5.4, 1.7 Hz, 1H, H-7), 5.99
(dd, J= 10.0, 2.4 Hz, 1H, H-4), 6.08 (d, J=2.4 Hz, 1H, H-3), 6.51 (d, J=8.7
Hz,
1H, NH), 7.26-7.43 (m, 3H, Ph-H-3', Ph-H-4', Ph-H-5'), 7.74 (d, J= 7.2 Hz, 2H,
Ph-H-2', Ph-H-5'), 7.81 (s, 1H, triazole-CH); 13C NMR (75 MHz, CDCI3): El
18.83,
19.31, 20.76, 20.92 (3 OCOCH3, isobut-2CH3), 35.55 (isobut-CH), 48.74 (C-5),
52.72 (COOCH3), 57.67 (C-4), 62.12 (C-9), 67.72 (C-7), 70.84 (C-8), 76.39 (C-
6), 107.25 (C-3), 118.84 (triazole-C-5), 125.83 (Ph), 128.47 (Ph), 128.89
(Ph),
129.97 (Ph q carbon), 145.81 (C-2), 148.19 (triazole-C-4), 161.35 (COOCH3),
170.18, 170.26, 170.71 (3 OCOCH3), 178.00 (isobut-CO). LRMS [C28F134N4010]
(m/z): (+ve ion mode) 608.9 [M+Na].
Sodium 2,6-
anhydro-3,4,5-trideoxy-5-isobutyramido-4-(4-phenyl-
[1,2,3,]triazol-1-y1)-b-glycero-b-galacto-non-2-enonate (1E984-5).
Date recue/ date received 2022-02-18
70
OH OH
LJN,OCOONa
OH
0
1E984-5
Yield = 89%. 1H NMR (300 MHz, D20): 8 0.94 (d, J = 6.9 Hz, 3H, isobut-CH3),
0.99 (d, J= 6.9 Hz, 3H, isobut-CH3), 2.43 (m, 1H, isobut-CH), 3.60-3.76(m, 2H,
H-9, H-7), 3.93 (dd, J= 12.0, 2.7 Hz, 1H, H-9'), 4.04 (ddd, J= 9.2, 6.3, 2.6
Hz,
1H, H-8), 4.51 (m, 1H, H-5), 4.62 (d, J= 11.0 Hz, 1H, H6), 5.58 (dd, J=
9.7,2.3
Hz, 1H, H-4), 5.88 (d, J= 2.2 Hz, 1H, H-3), 7.42-7.54 (m, 3H, Ph-H-3', Ph-H-
4',
Ph-H-5'), 7.78 (d, J= 7.1 Hz, 2H, Ph-H-2', Ph-H-6'), 8.36 (s, 1H, triazole-
CH);
13C NMR (75 MHz, D20): 6 18.38 (isobut-CH3), 18.65 (isobut-CH3), 35.10
(isobut-CH), 48.23 (C-5), 59.91 (C-4), 63.07 (C-9), 68.15 (C-7), 69.76 (C-8),
75.41 (C-6), 101.96 (C-3), 120.66 (Ph), 125.67 (Ph), 128.81 (triazole-C-5),
129.16 (Ph), 129.36 (Ph q carbon), 147.71 (triazole-C-4), 150.32 (C-2), 168.80
(COONa), 180.67 (isobut-CO). LRMS [C211-123N4Na07] (m/z): (+ve ion mode)
491.2 [M+Na]; HRMS (API) (m/z): [M+Na] calcd for C211-123N4Na207 [M+Na]
491.1513 ; found, 491.1515.
Methyl 5-acetamido-7,8,9-tri-O-acety1-2,6-anhydro-4-(4-(2-chloropheny1)-
[1,2,3,]triazol-1-y1)-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonate
(1E1172-70).
Date recue/ date received 2022-02-18
71
OAc OAc
yN!1,-1 OCOOCH3
N,N
ci j
1E1172-70
Purification by silica gel chromatography using acetone: hexane (3:2) yielded
(76%) of pure 1E1172-70. 1H NMR (400 MHz, CDCI3): 81.81 (s, 3H, NAc), 2.05
(s, 6H, 2 OAc), 2.07 (s, 3H, OAc), 3.82 (s, 3H, COOCH3), 4.20 (dd, J= 12.5,
7.0
Hz, 1H, H-9), 4.30 (q, J= 9.8 Hz, 1H, H-5), 4.71 (dd, J= 12.5, 2.7 Hz, 1H, H-
9'),
4.86 (dd, J= 10.7, 1.9 Hz, 1H, H-6), 5.42 (ddd, J= 6.8, 5.4, 2.6 Hz, 1H, H-8),
5.55 (dd, J= 5.3, 1.9 Hz, 1H, H-7), 5.91 (dd, J= 10.0, 2.4 Hz, 1H, H-4), 6.09
(d,
J= 2.3 Hz, 1H, H-3), 6.93 (d, J= 8.8 Hz, 1H, NH), 7.26 (td, J= 7.8, 1.8 Hz,
1H,
Ph-H), 7.34 (td, J= 7.6, 1.4 Hz, 1H, Ph-H), 7.41 (dd, J= 8.0, 1.3 Hz, 1H, Ph-
H),
8.05 (dd, J= 7.9, 1.7 Hz, 1H, Ph-H), 8.19 (s, 1H, triazole-CH); 13C NMR (101
MHz, CDCI3) El 20.75, 20.80, 20.93 (3 0000H3), 22.94 (NHCOCH3), 49.00 (C-
5), 52.74 (COOCH3), 57.92 (C-4), 62.18 (C-9), 67.81 (C-7), 70.86 (C-8), 76.48
(C-6), 107.11 (C-3), 122.63 (triazole-C-5), 127.22 (Ph), 128.62 (Ph, q
carbon),
129.44 (Ph), 129.80 (Ph), 130.28 (Ph), 131.42 (Ph, q carbon), 144.31 (triazole-
C-4), 145.96 (C-2), 161.34 (COOCH3), 170.20, 170.28, 170.79, 171.01
(NHCOCH3, 3 OCOCH3); LRMS [C26H29CIN4010] (m/z): (+ve ion mode) 615.1
[M+Na].
Sodium 5-acetamido-2,6-anhydro-4-(4-(2-chloropheny1)-(1 ,2,3,]triazol-1-y1)-
3,4,5-trideoxy-o-glycero-D-galacto-non-2-enonate (1E1172-78).
Date recue/ date received 2022-02-18
72
OH OH
yllizOCOONa
OH
AcHN
N,N
Cl
1E1172-78
Yield = 89%. 1H NMR (400 MHz, D20): 6 1.93 (s, 3H, NAc), 3.68 (dd, J= 12.0,
6.4 Hz, 1H, H-9), 3.73 (dd, J= 9.7, 1.3 Hz, 1H, H-7), 3.93 (dd, J= 12.0, 2.7
Hz,
1H, H-9'), 4.03 (ddd, J= 9.3,6.3, 2.6 Hz, 1H, H-8), 4.48 (t, J= 10.3 Hz, 1H, H-
5), 4.61 (dd, J= 11.1, 1.3 Hz, 1H, H-6), 5.58 (dd, J= 9.7, 2.3 Hz, 1H, H-4),
5.93
(d, J= 2.2 Hz, 1H, H-3), 7.37-7.51 (m, 2H, 2Ph-H), 7.58 (dd, J= 7.5, 1.9 Hz,
1H, Ph-H), 7.81 (dd, J= 7.0, 2.5 Hz, 1H, Ph-H), 8.49 (s, 1H, triazole-CH); 13C
NMR (101 MHz, D20): 8 21.70 (NHCOCH3), 48.67 (C-5), 60.10 (C-4), 63.09 (C-
9), 68.10 (C-7), 69.74 (C-8), 75.39 (C-6), 101.87 (C-3), 123.78 (triazole-C-
5),
127.36 (Ph), 128.03 (Ph q carbon), 129.94 (Ph), 130.10 (Ph), 130.19 (Ph),
131.50 (Ph q carbon), 144.37 (triazole-C-4), 150.41 (C-2), 168.78 (COONa),
173.56 (NHCOCH3); LRMS [Ci9H20CIN4Na07] (m/z): (+ve ion mode) 497.1
[M+Na].
Methyl 5-acetamido-7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-4-(4-(2-
methylpheny1)-(1,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate
(1E1172-72).
Date recue/ date received 2022-02-18
73
OAc OAc
yN!1,-1 OCOOCH3
I
OAci-..........õ,-
AcHN :
N,
H3C
N
1E1172-72
Purification by silica gel chromatography using acetone: hexane (4:3) yielded
(81%) of purelE1172-72. 1H NMR (400 MHz, CDCI3): 81.76 (s, 3H, NAG), 2.04
(s, 3H, OAc), 2.06 (s, 3H, OAc), 2.07 (s, 3H, OAc), 2.33 (s, 3H, Ph-CH3), 3.82
(s, 3H, COOCH3), 4.19 (dd, J= 12.5, 7.1 Hz, 1H, H-9), 4.39 (q, J= 9.9 Hz, 1H,
H-5), 4.71 (dd, J= 12.4, 2.7 Hz, 1H, H-9'), 4.82 (dd, J= 10.4, 2.0 Hz, 1H, H-
6),
5.41 (ddd, J= 7.6, 5.1, 2.7 Hz, 1H, H-8), 5.57 (dd, J= 5.2, 1.9 Hz, 1H, H-7),
5.86 (dd, J= 10.2, 2.4 Hz, 1H, H-4), 6.07 (d, J= 2.3 Hz, 1H, H-3), 7.16-7.30
(m,
4H, NH, 3PH-H), 7.60 (m, 1H, Ph-H), 7.70 (s, 1H, triazole-CH); 13C NMR (101
MHz, CDCI3) El 20.72, 20.81, 20.93 (3 0000H3), 21.09 (Ph-CH3), 22.82
(NHCOCH3), 48.63 (C-5), 52.73 (COOCH3), 58.03 (C-4), 62.21 (C-9), 67.76 (C-
7), 70.93 (C-8), 76.72 (C-6), 107.38 (C-3), 121.28 (triazole-C-5), 126.16
(Ph),
128.58 (Ph), 128.94 (Ph), 129.23 (Ph, q carbon), 130.90 (Ph), 135.64 (Ph, q
carbon), 145.85(C-2), 147.15 (triazole-C-4), 161.37 (COOCH3), 170.07,170.30,
170.80, 171.06 (NHCOCH3, 3 OCOCH3); LRMS [C27H32N4010] (m/z): (+ve ion
mode) 595.2 [M+Na].
Sodium 5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-(4-(2-methylpheny1)-
[1,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate (1E1172-82).
Date recue/ date received 2022-02-18
74
OH OH
yllizOCOONa
OH
AcHN
N,
/!\I
H3C
1E1172-82
Yield = 85%. 1H NMR (400 MHz, D20): 6 1.93 (s, 3H, NAc), 2.36 (s, 3H, Ph-
CH3), 3.68 (dd, J= 11.9, 6.3 Hz, 1H, H-9), 3.74 (d, J= 9.7 Hz, 1H, H-7), 3.93
(dd, J= 12.0, 2.7 Hz, 1H, H-9'), 4.03 (ddd, J= 9.3, 6.3, 2.6 Hz, 1H, H-8),
4.48 (t,
J=10.3 Hz, 1H, H-5), 4.60 (dd, J=10.8,1.3 Hz, 1H, H-6), 5.58 (dd, J=9.7,2.3
Hz, 1H, H-4), 5.92 (d, J= 2.3 Hz, 1H, H-3), 7.29-7.46 (m, 3H, 3Ph-H), 7.58 (d,
J
= 7.4 Hz, 1H, Ph-H), 8.19 (s, 1H, triazole-CH); 13C NMR (101 MHz, D20): 8
19.77 (Ph-CH3), 21.67 (NHCOCH3), 48.69 (C-5), 60.06 (C-4), 63.09 (C-9), 68.10
(C-7), 69.74 (C-8), 75.39(C-6), 101.92 (C-3), 122.60 (triazole-C-5), 126.17
(Ph),
128.94 (Ph q carbon), 129.01 (Ph), 129.03 (Ph), 130.76 (Ph), 136.45 (Ph q
carbon), 146.87 (triazole-C-4), 150.42 (C-2), 168.80 (COONa), 173.52
(NHCOCH3); LRMS [C201-123N4Na07] (m/z): (+ve ion mode) 477.2 [M+Na].
Methyl 5-acetamido-7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-4-(4-(2-
(trifluoromethyl)pheny1)41,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-
enonate (1E1172-74).
OAc OAc
000OCH3
AcHN
N,
F3C
1E1172-74
Purification by silica gel chromatography using acetone: hexane (3:2) yielded
Date recue/ date received 2022-02-18
75
(90%) of pure 1E1172-74. 1H NMR (400 MHz, CDCI3): 6 1.75 (s, 3H,
NAc), 2.04 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.08 (s, 3H, OAc), 3.83 (s, 3H,
COOCH3), 4.14-4.35 (m, 2H, H-9, H-5), 4.70 (dd, J= 12.4, 2.6 Hz, 1H, H-9'),
4.92 (dd, J= 10.6, 1.8 Hz, 1H, H-6), 5.42 (ddd, J= 6.8, 5.4, 2.6 Hz, 1H, H-8),
5.54 (dd, J= 5.5, 1.8 Hz, 1H, H-7), 5.97 (dd, J= 10.1, 2.4 Hz, 1H, H-4), 6.08
(d,
J= 2.3 Hz, 1H, H-3), 6.99 (d, J= 8.5 Hz, 1H, NH), 7.48 (t, J= 7.7 Hz, 1H, Ph-
H), 7.61 (td, J= 7.7, 1.4 Hz, 1H, Ph-H), 7.72 (dd, J= 8.1, 1.4 Hz, 1H, Ph-H),
7.75-7.84 (m, 2H, Ph-H, triazole-CH); 13C NMR (101 MHz, CDCI3) El 20.76,
20.79, 20.92 (3 OCOCH3), 22.73 (NHCOCH3), 49.38 (C-5), 52.74 (COOCH3),
57.48 (C-4), 62.16 (C-9), 67.80 (C-7), 70.79 (C-8), 76.25 (C-6), 107.09 (C-3),
122.58 (Ph, q carbon), 122.82 (q, J= 5.1, 4.6 Hz, triazole-C-5), 125.29 (Ph, q
carbon), 126.22 (q, J= 5.5 Hz, Ph), 127.61 (q, J= 30.4 Hz, CF3), 128.71 (Ph),
131.79 (Ph), 132.09 (Ph), 144.40 (triazole-C-4), 145.84 (C-2), 161.35
(COOCH3), 170.20, 170.26, 170.75, 171.19 (NHCOCH3, 3 OCOCH3); LRMS
[C27H29F3N4010] (m/z): (+ve ion mode) 649.1 [M+Na]t
Sodium 5-
acetamido-2,6-anhydro-3,4,5-trideoxy-4-(4-(2-
(trifluorometyppheny1)41,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-
enonate (1E1172-83).
OH OH
yNtizi
0 COONa
OH
AcHN
N,
F3C
1E1172-83
Yield = 77%. 1H NMR (400 MHz, D20): 6 1.94 (s, 3H, NAG), 3.68 (dd, J = 11.8,
6.3 Hz, 1H, H-9), 3.73 (d, J= 9.6 Hz, 1H, H-7), 3.93 (dd, J= 11.9, 2.7 Hz, 1H,
H-9'), 4.03 (ddd, J= 9.3, 6.2, 2.6 Hz, 1H, H-8), 4.51 (t, J= 10.2 Hz, 1H, H-
5),
4.59 (d, J= 10.9 Hz, 1H, H-6), 5.61 (dd, J= 9.7, 2.3 Hz, 1H, H-4), 5.93 (d, J=
Date recue/ date received 2022-02-18
76
2.2 Hz, 1H, H-3), 7.61-7.70 (m, 2H, 2Ph- H), 7.75 (t, J = 7.6 Hz, 1H, Ph-
H), 7.90 (d, J = 7.8 Hz, 1H, Ph-H), 8.23 (s, 1H, triazole-CH); 13C NMR (101
MHz, D20): 6 21.61 (NHCOCH3), 48.62 (C-5), 59.96 (C-4), 63.09 (C-9), 68.10
(C-7), 69.73 (C-8), 75.48 (C-6), 101.96 (C-3), 122.49 (Ph q carbon), 123.77
(q, J
= 3.0 Hz, triazole-C-5), 125.20 (Ph q carbon), 126.32 (q, J = 5.4 Hz, Ph),
127.39-128.51 (m, CF3), 129.38 (Ph), 131.99 (Ph), 132.27 (Ph), 144.83
(triazole-C-4), 150.33 (C-2), 168.75 (COONa), 173.52 (NHCOCH3); LRMS
[C201-120F3N4Na07] (m/z): (+ve ion mode) 531.2 [M+Na].
Methyl 5-
acetamido-7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-4-(5-
methoxymethy141,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate
(1E1172-79).
OAc OAc
OCOOCH3
OAc
AcHN
,N
N r0 C H 3
1E1172-79
Purification by silica gel chromatography using ethylacetate : acetone (6:1)
yielded (68%) of pure 1E1172-79. 1H NMR (400 MHz, CDCI3): 6 1.87 (s, 3H,
NAc), 2.01 (s, 3H, OAc), 2.03 (s, 3H, OAc), 2.07 (s, 3H, OAc), 3.34 (s, 3H,
CH2OCH3), 3.79 (s, 3H, COOCH3), 4.15-4.27 (m, 2H, H-5, H-9), 4.34-4.50 (m,
2H, CH20), 4.60 (dd, J= 12.5, 2.6 Hz, 1H, H-9'), 5.09 (dd, J= 10.7, 1.8 Hz,
1H,
H-6), 5.42 (td, J= 6.2, 2.6 Hz, 1H, H-8), 5.49 (dd, J= 6.3, 1.8 Hz, 1H, H-7),
5.91
(d, J= 2.4 Hz, 1H, H-3), 6.05 (dd, J= 9.9, 2.5 Hz, 1H, H-4), 7.26 (d, J= 7.8
Hz,
1H, NH), 7.46 (s, 1H, triazole-CH); 13C NMR (101 MHz, CDCI3) El 20.71, 20.76,
20.92 (3 OCOCH3), 23.04 (NHCOCH3), 50.03 (C-5), 52.60 (COOCH3), 55.20
(C-4), 58.59 (CH2OCH3), 61.94 (CH2OCH3), 62.10 (C-9), 67.74 (C-7), 70.25 (C-
8), 75.54 (C-6), 107.87 (C-3), 133.48 (triazole-C-4), 134.46 (triazole-C-5),
145.50 (C-2), 161.55 (COOCH3), 169.96, 170.21, 170.66, 171.54 (NHCOCH3, 3
OCOCH3); LRMS [C22H301\14011] (m/z): (+ve ion mode) 549.3 [M+Na].
Date recue/ date received 2022-02-18
77
Sodium 5-
acetamido-2,6-anhydro-3,4,5-trideoxy-4-(5-methoxymethyl-
[1,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate (1E1172-87).
OH OH
OCOONa
OH
AcHN
N 'OCH3
1E1172-87
Yield = 83%. 1H NMR (400 MHz, D20): 6 1.89 (s, 3H, NAG), 3.40 (s, 3H, OCH3),
3.65-3.74 (m, 2H, H-9, H-7), 3.93 (dd, J= 12.0, 2.7 Hz, 1H, H-9'), 4.03 (ddd,
J=
9.3,6.3, 2.6 Hz, 1H, H-8), 4.57 (d, J= 10.9 Hz, 1H, H-6), 4.61-4.73 (m, 3H, H-
5,
OCH2), 5.62 (dd, J= 9.6, 2.4 Hz, 1H, H-4), 5.85 (d, J= 2.4 Hz, 1H, H-3), 7.81
(s, 1H, triazole-CH); 13C NMR (101 MHz, D20): 8 21.73 (NHCOCH3), 47.97 (C-
5), 57.87 (OCH3), 58.92 (C-4), 61.34 (OCH2), 63.08 (C-9), 68.08 (C-7), 69.70
(C-8), 75.34 (C-6), 102.36 (C-3), 134.66 (triazole-C-5), 134.73 (triazole-C-
4),
150.02 (C-2), 168.75 (COONa), 173.61 (NHCOCH3); LRMS [Ci5H2iN4Na08]
(m/z): (-'-ye ion mode) 431.2 [M-'-Na].
Methyl 5-
acetamido-7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-4-(5-
pheny141,2,3,]triazol-1-y1)-o-glycero-D-galacto-non-2-enonate (1E1172-39).
OAc OAc
OCOOCH3
OAc
AcHN
,N
N
1E1172-39
Purification by silica gel chromatography using Hexane: acetone (4:3) yielded
(82%) of pure 1E1172-39. 1H NMR (400 MHz, CDCI3): 8 1.74 (s, 3H, NAc), 2.02
(s, 3H, OAc), 2.04 (s, 3H, OAc), 2.08 (s, 3H, OAc), 3.80 (s, 3H, COOCH3), 4.04
(td, J=10.1,7.3 Hz, 1H, H-5), 4.21 (m, 1H, H-9), 4.51 (m, 1H, H-9'), 5.05 (d,
J=
Date recue/ date received 2022-02-18
78
10.5 Hz, 1H, H-6), 5.31-5.46 (m, 2H, H-7, H-8), 5.98 (d, J= 2.5 Hz, 1H, H-
3), 6.09 (dd, J= 9.7, 2.5 Hz, 1H, H-4), 6.75 (d, J= 7.4 Hz, 1H, NH), 7.30-7.32
(m, 2H, 2Ph-H), 7.47-7.53 (m, 3H, 3Ph-H), 7.58 (s, 1H, triazole-CH); 13C NMR
(101 MHz, CDCI3) El 20.73, 20.79, 20.89 (3 0000H3), 23.03 (NHCOCH3), 50.85
(C-5), 52.58 (COOCH3), 54.24 (C-4), 62.01 (C-9), 67.63 (C-7), 69.87 (C-8),
74.78 (C-6), 108.02 (C-3), 126.01 (Ph q carbon), 129.07 (Ph), 129.23 (Ph),
130.07 (Ph), 132.70 (triazole-C-4), 139.35 (triazole-C-5), 145.49 (C-2),
161.49
(COOCH3), 169.79, 170.40, 170.58, 171.03 (NHCOCH3, 3 OCOCH3); LRMS
[C26H301\14010] (m/z): (+ve ion mode) 581.1 [M+Na].
Sodium 5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-(5-pheny141,2,3,]triazol-
1-y1)-D-glycero-D-galacto-non-2-enonate (1E1172-45).
OH OH
yNiily000ONa
OH
AcHN
,N
N
NNµ
1E1172-45
Yield = 88%. 1H NMR (400 MHz, D20): 6 1.72 (s, 3H, NAc), 3.55 (d, J= 9.7 Hz,
1H, H-7), 3.62 (dd, J= 12.0, 6.3 Hz, 1H, H-9), 3.87 (dd, J= 11.9, 2.7 Hz, 1H,
H-
9'), 3.95 (ddd, J= 9.3, 6.2, 2.7 Hz, 1H, H-8), 4.33-4.51 (m, 2H, H-5, H-6),
5.63
(dd, J = 9.3, 2.2 Hz, 1H, H-4), 5.98 (d, J= 2.3 Hz, 1H, H-3), 7.46-7.56 (m,
2H,
2Ph-H), 7.57-7.61 (m, 3H, 3Ph-H), 7.85 (s, 1H, triazole-CH); 13C NMR (101
MHz, D20): 6 21.88 (NHCOCH3), 48.83 (C-5), 57.52 (C-4), 63.00 (C-9), 67.95
(C-7), 69.64 (C-8), 75.01 (C-6), 103.14 (C-3), 125.71 (Ph q carbon), 129.13
(Ph), 129.28 (Ph), 130.10 (Ph), 133.02 (triazole-C-4), 139.88 (triazole-C-5),
149.90 (C-2), 168.80 (COONa), 173.30 (NHCOCH3); LRMS [C-19H211\14Na07]
(m/z): (+ve ion mode) 462.6 [M+Na].
Methyl 5-acetamido-7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-4-(4,5-
dipheny141,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-enonate (1E1172-
Date recue/ date received 2022-02-18
79
90).
OAc OAc
yN,OCOOCH3
OAc
AcHN
,N
1E1172-90
Purification by silica gel chromatography using Hexane: acetone (3:2) yielded
(79%) of purelE1172-90. 1H NMR (400 MHz, CDCI3): 8 1.82 (s, 3H, NAc), 2.03
(s, 6H, 20Ac), 2.10 (s, 3H, OAc), 3.78 (s, 3H, COOCH3), 4.17-4.27 (m, 2H, H-
5, H-9), 4.52 (dd, J= 12.5, 2.6 Hz, 1H, H-9'), 5.07 (d, J= 10.4 Hz, 1H, H-6),
5.40 (td, J= 6.3, 2.5 Hz, 1H, H-8), 5.45 (dd, J= 6.8, 1.7 Hz, 1H, H-7), 5.79-
5.93
(m, 2H, H-3, H-4), 7.13-7.27 (m, 6H, NH, 5Ph-H), 7.28-7.34 (m, 2H, 2Ph-H),
7.38-7.48 (m, 3H, 3Ph-H); 13C NMR (101 MHz, CDCI3) El 20.75, 20.76, 20.89(3
OCOCH3), 23.33 (NHCOCH3), 50.56 (C-5), 52.54 (COOCH3), 54.97 (C-4),
62.09 (C-9), 67.54 (C-7), 69.93 (C-8), 75.13 (C-6), 108.41 (C-3), 126.48 (Ph q
carbon), 127.15 (Ph), 128.09 (Ph), 128.44 (Ph), 129.31 (Ph), 130.11 (Ph),
130.14 (Ph), 130.18 (Ph q carbon), 135.11 (triazole-C), 144.35 (triazole-C),
145.49 (C-2), 161.50 (COOCH3), 169.80, 170.27, 170.63, 171.37 (NHCOCH3, 3
OCOCH3); LRMS [C32H34N4010] (m/z): (+ye ion mode) 657.3 [M+Na].
Sodium
phenyl-
LI (1E1172-102).
Date recue/ date received 2022-02-18
80
OH OH
LJN,OCOONa
OH
AcHN -
,N
1E1172-102
Yield = 84%. 1H NMR (400 MHz, D20): 6 1.83 (s, 3H, NAG), 3.58 (d, J= 9.7 Hz,
1H, H-7), 3.63 (dd, J= 12.0, 6.2 Hz, 1H, H-9), 3.88 (dd, J= 12.0, 2.7 Hz, 1H,
H-
9'), 3.94 (ddd, J= 9.4, 6.2, 2.7 Hz, 1H, H-8), 4.37 (d, J= 11.0 Hz, 1H, H-6),
4.59
(dd, J= 11.2, 9.2 Hz, 1H, H-5), 5.48 (d, J= 9.7 Hz, 1H, H-4), 5.90 (s, 1H, H-
3),
7.36-7.59 (m, 10H, Ph-H); 13C NMR (101 MHz, D20): 8 21.94 (NHCOCH3),
48.33 (C-5), 58.44 (C-4), 63.01 (C-9), 67.98 (C-7), 69.61 (C-8), 74.96 (C-6),
103.15 (C-3), 126.05 (Ph q carbon), 127.31 (Ph), 128.55 (Ph), 128.80 (Ph),
129.21 (Ph), 129.63 (Ph q carbon), 130.25 (Ph), 130.42 (Ph), 135.79 (triazole-
C), 144.67 (triazole-C), 149.71 (C-2), 168.67 (COONa), 173.41 (NHCOCH3);
LRMS [C25H25N4Na07] (m/z): (+ve ion mode) 539.2 [M+Na].
Methyl 5-acetamido-7,8,9-tri-O-acety1-2,6-anhydro-4-(4-(2-bromopheny1)-
[1,2,3,]triazol-1-y1)-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonate
(1E1257-75).
OAc OAc
OCOOCH3
ORc
AcHN -
N,N
Br \ 11\1
1E1257-75
Purification by silica gel chromatography using hexane : acetone (3:2) yielded
Date recue/ date received 2022-02-18
81
(88%) of pure 1E1257-75. 1H NMR (400 MHz, CDCI3): 6 1.85 (s, 3H,
NAc), 2.06 (s, 3H, OAc), 2.08 (s, 3H, OAc), 2.09 (s, 3H, OAc), 3.84 (s, 3H,
COOCH3), 4.16-4.28 (m, 2H, H-5, H-9), 4.68 (dd, J= 12.5, 2.6 Hz, 1H, H-9'),
4.91 (dd, J= 10.7, 1.8 Hz, 1H, H-6), 5.43 (ddd, J= 6.7, 5.6, 2.6 Hz, 1H, H-8),
5.53 (dd, J= 5.8, 1.7 Hz, 1H, H-7), 6.00 (dd, J= 9.9, 2.5 Hz, 1H, H-4), 6.11
(d, J
= 2.2 Hz, 1H, H-3), 6.59 (d, J= 8.4 Hz, 1H, NH), 7.20 (ddd, J= 8.1,7.3, 1.6
Hz,
1H, PH-H), 7.40 (td, J= 7.5, 1.3 Hz, 1H, Ph-H), 7.63 (dd, J= 8.0, 1.2 Hz, 1H,
Ph-H), 7.96 (dd, J= 7.9, 1.7 Hz, 1H, Ph-H), 8.22 (s, 1H, triazole-CH); 13C NMR
(101 MHz, CDCI3) El 20.80, 20.95 (3 0000H3), 23.13 (NHCOCH3), 49.56 (C-5),
52.75 (COOCH3), 57.49 (C-4), 62.10 (C-9), 67.81 (C-7), 70.62 (C-8), 76.10 (C-
6), 107.03 (C-3), 121.42 (Ph q carbon), 122.66 (Ph), 127.76 (Ph), 129.75 (Ph),
130.65 (Ph), 133.59 (triazole-05), 145.61 (triazole-C4), 145.94 (C-2), 161.33
(COOCH3), 170.15, 170.29, 170.71, 171.09 (NHCOCH3, 3 OCOCH3).
Sodium 5-acetamido-2,6-anhydro-4-(4-(2-bromopheny1)-(1 ,2,3,]triazol-1-y1)-
3,4,5-trideoxy-o-glycero-D-galacto-non-2-enonate (1E1257-84).
OH OH
OCOONa
OH
AcHN -
N,N
Br \
1E1257-84
Yield = 89%. 1H NMR (400 MHz, D20): 6 1.93 (s, 3H, NAc), 3.62-3.77 (m, 2H,
H-7, H-9), 3.92 (dd, J= 12.0, 2.7 Hz, 1H, H-9'), 4.02 (ddd, J= 9.2, 6.2, 2.7
Hz,
1H, H-8), 4.49 (dd, J=10.9, 9.6 Hz, 1H, H-5), 4.60 (dd, J=10.9,1.3 Hz, 1H, H-
6), 5.58 (dd, J= 9.7, 2.3 Hz, 1H, H-4), 5.92 (d, J= 2.3 Hz, 1H, H-3), 7.36
(ddd, J
= 7.9, 7.3, 1.7 Hz, 1H, Ph-H), 7.49 (td, J= 7.6, 1.3 Hz, 1H, Ph-H), 7.69 (dd,
J=
7.8, 1.7 Hz, 1H, Ph-H), 7.77 (dd, J = 8.1, 1.2 Hz, 1H, Ph-H), 8.45 (s, 1H,
triazole-CH); 13C NMR (101 MHz, D20): 621.77 (NHCOCH3), 48.68 (C-5), 60.07
Date recue/ date received 2022-02-18
82
(C-4), 63.10 (C-9), 68.11 (C-7), 69.75 (C-8), 75.42 (C-6), 101.91 (C-3),
121.49 (Ph q carbon), 123.72 (Ph), 127.90 (Ph), 129.16 (Ph), 130.16 (Ph q
carbon), 130.42 (Ph), 130.71 (Ph), 133.42 (triazole-05), 145.89 (triazole-C4),
150.39 (C-2), 168.78 (COONa), 173.54 (NHCOCH3).
Methyl 5-acetamido-7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-4-(4-(2-
methoxycarbonyl)pheny1)11,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-
enonate (1E1398-25).
OAc OAc
LJN,OCOOCH3
OAc
AcHN
N,
H3COOC
1E1398-25
Purification by silica gel chromatography using hexane : acetone (4:3) yielded
(91%) of pure 1E1398-25. 1H NMR (400 MHz, CDCI3): 8 1.76 (s, 3H, NAc), 2.02
(s, 3H, OAc), 2.04 (s, 3H, OAc), 2.05 (s, 3H, OAc), 3.75 (s, 3H, Ph-COOCH3),
3.80 (s, 3H, C2-COOCH3), 4.17 (dd, J= 12.4,7.1 Hz, 1H, H-9), 4.31 (q, J= 9.8
Hz, 1H, H-5), 4.69 (dd, J= 12.5, 2.8 Hz, 1H. H-9'), 4.78 (d, J= 10.3 Hz, 1H, H-
6), 5.38 (ddd, J= 7.6, 5.4, 2.8 Hz, 1H, H-8), 5.52 (dd, J= 5.0, 1.9 Hz, 1H, H-
7),
5.78 (dd, J= 10.2, 2.5 Hz, 1H, H-4), 6.03 (d, J= 2.4 Hz, 1H, H-3), 7.13 (d, J=
8.9 Hz, 1H, NH), 7.38 (t, J= 7.8 Hz, 1H, Ph-H), 7.50 (td, J=7.7,1.4 Hz, 1H, Ph-
H), 7.65 (d, J= 7.7 Hz, 1H, Ph-H), 7.76 (d, J= 7.6 Hz, 1H, Ph-H), 7.84 (s, 1H,
triazole-CH); 13C NMR (101 MHz, CDCI3) El 20.72, 20.79, 20.91 (3 00001-13),
22.80 (NHCOCH3), 48.65 (C-5), 52.29, 52.66 (2 COOCH3), 57.96 (C-4), 62.23
(C-9), 67.78 (C-7), 70.91 (C-8), 76.66 (C-6), 107.37 (C-3), 122.06 (Ph),
128.35
(Ph), 129.85 (Ph), 129.99 (Ph q carbon), 130.15 (Ph q carbon), 130.35 (Ph),
131.62 (triazole-05), 145.79 (triazole-C4), 145.89(C-2), 161.36 (C2-COOCH3),
168.39 (Ph-COOCH3), 170.07, 170.27, 170.76, 171.02 (NHCOCH3, 3
Date recue/ date received 2022-02-18
83
OCOCH3); LRMS [C281-132N4012] (m/z): (+ve ion mode) 639.3 [M+Na].
Sodium 5-
acetamido-2,6-anhydro-3,4,5-trideoxy-4-(4-(2-
methoxycarbonyl)pheny1)11,2,3,]triazol-1-y1)-D-glycero-D-galacto-non-2-
enonate (1E1398-33).
OH OH
Ny000ONa
OH I
AcHN :
N ,N
NaOOC \ r(j
1E1398-33
Yield = 68%. 1H NMR (400 MHz, D20): 6 1.94 (s, 3H, NAc), 3.66 (dd, J = 12.2,
6.0 Hz, 1H, H-9), 3.72 (dd, J= 9.8, 1.4 Hz, 1H, H-7), 3.93 (dd, J= 12.0, 2.9
Hz,
1H, H-9'), 4.03 (ddd, J= 9.4,6.4, 2.7 Hz, 1H, H-8), 4.47 (t, J= 10.3 Hz, 1H, H-
5), 4.61 (dd, J= 10.9, 1.4 Hz, 1H, H-6), 5.59 (dd, J= 9.5, 2.1 Hz, 1H, H-4),
5.95
(d, J = 2.2 Hz, 1H, H-3), 7.43-7.55 (m, 3H, 3 Ph-H), 7.75 (dd, J = 6.6, 1.5
Hz,
1H, Ph-H), 8.18 (s, 1H, triazole-CH); 13C NMR (101 MHz, D20): 8 21.76
(NHCOCH3), 48.80 (C-5), 59.69 (C-4), 63.10 (C-9), 68.13 (C-7), 69.77 (C-8),
75.40 (C-6), 102.22 (C-3), 122.33 (triazole-05), 125.00 (Ph q carbon), 126.44
(Ph), 128.30 (Ph), 128.57 (Ph), 128.79 (Ph), 138.95 (Ph q carbon), 146.15
(triazole-C4), 150.22 (C-2), 168.85 (C2-COONa), 173.80 (NHCOCH3), 178.10
(Ph-COONa); LRMS [C2oH2oN4Na209] (m/z): (+ve ion mode) 528.8 [M+Na].
Methyl 7,8,9-
tri-O-acety1-3,4,5-trideoxy-3-fluoro-5-isobutyramido-4-(4-
methoxymethy141,2,3,]triazol-1-y1)-D-erythro-13-L-gluco-non-2-
ulopyranosylonate fluoride (1E1257-22).
Date recue/ date received 2022-02-18
84
OAc COOCH3
AcON41 OAc 0 F
0
OCH3
1E1257-22
Purification by silica gel chromatography using hexane/acetone (3:2) yielded
(57
mg, 81%) of pure 10. 1H NMR (400 MHz, CDCI3): 8 0.96-1.01 (m, 6H, isobut-
2CH3), 2.01 (s, 3H, OAc), 2.09 (s, 3H, OAc), 2.13 (s, 3H, OAc), 2.23 (dq, J=
13.0, 6.8 Hz, 1H, isobut-CH), 3.36 (s, 3H, OCH3), 3.90-3.96 (m, 4H, COOCH3,
H-5), 4.19 (dd, J= 12.6, 4.6 Hz, 1H, H-9), 4.27 (dd, J= 12.6, 2.5 Hz, 1H, H-
9'),
4.54 (s, 2H, OCH2), 4.99-5.30 (m, 3H, H-3, H-6, H-7), 5.37 (ddd, J= 8.6, 4.6,
2.4 Hz, 1H, H-8), 6.19-6.29 (m, 2H, H-4, NH), 7.60 (s, 1H, triazole-CH); 13C
NMR (100 MHz, CDCI3): El 18.86 (isobut-0H3), 19.32 (isobut-CH3), 20.59, 20.75,
20.79 (3 OCOCH3), 35.53 (isobut-CH), 50.84 (d, J = 5.8 Hz, C-5), 53.62
(COOCH3), 58.34 (OCH3), 59.00-59.40 (m, C-4), 61.86 (C-9), 65.50 (OCH2),
67.08 (C-7), 68.29 (C-8), 71.51 (C-6), 90.64 (dd, J = 196.1, 30.3 Hz, C-3),
105.58 (dd, J= 230.3, 26.8 Hz, C-2), 124.52 (triazole-CH), 144.83 (triazole-q
carbon), 164.51 (d, J = 32.9 Hz, COOCH3), 169.56 , 170.41, 170.69 (3
OCOCH3), 178.35 (isobut-00); 19F NMR (376 MHz, CDCI3): 8 -118.67 (d, J=
14.0 Hz, F-2a), -197.42 (d, J= 13.2 Hz, F-313); LRMS [C24H34F2N4011] (m/z):
(+ve ion mode) 615.3 [M+Na].
3,4,5-Trideoxy-3-fluoro-5-isobutyramido-4-(4-methoxymethy141,2,3,priazol-
1-y1)-D-erythro-p-L-gluco-non-2-ulopyranosonic fluoride (1E1257-24).
HO OH OH COOH
H 0 F
0 N
N ¨N
OCH3
1E1257-24
Date recue/ date received 2022-02-18
85
1H NMR (400 MHz, D20): 8 0.81 (d, J = 6.9 Hz, 3H, isobut-CH3), 0.94 (d, J=
6.9 Hz, 3H, isobut-CH3), 2.35 (p, J = 6.9 Hz, 1H, isobut-CH), 3.38 (s, 3H,
OCH3), 3.54 (d, J= 9.2 Hz, 1H, H-7), 3.61 (m, 1H, H-9), 3.78-3.91 (m, 2H, H-8,
H-9'), 4.52-4.76 (m, 3H, OCH2, H-6), 4.85 (m, 1H, H-5), 5.32 (ddd, J = 49.5,
13.7, 9.7 Hz, 1H, H-3), 5.75 (q, J = 11.2 Hz, 1H, H-4), 8.28 (s, 1H, triazole-
CH);
13C NMR (100 MHz, D20): 6 18.11 (isobut-0H3), 18.65 (isobut-CH3), 34.87
(isobut-CH), 48.15 (d, J= 6.1 Hz, C-5), 57.26 (OCH3), 63.16 (C-9), 63.18-63.58
(m, C-4), 64.13 (OCH2), 67.85 (C-7), 69.83 (C-8), 73.73 (d, J= 3.3 Hz, C-6),
90.22 (dd, J = 190.9, 32.6 Hz, C-3), 106.79 (dd, J = 224.1, 27.8 Hz, C-2),
124.89 (triazole-CH), 144.09 (trizaole-q C), 169.21 (d, J = 30.7 Hz, COOH),
180.88 (isobut-00); 19F NMR (376 MHz, D20): 8 -112.75 (d, J = 13.8 Hz, F-2a),
-199.41 (d, J= 14.3 Hz, F-3[3); LRMS [Ci7H25F2N4Na08] (m/z): (+ve ion mode)
496.8 [M+Na]; HRMS (API) (m/z): [M+1]+ calcd for C17H26F2N408 [M+1]+
453.1791; found, 453.1810.
Methyl 5-acetamido-7,8,9-tri-O-acety1-2,6-anhydro-4-(1-cyano-2H-isoindol-
2-y1)-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonate (1E889-76).
OAc OAc
COOCH3
OAc
AcHN
CN
1E889-76
1H NMR (300 MHz, CDCI3): 6 1.60 (s, 3H, NAc), 1.82 (s, 6H, 2 OAc), 1.84 (s,
3H, OAc), 3.60 (s, 3H, COOCH3), 3.96 (dd, J= 12.7, 7.0 Hz, 1H, H-9), 4.19 (q,
J
= 9.9 Hz, 1H, H-5), 4.40-4.50 (m, 2H, H-6, H-9'), 5.16 (ddd, J= 7.5, 6.0, 2.4
Hz,
1H, H-8); 5.22-5.33(m, 2H, H-4, H-7), 5.86 (d, J= 1.6 Hz, 1H, H-3), 6.20 (d,
J=
9.6 Hz, 1H, NHAc), 6.84 (m, 1H, Ar-H), 6.99 (m, 1H, Ar-H), 7.26(s, 1H, Ar-H-
3'),
7.37 (m, 2H, Ar-H-4', Ar-H-7'); 13H NMR (75 MHz, CDCI3): 8 20.76, 20.92 (3
OCOCH3), 22.97 (NHCOCH3), 49.26 (C-5), 52.79 (COOCH3), 58.00 (C-4),
Date recue/ date received 2022-02-18
86
62.08 (C-9), 67.67 (C-7), 70.86 (C-8), 77.06 (C-6), 93.82 (Ar-C-CN), 107.66
(C-3), 114.69 (CN), 117.55 (Ar), 117.78 (Ar), 121.14 (Ar), 123.23 (Ar), 124.63
(Ar q carbon), 126.08 (Ar), 131.60 (Ar q carbon), 146.63 (C-2), 161.29
(COOCH3), 170.17, 170.30, 170.63 (NHCOCH3, 3 OCOCH3); LRMS
[C27H29N3010] (m/z): (+ve ion mode) 578.1 [M+Na].
Sodium 5-acetamido-2,6-anhydro-4-(1-cyano-2H-isoindo1-2-y1)-
3,4,5-
trideoxy-D-glycero-D-galacto-non-2-enonate (1E889-80).
OH OH
LJN,OCOONa
OH
AcHN -
N CN
1E889-80
1H NMR (300 MHz, D20): 8 1.91 (s, 3H, NAc), 3.61-3.77 (m, 2H, H-7, H-9), 3.94
(dd, J= 11.9, 2.6 Hz, 1H, H-9'), 4.05 (ddd, J= 9.2, 6.2, 2.6 Hz, 1H, H-8),
4.50
(m, 1H, H-5), 4.64 (d, J= 11.0 Hz, 1H, H-6), 5.47 (dd, J= 9.4, 2.3 Hz, 1H, H-
4),
5.96 (d, J= 2.3 Hz, 1H, H-3), 7.21 (m, 1H, Ar-H), 7.37 (ddd, J= 8.9,6.7, 1.1
Hz,
1H, Ar-H), 7.65-7.87 (m, 3H, Ar-H-3', Ar-H-4', Ar-H-7'); 13C NMR (75 MHz,
D20): 6 21.77 (NHCOCH3), 49.83 (C-5), 59.20 (C-4), 63.08 (C-9), 68.09 (C-7),
69.77 (C-8), 75.41 (C-6), 92.08 (Ar-C-CN), 103.30 (C-3), 115.30 (CN), 117.35
(Ar), 119.65 (Ar), 121.36 (Ar), 122.82 (Ar), 124.09 (Ar q carbon), 125.99
(Ar),
132.03 (Ar q carbon), 150.56 (C-2), 168.78 (COONa), 173.36 (NHCOCH3);
LRMS [C201-120N3Na07] (m/z): (+ve ion mode)460.1 [M-'-Na]; HRMS (API) (m/z):
[M+Na] calcd for C201-120N3Na207[M+Na] 460.1091; found, 460.1097.
Methyl 7,8,9-tri-O-acety1-2,6-anhydro-4-(1-cyano-2H-isoindol-2-y1)-3,4,5-
trideoxy-5-isobutyramido-D-glycero-D-galacto-non-2-enonate (1E889-92).
Date recue/ date received 2022-02-18
87
OAc OAc
LJ,OCOOCH3
OAc
0 N-
CN
1E889-92
1H NMR (300 MHz, CDCI3): El 0.92 (d, J= 6.8 Hz, 3H, isobutyryl-CH3), 1.00 (d,
J
= 6.8 Hz, 3H, isobutyryl-CH3), 2.07 (s, 3H, OAc), 2.09 (s, 3H, OAc), 2.10 (s,
3H,
OAc), 2.27 (m, 1H, isobutyryl-CH), 3.86 (s, 3H, COOCH3), 4.23 (dd, J= 12.4,
6.6 Hz, 1H, H-9), 4.50 (m, 1H, H-5), 4.68 (dd, J= 12.5, 2.7 Hz, 1H, H-9'),
4.77
(d, J= 10.6 Hz, 1H, H-6), 5.40 (m, 1H, H-8), 5.51 (dd, J= 5.6, 1.6 Hz, 1H, H-
7),
5.62 (dd, J= 9.7, 2.4 Hz, 1H, H-4), 6.15 (d, J=2.4 Hz, 1H, H-3), 6.24 (d,
J=9.4
Hz, 1H, NH), 7.11 (dd, J= 8.6, 6.7 Hz, 1H, Ar-H), 7.28 (dd, J= 8.4, 6.6 Hz,
1H,
Ar-H), 7.50 (s, 1H, Ar-H-3'), 7.60-7.64 (m, 2H, Ar-H-4', Ar-H-7'); 13H NMR (75
MHz, CDCI3): 8 18.77, 19.05 (isobutyry1-2CH3), 20.69, 20.73, 20.90 (3
OCOCH3), 35.51 (isobutyryl-CH), 49.11 (C-5), 52.78 (COOCH3), 57.88 (C-4),
62.05 (C-9), 67.61 (C-7), 70.80 (C-8), 77.01 (C-6), 93.83 (Ar-C-CN), 107.56 (C-
3), 114.80 (CN), 117.58 (Ar), 117.81 (Ar), 121.20 (Ar), 123.22 (Ar), 124.66
(Ar q
carbon), 126.15 (Ar), 131.56 (Ar q carbon), 146.50 (C-2), 161.31 (COOCH3),
170.10, 170.14, 170.57 (3 OCOCH3), 177.07 (isobutyryl-00); LRMS
[C29H33N3010] (m/z): (+ve ion mode) 606.4 [M+Na].
Sodium 2,6-
anhydro-4-(1-cyano-2H-isoindo1-2-y1)-3,4,5-trideoxy-5-
isobutyramido-D-glycero-D-galacto-non-2-enonate (1E889-99).
Date recue/ date received 2022-02-18
88
OH OH
sz-1 OCOONa
OH
11\1CN
N
1E889-99
1H NMR (300 MHz, D20): 8 0.88 (d, J= 6.9 Hz, 3H, isobutyryl-CH3), 0.97 (d, J=
6.9 Hz, 3H, isobutyryl-CH3), 2.44 (m, 1H, isobutyryl-CH), 3.62-3.75 (m, 2H, H-
7,
H-9), 3.93 (dd, J= 12.0, 2.7 Hz, 1H, H-9'), 4.04 (ddd, J= 9.3, 6.3, 2.6 Hz,
1H,
H-8), 4.56-4.66 (m, 2H, H-5, H-6), 5.47 (dd, J= 9.6, 2.4 Hz, 1H, H-4), 5.95
(d, J
= 2.2 Hz, 1H, H-3), 7.20 (ddd, J= 7.8,6.8, 1.0 Hz, 1H, Ar-H), 7.36 (ddd, J=
8.3,
6.8, 1.0 Hz, 1H, Ar-H), 7.70 (dd, J= 8.6, 1.1 Hz, 1H, Ar-H), 7.74-7.87 (m, 2H,
2
Ar-H); 13C NMR (75 MHz, D20): El 18.16, 18.59 (isobutyry1-20H3), 35.06
(isobutyryl-CH), 49.13 (C-5), 59.30 (C-4), 63.07 (C-9), 68.20 (C-7), 69.81 (C-
8),
75.45 (C-6), 92.08 (Ar-C-CN), 103.34 (C-3), 115.47 (CN), 117.33 (Ar), 120.04
(Ar), 121.38 (Ar), 122.81 (Ar), 124.04 (Ar q carbon), 126.01 (Ar), 132.04 (Ar
q
carbon), 150.37 (C-2), 168.87 (COONa), 180.37 (isobutyryl-00); LRMS
[C22H24N3Na07] (m/z): (+ve ion mode) 488.1 [M+Na]; HRMS (API) (m/z):
[M+Na] calcd for C22H24N3Na207[M+Na] 488.1404; found, 488.1400.
Methyl 7,8,9-tri-O-acety1-2,6-anhydro-4-(1-cyano-2H-isoindol-2-y1)-3,4,5-
trideoxy-5-(2,2,2-trifluoroacetamido)-D-glycero-D-galacto-non-2-enonate
(1E927-93).
OAc OAc
LJN,OCOOCH3
OAc
N GNI
1E927-93
Date recue/ date received 2022-02-18
89
1H NMR (300 MHz, CDCI3): 6 2.07 (s, 3H, OAc), 2.08 (s, 3H, OAc),2.10 (s,
3H, OAc), 3.86 (s, 3H, COOCH3), 4.22 (dd, J= 12.5, 6.6 Hz, 1H, H-9), 4.54 (q,
J
= 9.9 Hz, 1H, H-5), 4.68 (dd, J= 12.5, 2.6 Hz, 1H, H-9'), 4.82 (dd, J= 10.6,
1.9
Hz, 1H, H-6), 5.43 (td, J= 6.0, 5.5, 2.6 Hz, 1H, H-8), 5.52 (dd, J= 5.6, 1.8
Hz,
1H, H-7), 5.62 (dd, J= 9.7, 2.4 Hz, 1H, H-4), 6.17 (d, J= 2.4 Hz, 1H, H-3),
7.13
(ddd, J= 7.9, 6.8, 1.0 Hz, 1H, Ar-H), 7.28 (ddd, J= 8.4, 6.7, 1.0 Hz, 1H, Ar-
H),
7.52 (s, 1H, Ar-H-3'), 7.58-7.69 (m, 2H, Ar-H-4', Ar-H-7'), 7.91 (d, J= 9.6
Hz,
1H, NH); 13H NMR (75 MHz, CDCI3): O 20.50,20.71, 20.91 (3 OCOCH3), 49.81
(C-5), 52.93 (COOCH3), 57.45 (C-4), 61.93 (C-9), 67.46 (C-7), 70.64 (C-8),
76.40 (C-6), 93.61 (Ar-C-CN), 107.14 (C-3), 113.24-117.05 (CF3), 114.37 (CN),
117.73 (Ar), 117.80 (Ar), 121.08 (Ar), 123.65 (Ar), 124.93 (Arq carbon),
126.55
(Ar), 131.85 (Ar q carbon), 146.73 (C-2), 157.56 (q, JC,F = 38.8 Hz, COCF3),
161.03 (COOCH3), 169.91, 170.38, 170.71 (3 OCOCH3); LRMS [C27H26-
F3N3010] (m/z): (+ve ion mode) 632.1 [M+Na].
Sodium 2,6-anhydro-4-(1-cyano-2H-isoindo1-2-y1)-3,4,5-trideoxy-5-(2,2,2-
trifluoroacetamido)-D-glycero-D-galacto-non-2-enonate (1E927-99).
OH OH
.)NI-11,000OH
OH
HN
N CN
1E927-99
1H NMR (300 MHz, D20): O 3.60-3.75 (m, 2H, H-7, H-9), 3.93 (dd, J= 11.9, 2.7
Hz, 1H, H-9'), 4.07 (ddd, J= 9.4, 6.4, 2.6 Hz, 1H, H-8), 4.64-4.74 (m, 2H, H-
5,
H-6), 5.57 (dd, J= 9.4,2.3 Hz, 1H, H-4), 6.00 (d, J= 2.3 Hz, 1H, H-3), 7.21
(m,
1H, Ar-H), 7.36 (m, 1H, Ar-H), 7.69 (d, J= 8.6 Hz, 1H, Ar-H), 7.77 (d, J= 8.5
Hz, 1H, Ar-H), 7.84 (s, 1H, Ar-H-3'); 13C NMR (75 MHz, D20): El 50.48 (0-5),
58.73 (C-4), 63.00 (C-9), 68.08 (C-7), 69.66 (C-8), 75.05 (C-6), 91.94 (Ar-C-
CN), 103.21 (C-3), 109.60-118.88 (CF3), 115.01 (CN), 117.34 (Ar), 121.36 (Ar),
Date recue/ date received 2022-02-18
90
123.02 (Ar), 124.19 (Ar q carbon), 126.23 (Ar), 132.12 (Ar q carbon),
150.62 (C-2), 158.20 (q, JC,F = 38.8 Hz, COCF3), 168.44 (COONa); LRMS
[C2oHi7F3N3Na07] (m/z): (+ve ion mode) 514.1 [M+Na], 492.2; HRMS (API)
(m/z): [M+Na] calcd for C2oHi7F3N3Na207[M+Na] 514.0830; found, 514.0836.
Methyl 5-acetamido-7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-44/H-
tetrazol-1-y1)-D-glycero-D-galacto-non-2-enonate (1E832-86).
OAc OAc
LJN,OCOOCH3
OAc
AcHN"
N,
N
1E832-86
1H NMR (300 MHz, CDCI3): El 1.95 (s, 3H, NAc), 2.06 (s, 3H, OAc), 2.09 (s, 3H,
OAc), 2.10 (s, 3H, OAc), 3.84 (s, 3H, COOCH3), 4.02 (m, 1H, H-5), 4.22 (dd, J=
12.6, 6.4 Hz, 1H, H-9), 4.63 (dd, J= 12.5, 2.6 Hz, 1H, H-9'), 4.95 (dd, J=
10.5,
1.8 Hz, 1H, H-6), 5.38 (td, J= 6.2, 2.6 Hz, 1H, H-8), 5.49 (dd, J= 5.9, 1.8
Hz,
1H, H-7), 6.05 (d, J = 2.5 Hz, 1H, H-3), 6.11 (dd, J = 9.8, 2.5 Hz, 1H, H-4),
6.67
(d, J= 8.2 Hz, 1H, NH), 8.70 (s, 1H, tetrazole-CH); 13H NMR (75 MHz, CDCI3): 8
20.72, 20.75, 20.91 (3 OCOCH3), 23.13 (NHCOCH3), 49.72 (C-5), 52.87
(COOCH3), 55.92 (C-4), 61.93 (C-9), 67.62 (C-7), 70.50 (C-8), 75.70 (C-6),
105.19 (C-3), 140.84 (Tetrazole-05), 146.64 (C-2), 161.07 (COOCH3), 170.17,
170.27, 170.63, 171.54 (NHCOCH3, 3 OCOCH3); LRMS [C19H25N5010] (m/z):
(+ve ion mode) 506.5 [M+Na].
Sodium 5-acetamido-2,6-anhydro-3,4,5-trideoxy-44/H-tetrazol-1-y1)-D-
glycero-D-galacto-non-2-enonate (1E832-98).
Date recue/ date received 2022-02-18
91
OH OH
LJ,OCOONa
OH
AcHN
N¨N
1E832-98
1H NMR (300 MHz, D20): 8 1.94 (s, 3H, NAc), 3.65-3.74 (m, 2H, H-7, H-9), 3.92
(dd, J= 11.9, 2.7 Hz, 1H, H-9'), 4.02 (ddd, J= 9.3, 6.2, 2.7 Hz, 1H, H-8),
4.44
(dd, J = 10.9, 9.7 Hz, 1H, H-5), 4.62 (dd, J = 11.0, 1.4 Hz, 1H, H-6), 5.73
(dd, J
= 9.6, 2.3 Hz, 1H, H-4), 5.88 (d, J = 2.3 Hz, 1H, H-3); 13C NMR (75 MHz, D20):
O 21.63 (NHCOCH3), 48.44 (C-5), 58.77 (C-4), 63.04 (C-9), 67.99 (C-7), 69.67
(C-8), 75.29 (C-6), 100.61 (C-3), 143.99 (Tetrazole-05), 150.85 (C-2), 168.53
(COOCH3), 173.82 (NHCOCH3); LRMS [Ci2Hi6N5Na07] (m/z): (+ve ion mode)
388.4 [M+Na]; HRMS (API) (m/z): [M+Na] calcd for C12H16N5Na207[M+Na]
388.083964; found, 388.084945.
Methyl 7,8,9-tri-O-acety1-2,6-anhydro-3,4,5-trideoxy-5-isobutyramido-44/H-
tetrazol-1-y1)-D-g/ycero-D-ga/acto-non-2-enonate (1E889-36).
1H NMR (300 MHz, CDCI3): 0 1.05 (d, J = 6.9 Hz, 6H, isobutyramido-2CH3),
2.01 (s, 3H, OAc), 2.05 (s, 6H, 20Ac), 2.34 (m, 1H, isobutyramido-CH), 3.81
(s,
3H, COOCH3), 4.01 (m, 1H, H-5), 4.18 (dd, J= 12.5, 6.3 Hz, 1H, H-9), 4.60 (dd,
J= 12.6, 2.6 Hz, 1H, H-9'), 5.03 (dd, J= 10.5, 1.7 Hz, 1H, H-6), 5.32 (td, J=
6.1, 2.5 Hz, 1H, H-8), 5.46 (dd, J= 5.9, 1.8 Hz, 1H, H-7), 6.03 (d, J= 2.4 Hz,
1H, H-3), 6.14 (dd, J= 9.8, 2.5 Hz, 1H, H-4), 6.94 (d, J= 8.1 Hz, 1H, NH),
8.65
(s, 1H, tetrazole-CH); 13H NMR (75 MHz, CDCI3): 8 18.85, 19.27
(isobutyramido-2CH3), 20.66, 20.84 (3 OCOCH3), 35.56 (isobutyramido-CH),
49.69 (C-5), 52.79 (COOCH3), 55.77 (C-4), 61.91 (C-9), 67.49 (C-7), 70.51 (C-
8), 75.64 (C-6), 105.15 (C-3), 140.81 (Tetrazole-05), 146.70 (C-2), 161.18
(COOCH3), 170.04, 170.15, 170.58 (3 OCOCH3), 178.53 (isobutyramido-00);
LRMS [C21H29N5010] (m/z): (+ve ion mode) 534.3 [M+Na]; HRMS (API) (m/z):
Date recue/ date received 2022-02-18
92
[M+Na] calcd for C211-129N3Na010 [M+Na] 534.180663;
found,
543.1788531.
Sodium 2,6-anhydro-3,4,5-trideoxy-5-isobutyramido-44/H-tetrazol-1-y1)-D-
g/ycero-D-ga/acto-non-2-enonate (1E889-42).
OH OH
y000ONa
OH I
HNi-
N
0 'N
N¨N
1E889-42
1H NMR (300 MHz, D20): 6 0.99-1.04 (m, 6H, isobutyramido-2CH3), 2.46 (m,
1H, isobutyramido-CH), 3.59-3.75 (m, 2H, H-7, H-9), 3.93 (dd, J= 12.0, 2.6 Hz,
1H, H-9'), 4.03 (ddd, J= 9.7, 6.2, 2.6 Hz, 1H, H-8), 4.49 (dd, J= 10.9, 9.7
Hz,
1H, H-5), 4.65 (dd, J= 10.9, 1.2 Hz, 1H, H-6), 5.76 (dd, J= 9.7, 2.3 Hz, 1H, H-
4), 5.88 (d, J = 2.2 Hz, 1H, H-3), 9.38 (s, 1H, tetrazole-CH); LRMS
[Ci4H201\13Na07] (m/z): (+ve ion mode) 416.0 [M+Na]; HRMS (API) (m/z):
[M+Na] calcd for Ci4H2oN5Na207[M+Na] 416.115264; found, 416.116886.
Biology
Cells and virus:
A549 cells (adenocarcinomic human alveolar basal epithelial cells) were
provided by the European Collection of Cell Cultures (86012804-1VL, Sigma
Aldrich). Cells were propagated in Dulbecco's Modified Eagle Medium (DMEM)
(Lonza, Basel, Switzerland) supplemented with 1% Glutamine (200 mM) and
5% foetal bovine serum. For infection and post-infection procedures, A549
cells
were maintained in DMEM supplemented with 1% Glutamine only. Normal
human bronchial/tracheal epithelial (NHBE) cells (CC-2540, lot 313831, Lonza)
were amplified in BALI TM growth medium (Lonza) and the same medium was
used for infection and post-infection studies. LLC-MK2 cells (Rhesus monkey
kidney, ATCC CCL-7) were cultured in Eagle's minimal essential medium
Date recue/ date received 2022-02-18
93
(EMEM) (Lonza) supplemented with 1% Glutamine (200 mM) and 2% of
heat-inactivated foetal bovine serum. During hPIV-3 infection and post-
infection
incubation, LLC-MK2 cells were maintained in EMEM supplemented with 1%
glutamine. All cell lines were incubated at 37 C in a humidified atmosphere
of
5% 002.
hPIV-3 (strain C-243) was obtained from the American Type Culture Collection
(ATCC, Manassas, VA). The virus was propagated in LLC-MK2 cells with
EMEM supplemented with glutamine (EMEMinf) at 35 C in a humidified
atmosphere of 5% CO2. Virus-containing culture supernatant was collected 3t0
4 days post-infection, while monitoring cytopathic effects, and clarified from
cell
debris by centrifugation (3,000 RCF for 15 min). Virus was concentrated at
least
times using 30 kDa Amicon Ultra filter unit (Millipore, Billerica, MA) for use
in
Haemagglutination Inhibition (HI) assays. Neuraminidase Inhibition (NI) assays
and STD-NMR experiments used virus that was PEG-precipitated and then
purified as described above.
Clarified hPIV-3 supernatant was mixed with PEG6000 (8% final concentration)
and NaCI (0.4 M final concentration) then incubated overnight at 4 C under
gentle agitation. PEG6000/hPIV-3 complex was pelleted by centrifugation at
3,000 RCF for 30 min at 4 C. The supernatant was discarded and a volume of
GNTE buffer (200 mM glycine, 200 mM NaCI, 20 mM Tris-HCI, 2 mM EDTA, pH
7.4) corresponding to at least 1:40 of the initial virus suspension volume was
used to resuspend the pellet overnight at 4 C. The virus suspension was
homogenized by up and down pipetting followed by a mechanical disruption of
the remaining virus aggregates using a douncer with "tight" pestle. The hPIV-3
homogenate was loaded on top of a 30% - 60% non-linear sucrose gradient
prepared in GNTE buffer and centrifuged at 100,000 RCF for 2 h 30 min at 4 C
without brake for deceleration. The virus was concentrated at the 30% - 60%
sucrose interface and then collected and stored at -80 C for NI assays or at
Date recue/ date received 2022-02-18
94
4 C for STD-NMR experiments.
hPIV-3 HN inhibitors: Compounds 2, 3, 5-10 were each provided as a
lyophilized powder and then solubilized in sterile water to generate a 10 mM
stock solution. Solutions were sonicated for 15 min to allow complete
dissolution
and then filter-sterilized. The stock solution was stored in a glass vial at -
20 C
and freshly diluted in appropriate buffer before use. For STD NMR experiments,
stock solutions were prepared in D20 at 100 mM. Solutions were processed and
stored as described above.
Recombinant HN expression and purification: The HN protein was expressed
using the Bac-to-Bac baculovirus expression system (Invitrogen, Carlsbad, CA)
based on a substantially modified literature procedure. Thus, the nucleotide
sequence for a honeybee melittin signal peptide (HBM) was added downstream
to the sequence encoding for the HN ectodomain (amino acids 125 to 572). This
sequence (HBM+HN) was codon optimised for expression in Spodoptera
frugiperda cells (Sf9) and ordered directly through the DNA2.0 gene synthesis
service (DNA2.0, Menlo Park, CA) as a gene named HBM-HNhPIV-300. HBM-
HNhP1V-300 was amplified by PCR and ligated into a pFastBaciCT-TOPO
vector that provides an additional C-terminal 6-histidine tag (His-Tag) for
purification and detection purposes.
The generation and amplification of recombinant baculovirus containing HBM-
HNhP1V-300 were performed according to the manufacturer's instructions. Sf9
cells (Invitrogen), cultured in Insect-XPRESS protein free insect cell medium
(Lonza), were infected with high MOI of HBM-HNhP1V-300 baculovirus. Four
days post-infection the supernatant, containing recombinant HN, was collected
to yield the highest protein expression. The supernatant was clarified by
centrifugation (3,000 RCF for 15 min) to remove cell debris and then purified
on
a HisTrap excel 5 mL column (GE Healthcare life sciences, Buckinghamshire,
Date recue/ date received 2022-02-18
95
England) following the manufacturer's protocol. Recombinant HN was eluted
with 500 mM imidazole solution and collected fractions were assessed by a
neuraminidase activity (NA) assay (see below). The most active fractions were
pooled and concentrated with a 10 kDa Amicon Ultra filter unit (Millipore) to
a
final volume of 800 pL. An additional purification step was performed that
employed fast protein liquid chromatography (Amersham Biosciences) over a
Superdex 75 gel filtration column (GE Healthcare) at 4 C and 1 mL fractions
were collected with a Frac-920. Protein-containing fractions, as determined by
monitoring fraction collection at 280 nm, were assessed in a NA assay as well
as subjected to SDS-PAGE. Purified and concentrated recombinant HN protein
was stored at 4 C.
Haemagglutination inhibition assay: The HN inhibitors were assessed in
duplicate in a U-bottom 96 well plate assay. Compounds were diluted in PBS as
a 4X solution for each concentration tested (25 pL/well, 1X final). Each
dilution
was mixed with 4 haemagglutination units (HAU) of hPIV-3 (25 pL/well, 1 HAU
final) and incubated for 20 min at room temperature. The plate was transferred
on ice and an equivalent volume (50 pL) of ice-cold 0.75% guinea pig red blood
cells (Gp-RBC) or 1% human red blood cells (h-RBC) was added to each well.
The plate was then incubated for 1 h 30 min at 4 C before reading the extent
of
haemagglutination. The HI IC50 was considered as the concentration of
inhibitor
that reduced the haemagglutinin activity (agglutination) by 50% compared to
those of a non-treated virus suspension.
Neuraminidase inhibition assay
Purified hPIV-3, inhibitors and MUN were prepared and diluted in NA Reaction
Buffer (Na0Ac 50 mM, CaCl2 5 mM, pH 4.6). NA, employing different hPIV-3
dilutions, were initially measured to determine the lowest virus concentration
to
be used in the assays. The NA assays were performed with enough purified
virus to obtain a maximal fluorescence signal at least 5 times higher than the
Date recue/ date received 2022-02-18
96
background for the experiment to be considered statistically significant.
Neuraminidase inhibition (NI) assays were done in triplicate. For each
concentration tested, 2 pL of purified hPIV-3 and 4 pL of 2.5X inhibitor
solution
(1X final) was added to each well. The plate was kept at room temperature for
20 min before 4 pL of 5 mM 2"-(4-methylumbelliferyl) u-D-N-acetylneuraminide
(MUN) (2 mM final) was added to each well and then the plate incubated at 37
C for 30 min with agitation (1000 rpm). The enzymatic reaction was stopped by
the addition of 190 pL of glycine buffer (glycine 0.25 M, pH 10.4) to each
well. A
negative control was included by the addition of MUN to virus and then the
enzymatic reaction stopped at t = 0. Relative fluorescence (RF) was measured
with a Victor 3 multilabel reader (PerkinElmer, Waltham, MA). Data were
processed by background subtraction (negative control RF) and then analysed
with GraphPadPrism 4 (GraphPad Software Inc., La Jolla, CA) to calculate IC50
values (nonlinear regression (curve fit), Dose-response - inhibition, 3
parameter
logistic). The concentration of inhibitor that reduced neuraminidase activity
(relative fluorescence) by 50% compared to those of a non-treated virus
suspension was considered to be the NI IC50 value. k values of inhibitors 6
and
were determined by enzyme kinetic experiments with whole hPIV-3 virus
based on previously published procedures. Thus, neuraminidase activity was
measured every 5 min over a 20 min period, at five substrate concentrations
[S]:
2, 4, 8, 10 and 16 mM, and four inhibitor concentrations [I]: 0, 0.5, 2.5 and
5 pM
for 10 or 0, 10, 20 and 60 pM for 6. All assays were performed in triplicate
and
the final data were fitted to the Michaelis¨Menten equation for competitive
inhibition using GraphPadPrism 4 (GraphPad Software Inc., La Jolla, CA) to
determine the Michaelis¨Menten constant (Km), using data from the [I] = 0 and
variable [S] experiments, and KJ values.
Virus growth inhibition assay: Before assessing the best inhibitors in cell-
based
assays, an MTT assay was performed to evaluate compound cytotoxicity. No
cytotoxic effect was observed after incubation for 48 h of LLC-MK2 cells with
6,
Date recue/ date received 2022-02-18
97
8 and 10 at 303 pM, the highest concentration tested. Virus growth
inhibition was assessed using a focus-forming assay by titration of progeny in
the presence of 2 pM of 6, 8 and 10 in EMEMinf from a low MOI infected
confluent LLC-MK2 monolayer in a 48 well plate format. Virus inoculum (100
FFU/well) was pre-incubated with 6, 8 and 10 for 20 min. Infection was
performed in duplicate and continued for 1 h at 37 C with gentle agitation
every
15 min. Inocula were removed and replaced with 500 pL/well of each respective
2 pM compound dilution (in EMEMinf).
A positive control for infection was included using the same conditions minus
the compound. Virus proliferation on infected cell monolayers were maintained
for 48 h at 37 C, 5% CO2. Culture supernatants from duplicates were
collected,
pooled and clarified at 15,000 RCF for 10 min and stored at -80 C.
Supernatants were diluted in EMEMinf by 10-5, 10-4 and 10-5 to avoid any
remaining compound effect on the subsequent virus titration. Virus titrations
were done in duplicate using the previously described conditions for virus
infection. After 1 h, Avicel (FMC BioPolymer, Philadelphia, PA) in EMEMinf was
directly added to the inoculum (1% final concentration) to restrict and
localise
virus proliferation. The plate was incubated for 36 to 40 h at 37 C, 5% CO2
to
allow focus formation. Avicel was gently removed and replaced with 3.7%
Paraformaldehyde/PBS and the plate was then kept for 15 min at room
temperature for virus inactivation and cell fixation. Cell monolayers were
washed three times for 5 min each with PBS and then endogenous peroxidase
inactivated with 0.3% H202/PBS for 30 min at 37 C. The plate was washed
again three times for 5 min each with PBS and incubated with mouse
monoclonal IgG anti-hPIV-3 HN (Fitzgerald, clone# M02122321, 2.0 mg/mL) at
1 pg/mL in 5% milk/PBS for 1 h at 37 C. Cell monolayers were washed 3 times
for 5 min with 0.02% Tween20/PBS. Goat anti-Mouse-IgG(H+L)-HRP conjugate
(BioRad, ref# 170-6516) diluted at 1:1000 in 5% milk/PBS was added to each
well and incubated for 1 h at 37 C. Cell monolayers were washed as previously
Date recue/ date received 2022-02-18
98
described with 0.02% Tween20/PBS and then rinsed twice with PBS. Foci
were revealed by adding TrueBlue solution (HRP substrate) on each well and
incubating the plate for 1 h at 37 C. The TrueBlue solution was discarded and
the plate rinsed twice with water then dried before being scanned (FIG 1) and
foci counted. The IC50 value was considered as the concentration of inhibitor
that reduced the progeny virus titre by 50% compared to a non-treated infected
LLC-MK2 monolayer.
In situ ELISA: In situ ELISA is a useful technique to evaluate virus growth
inhibition. It measures, in one step, the expression level of hPIV-3 HN at the
cell
surface of an infected cell monolayer. The expression level is directly
correlated
to the ability of a non-immobilized virus to infect and re-infect target
cells.
Infection was performed on a confluent cell monolayer seeded in a 96 well
plate. Virus (40 FFU/well) was pre-incubated for 20 min with compound 6 and
at a final concentration from 1000 pM to 0.001 pM as a 10-fold dilution
series. Infection was done in triplicate and continued for 1 h at 37 C with
gentle
agitation every 15 min. Inocula were removed and replaced with 200 pL/well of
each respective compound dilution. A positive control for infection was
incorporated by the use of identical experimental conditions, minus inhibitor.
Infected cell monolayers were kept for 36 - 40 h at 37 C, 5% CO2 for virus
proliferation. Virus was inactivated and cells fixed by the direct addition of
100
pL of 11.1% paraformaldehyde/PBS. The plate was maintained at room
temperature for 15 min and then washed 3 times for 5 min with PBS and then
endogenous peroxidases were inactivated by treatment with 0.3% H202/PBS for
30 min at 37 C. The cell monolayers were washed and incubated with mouse
monoclonal IgG anti-hPIV-3HN (Fitzgerald, clone# MO2122321, 2.0 mg/mL) at 1
pg/mL in 5% milk/PBS for 1 h at 37 C. The wells were washed 3 times for 5
min with 0.02% Tween20/PBS. Goat anti-Mouse-IgG(H+L)-HRP conjugate
(BioRad, ref# 170-6516), diluted at 1:2000 in 5% milk/PBS, was added to each
well and incubated for 1 h at 37 C. Cell monolayers were washed with 0.02%
Date recue/ date received 2022-02-18
99
Tween20/PBS and then rinsed twice with PBS. BD OptEIATMB substrate
(BD Biosciences, San Jose, CA, 100 pL) was added to each well and the plate
was then incubated at 37 C. The enzymatic reaction was stopped after 3 - 5
min by the addition of 50 pL of 0.6 M of H2504 per well. Raw data were
obtained by reading the absorbance (OD) of each well at 450 nm for 0.1 sec
with a Victor 3 multilabel reader (PerkinElmer, Waltham, MA). Final ODs were
obtained by subtraction of the negative control (non-infected cells) OD from
the
initial OD reading and the data analysed with GraphPadPrism4 (GraphPad
Software Inc., La Jolla, CA) to calculate IC50 values (nonlinear regression
(curve
fit), Dose-response - inhibition, 4 parameter logistic). The IC50 value was
considered as the concentration of inhibitor that reduced the absorbance at
450
nm by 50%, compared to a non-treated infected cell monolayer.
Compounds of the present invention can be tested in a hPIV-3 inhibition assay
on well-differentiated human airway epithelal (HAE) cells using a published
model. In brief the testing procedure is as follows: Human airway epithelial
(HAE) cells are isolated, cultured and differentiated as previously described
(Muller et al., 2013). Briefly, human nasal airway epithelial cells are
isolated,
expanded and seeded on collagen-coated permeable membrane supports.
Once the cells are confluent, the apical medium is removed and cells are
maintained at the air-liquid interface for approximately 4 to 6 weeks to allow
epithelial differentiation. Cultures containing ciliated cells are inoculated
via the
luminal surface with 5000 focus forming units of hPIV-3 per well for 1 hour.
Test
compounds of formula (1), (11), (111) and (111a) at various concentrations are
added
to the basolateral medium just after the cells have been infected with the
virus.
Viral load reduction is assessed at 1, 3 and 6 days post-infection by virus
titration using focus forming assay or in situ ELISA in A549 or LLC-MK2 cells,
as previously published (Guillon et al., 2014). These results may be compared
with a prior art reference compound such as a BCX compound including BCX-
2855 to give an indication of relative potency (Gunton, P., Dirr, L, El-Deeb,
LM.,
Winger, M., Bailly, B., Haselhorst, T., Dyason, J.C., and von Itzstein, M.
(2014). Structure-
Date recue/ date received 2022-02-18
100
guided discovery of potent and dual-acting human
parainfluenza virus haemagglutinin¨
neuraminidase inhibitors. Nat. Commun. 5.; and Mailer, L, Brighton, LE,
Carson, J.L., Fischer,
WA., and Jaspers, I. (2013). Culturing of Human Nasal Epithelial Cells at Air
Liquid Interface. J.
Vis. Exp.)
Results
A comparison of the potency of the synthesised C4 modified Neu5Ac2en
derivatives against hPIV-3 HN was undertaken and, for convenience sake, the
I C50 values were divided into two groups based on the acylamino group present
at C5. Group 1 inhibitors have a C5 acetamido functionality and Group 2
inhibitors have a C5 isobutyramido functionality (FIG 2 and FIG 3A-C). The
benchmark and well-characterised broad spectrum neuraminidase inhibitor
Neu5Ac2en (2) showed the weakest inhibition with I C50 values of 1565 pM and
1438 pM for hPIV-3 HN NI and HI, respectively. The inhibition observed for 3,
the C5 acetamido analogue of BCX 2798 (6), was improved when compared to
2, although it was still in the high micromolar range with IC50 values of 138
pM
and 210 pM for hPIV-3 HN NI and HI, respectively. These IC50 values were
similar to those observed for our novel inhibitor 7, a C4 methoxymethyl
functionalised triazole Neu5Ac2en derivative, with experimentally determined
hPIV-3 HN NI and HI IC50 values of 154 pM and 313 pM, respectively. A
significant improvement in potency was observed upon replacement of the C4
triazole's methoxymethyl moiety (7) with a bulkier phenyl group (8). I C50
values
of 6.5 pM and 4.6 pM were determined for hPIV-3 HN NI and HI for 8,
respectively. The values are summarised in table 2.
In the second group of inhibitors, that contain a C5 isobutyramido
functionality, it
was obvious that the affinity of each inhibitor was improved relative to its
C5
acetamido analogue. The order of potency, not unexpectedly, was identical
within the same group. Thus, the weakest inhibition was found for 5, the C5
isobutyramido analogue of Neu5Ac2en, with I C50 values of 188 pM and 358 pM
for NI and HI respectively and IC50 values of 21.5 pM and 16.1 pM for NI and
HI,
Date recue/ date received 2022-02-18
101
respectively were determined for the reference hPIV inhibitor BCX 2798
(6). Inhibitor 9, with the relatively small methoxymethyl substituent on the
triazole ring, had IC50 values close to those determined for the C4 azido
analogue 6 (IC50 = 14.2 pM and 13.8 pM for NI and HI respectively). Similarly
as
observed in the C5 acetamido-containing Group 1 inhibitors, increasing the
substituent size from the methoxymethyl group in inhibitor 9 to a bulkier
phenyl
moiety as in inhibitor 10, resulted in a remarkable improvement in potency
with
IC50 values of 2.7 pM and 1.5 pM for NI and HI, respectively. Interestingly,
an
improvement in HI IC50 values was observed when human red blood cells were
used instead of guinea pig red blood cells (FIG 1). This improvement most
likely
reflects sialic acid content and/or linkage presentation differences between
human and guinea pig red blood cells. For example, it is well known that human
tissues and cells, including red blood cells, only express N-acetylneuraminic
acid-containing glycoconjugate receptors, whereas other animals also express
N-glycolylneuraminic-acid-based receptors. Nevertheless, irrespective of the
specific red blood cells used, our designer inhibitor 10 had significantly
higher
potency when compared to the benchmark compound 6. A Km value for MUN of
5.1 mM and k values of 1.3 pM and 16 pM for inhibitor 10 and 6, respectively.
2 3 7 8
Inhibitor
NI HI NI HI NI HI NI HI
Mean ICso 1565 1438 138.1 210 154.4 312.5 6.512
4.583
Std. deviation 439.1 427 55.69 65.19 18.93 25 0.6305
0.7217
Std. error 219.6 213.5 21.05 29.15 8.467 12.5 0.364
0.4167
5 6 9 10
NI HI NI HI NI HI NI HI
187.7 358.3 21.46 16.12 14.16 13.75 2.74
1.458
39.52 52.04 4.753 4.891 2.028 4.787 0.2319
0.3608
19.76 30.05 1.797 2.187 1.171 2.394 0.1339
0.2083
Table 2: NI and HI IC50 values. Mean IC50 values for each of the tested
compounds with calculated standard deviation and standard error.
Date recue/ date received 2022-02-18
102
Cell-based assays
Following initial enzymatic screening, the most potent inhibitor 10 and the
reference hPIV inhibitor (BCX 2798, 6) were then evaluated in a growth
inhibition assay to compare their capacity to inhibit hPIV-3 virus infection
and
propagation in LLC-MK2 cells (FIG 4 A and B). Compound 6 was chosen as a
reference inhibitor as it is the most documented hPIV-3 Neu5Ac2en-based
inhibitor to date and has reasonable in vitro hPIV-3 antiviral potency. In an
initial
assay, at an inhibitor concentration of 2 pM, the virus was propagated for 48
h
in the presence of 6 or 10 and virus titres were determined. At this inhibitor
concentration, a reduction of 14% and 94% in virus titre by 6 and 10
respectively was calculated (FIG 4B). Virus growth inhibition IC50 values were
then determined for the two inhibitors in a well-established in situ ELISA
technique using three different cell lines. The LLC-MK2 (monkey kidney
epithelial cells) cell line was chosen as it is extensively used in hPIV-3
cell-
based infection studies, as well as the hPIV-3 susceptible human respiratory
cell lines A549 (lung adenocarcinoma epithelial cells) and normal human
bronchial epithelial (NHBE) primary cells to investigate virus growth
inhibition in
natural tissue-related cells. The method itself has useful advantages over the
virus titration method, as it is a faster, one-step, non-subjective technique
that
correlates non-immobilized virus growth to HN expression levels of a low
multiplicity of infection (M01) infected cell monolayer. Interestingly,
slightly lower
virus growth inhibition IC50 values were determined for 10 and 6 with the
laboratory established cell line LLC-MK2 in relation to the human cell lines.
Overall, the same trend is observed for all three cell lines in that a
significantly
stronger antiviral effect of inhibitor 10 (IC50 = 2.1-13.9 pM) is determined
compared to inhibitor 6 (IC50 = 54.6-130.6 pM) (FIG 5).
Structural biology
Sample preparation and 1H NMR experiments: All NMR experiments were
performed on a 600 MHz NMR spectrometer (Bruker) equipped with a 5-mm
Date recue/ date received 2022-02-18
103
TXI probe with triple axis gradients. Intact virus suspension or
recombinant hPIV-3 HN were buffer exchanged against 50 mM deuterated
sodium acetate, 5 mM CaCl2 in D20 at pD 4.6 by ultrafiltration using an Am
icon
Filter Unit (Millipore) with a cut-off value of 30 kDa or 10 kDa,
respectively. For
each experiment 20 pM hPIV-3 HN protein and a protein:ligand molar ratio of
1:100 in a final volume of 200 pL was used.
1H NMR spectra were acquired with 32 scans at 283 K, a 2 s relaxation delay
over a spectral width of 6000 Hz. Due to the safer and easier handling of
protein
compared to virus and in order to provide exactly the same protein
concentration in each experiment, the initial STD NMR experiment was carried
out for compound 10 in complex with intact hPIV-3 virus, while all subsequent
experiments were carried out using the recombinant HN protein.
Saturation Transfer Difference (STD) NMR experiments: The protein was
saturated on-resonance at -1.0 ppm and off-resonance at 300 ppm with a
cascade of 60 selective Gaussian-shaped pulses of 50 ms duration, resulting in
a total saturation time of 3 s and the relaxation delay was set to 4 s. Each
STD
NMR experiment was acquired either with a total of 1056 scans (recombinant
hPIV-3 HN) or 1512 scans (intact virus) and a WATERGATE sequence was
used to suppress the residual HDO signal. A Spin-lock filter with 5 kHz
strength
and duration of 10 ms was applied to suppress protein background. Control
STD NMR experiments were performed with an identical experimental setup
and the same ligand concentration but in the absence of protein. On- and off-
resonance spectra were stored and processed separately, and the final STD
NMR spectra were obtained by subtracting the on- from the off-resonance
spectra. All STD effects were quantified using the equation ASTD= (Jo-
'sat) no = 'STD/ IQ. Therefore signal intensities of the STD NMR spectrum
(ism)
were compared to the corresponding signal intensities of a reference spectrum
(Jo). The strongest STD signal in the spectrum was assigned to a value of 100%
Date recue/ date received 2022-02-18
104
and used as a reference to calculate relative STD effects accordingly.
Saturation Transfer Difference (STD) NMR experiments of 8 in complex with
recombinantly-expressed hPIV-3 HN (FIG 6) and the most potent inhibitor 10 in
complex with either recombinantly-expressed hPIV-3 HN (FIG 7) or intact hPIV-
3 virus (FIG 8) were undertaken to further support the computational and
biological studies that demonstrated specific binding and inhibition.
STD NMR signal intensities for all protons associated with 8 or 10 were
clearly
observed, to varying extents, when the inhibitor is in complex with either
intact
virus or recombinant hPIV-3 HN and clearly demonstrated that the ligand binds
in both instances. The minor signals visible at 3.25, 3.5 and 4.0 ppm in the
1H
NMR spectrum of 10 acquired in the presence of intact virus particles were a
consequence of impurities from the virus purification process and belong to
neither the virus particles nor 10. As anticipated, none of these signals were
observed in the STD NMR spectrum and clearly demonstrate that the impurities
do not bind to the virus (FIG 8). These experiments clearly demonstrate the
specific binding of 10 to both intact hPIV-3 virus and hPIV-3 HN, further
substantiating the inhibitor's biological relevance and potential.
Importantly, an overlay of the aromatic phenyl protons signals observed at 7.1-
7.6 ppm in the STD NMR spectra for both the intact virus and recombinant HN
protein also reveals that the binding epitope of inhibitor 10 is similar, if
not
identical, when bound either to intact hPIV-3 virus or to recombinant hPIV-3
HN
protein (FIG 9).
Epitope mapping of inhibitor 10
A complete ligand binding epitope was determined by the analysis of STD NMR
spectra (FIG 7) of hPIV-3 HN protein in complex with 10. All STD NMR signals
of 10 were normalised to the strongest STD NMR signal observed, the
Date recue/ date received 2022-02-18
105
inhibitor's H4" proton at 7.18 ppm.
Relative STD NMR effects for all
protons of the inhibitor were then calculated (Table 2). The extent of the STD
NMR signal intensity strongly depends on the proton's proximity to the protein
surface and reveals how the designed inhibitor 10 engages the HN protein's
binding site.
Inhibitor 8 Inhibitor 10
(0/0) (0/0)
Triazo1e CH 63 75
ArH2' ArH6' 92 95
ArH3' ArH5' 100 100
ArH4' 100 100
H3 85 80
H4 59 59
H5 50 49
H6 49 47
H7 30 36
H8 30 35
H9 12 24
H9' 18 21
Isoprop-CH - 54
Isoprop-2CH3 - 42
NHAc 41 -
Table 3: Relative STD NMR effectsa of 8 and 10 in complex with hPIV-3 HN. aSTD
effects calculated according to the formula Asm = (Jo ¨ /sad no ¨ Ism no. All
STD NMR
effects are given relative to the strongest STD NMR intensity of the C4
triazolo ArH4".
Notably, very strong relative STD NMR effects were observed for the phenyl
group protons H2", H3", H4", H5-and H6" between 7.1 ppm and 7.6 ppm
revealing a close contact in that region of the molecule to the protein
surface.
Moreover, a significant STD NMR effect was likewise detected for the CH of the
triazole moiety. In contrast, the C5 isobutyramido moiety's protons of the
inhibitor showed less effect (relative STD NMR signal intensities in the range
of
42-54%).
Date recue/ date received 2022-02-18
106
The protons associated with the Neu5Ac2en core structure of 10 displayed
variable relative STD NMR effects. A significant H3 relative STD NMR signal
intensity (80%) suggests a strong interaction of this part of the molecule
with
hPIV-3 HN. Furthermore, relative STD NMR signal intensities for H4, H5 and H6
of 59%, 50% and 49%, respectively, demonstrate that the ring protons of the
Neu5Ac2en core structure are also involved in inhibitor engagement to the
protein.
Finally, weaker relative STD NMR effects of 36%, 35%, 24% and 21%, were
observed for the glycerol side chain protons H7, H8, H9 and H9", respectively
and suggest that the glycerol sidechain makes less of a contribution to the
inhibitor binding event compared with the C4 triazolo functionality and the
inhibitor's core ring structure (FIG 7). The inhibitor 8 epitope map (FIG 6)
was
for all intents and purposes identical to that of inhibitor 10, with the C4
triazolo
moiety clearly in close contact to the protein surface.
Difluoro Analogues
The compounds may include diflouronated compounds and testing has been
performed on select members of this class (1-170, 1-179 and 1-104 shown
below). The target of such compounds is the haemagglutinin-neuraminidase of
hPIV-3 and hPIV-1. A co-crystal structure of hPIV-3 HN in complex with 1-170
has been obtained. All of the below compounds have been tested in (i) NI
enzymatic assays against hP1V-3 (and 170 also against hP1V-1); (ii) cell based
assays with the human cell line A549 cells (adenocarcinomic human alveolar
basal epithelial cells) have been evaluated using hPIV-3; (iii) cell
cytotoxicity
tests of the compounds against A549 cells; and (iv) NI enzymatic assays
against the human Neuraminidase 2 showed no activity. No cell cytotoxicity was
observed for any of the compounds at 150 pM using A549 cells as shown in FIG
10. No activity was observed against human Neu2 as indicated in FIG 11.
Date recue/ date received 2022-02-18
107
OH COONa
OH
HO
0 F F
OH COOH 0
pH
HO
H 0 FF kk
N
N3
1-170 1-179
OH OH COONa
HO
0 F F
HN
0 NNµ
1-104
pM 6 1-70 1-57 1-79 1-40 1-104
NI hPIV-3 18 6 2.5 63 12 4
IC50
Cell-based 130 14 10 45 80 25
ELISA IC50
Table 4: Enzymatic and cell-based assays for select difluorinated compounds
with 1-57
and 1-40 as the corresponding non-fluorinated 'en' compounds for comparison.
Influenza Virus Sialidase Activity Assay
In a standard 96-well plate format, by use of sialidase from Influenza A and
B,
the synthesized compounds can be assayed for their capacity to inhibit
influenza virus sialidase by a modification (Biochim. Biophys. Acta 1991, 10
,65
- 71) of the fluorometric method of Potier et al. (Anal. Bio- chem. 1979, 94 ,
287 - 296) using the fluorogenic substrate 4-methylumbelliferyl N-acetyl-a-D-
neuraminide (MUN). All inhibition assays can be done in triplicate over six
inhibitor concentrations and at with 0.1 mM MUN. Specifically, 7 pL of 50 mM
sodium acetate-6 mM CaCl2 buffer (pH 5.5) is added to each well of a 96-well
Date recue/ date received 2022-02-18
108
solid black plate on ice, followed by 1 pL of
inhibitor, 1 pL of sialidase, and
finally 1 pL of the substrate MUN. The plate is then briefly centrifuged up to
1000 rpm for approximately 10 s to combine all components, and the mixture
can be incubated at 37 C with 900 rpm shaking for 20 min. To stop the
reaction, 250 pL of 0.25 M glycine, pH 10, may be added to each well, and the
fluorescence read (1 s per well) at an excitation of 355 nm and emission of
460
nm with a Victor 3 multilabel reader (PerkinElmer, Waltham, MA). Data can be
processed by background subtraction (negative control RF) and then analysed
with GraphPadPrism 4 (GraphPad Software Inc., La Jolla, CA) to calculate IC50
values (nonlinear regression (curve fit), Dose-response - inhibition, 3
parameter
logistic).
In situ cellular ELISA for Influenza A and B
To evaluate virus growth inhibition of Influenza A and Influenza B virus for
the
synthesised compounds, MDCK cells will be infected with influenza A or
Influenza B virus in an in situ cellular ELISA developed based on the
principles
described by Berkowitz and Levin, 1985 (Antimicrob. Agents Chemother, 28,
207-210) and adapted to IAV by Myc et al, 1999 (J. Virol. Methods 77, 165-177
(1999)). MDCK cells in 100 pl Eagle's Minimum Essential Medium (EMEM)
supplemented with 2mM glutamine and 10% FBS are seeded on flat-bottom 96-
well microtiter plates and incubated overnight. On the next day, the culture
medium is removed and cells washed with medium. A total of 50 pl of viral
inoculum (40 FFU/well) are added to the wells and incubated at 37 C, 5% CO2
for 1h with gentle agitation every 15 minutes. The viral inoculum is then
removed and replaced with 100 pl of infection medium (EMEM supplemented
with 2 mM glutamine and 3.0 pg/ml ot TPCK treated trypsin). Infected MDCK
cells are incubated for an additional 12-20h, as necessary, and medium will be
aspirated. The cells can be fixed with 3.7% paraformaldehyde in PBS. On the
day of assay, fixed cells are washed and endogenous peroxidases inactivated
with 0.35% H202/PBS for 30 minutes at 37 C. The wells are washed again and
Date recue/ date received 2022-02-18
109
incubated with 50 pl of 1.5 mg/ml of mouse
monoclonal anti-influenza A or
anti-influenza B Haemagglutinin and incubated for 45 min at 37 C. The cells
are
washed four times with washing buffer (PBS and 0.02% Tween-20), and
incubated with 50 pl of 1:2000 dilution of goat anti-mouse IgG (H+L) HRP
conjugated (BioRad, ref. 170-6516) for 45 min at 37 C. Plates are washed as
previously with washing buffer and 100 pl of BD OptEIATMB substrate (BD
Biosciences, San Jose, CA) added to each well then the plate can be incubated
at 37 C.
The enzymatic reaction can be stopped after 3 - 5 min by the addition of 50 pL
of 1 M of H2504 per well. Raw data is obtained by reading the absorbance
(OD) of each well at 450 nm for 0.1 sec with a Victor 3 multilabel reader
(PerkinElmer, Waltham, MA). Final ODs are obtained by subtraction of the
negative control (non-infected cells) OD from the initial OD reading and the
data
analysed with GraphPadPrism4 (GraphPad Software Inc., La Jolla, CA) to
calculate IC50 values (nonlinear regression (curve fit), Dose-response -
inhibition, 4 parameter logistic). The IC50 value is considered as the
concentration of inhibitor that reduced the absorbance at 450 nm by 50%,
compared to a non-treated infected cell monolayer.
The in situ cell based ELISA can be performed as for hPIV-3 with minor
modifications including differences between hPIV-1 and 3 tests such as:
Primary antibody: Mouse monoclonal anti-hPIV-3 HN (Fitzgerald, clone
M02122321); Mouse monoclonal anti-hPIV-1 HN (LSbio, ref LS-C74109); hPIV-
3 infection media: EMEM + 2 mM glutamine; hPIV-1 infection media: EMEM + 2
mM glutamine + TrypLE select 1.2%.
hPIV-3 NI and hPIV-1 NI IC50 values for compounds of the invention
IC50 values for a number of compounds of the first aspect were determined by
standard assay methods previously described in Guillon, P et a/, Nature
Date recue/ date received 2022-02-18
110
Communications (2014). In the below tables are IC50 values for prepared
compounds wherein the chemistry ID aligns with those references and
compound structures provided in the experimental characterisation section.
hPIV-3 NI (IC50 values) hPIV-1 NI (IC50 values)
Chemistry ID IC50 (pM) Chemistry ID IC50 (pM)
1E1172-78 2.47 1E1172-78 75.15
1E1172-82 3.95 1E1172-82 57.18
1E1172-83 5.61 1E1172-83 73.62
1E1172-87 77.35 1E1172-87 92.79
1E1172-45 315 1E1172-45 >1000
1E1172-102 >1000 1E1172-102 793.4
1E1257-84 2.19 1E1257-84 24.88
1E1398-33 1.97 1E1398-33 no data
1E832-8 54.43 1E832-8 300.6
1E832-12 51.85 1E832-12 215.3
1E832-17 148.5 1E832-17 19.82
1E832-20 6.28 1E832-20 192.7
1E832-26 67.67 1E832-26 95.49
1E832-27 106.1 1E832-27 301.9
1E832-31 22.92 1E832-31 303.5
1E832-37 2.4 1E832-37 200.6
1E889-34 3.23 1E889-34 30.3
1E889-52 5.85 1E889-52 168.5
1E927-60 13.13 1E927-60 0.489
1E927-67 114.3 1E927-67 47.74
1E984-5 1.38 1E984-5 21.88
1E1257-24 8.49 1E1257-24 0.36
1E889-80 2.68 1E889-80 16.9
1E889-99 0.599 1E889-99 6.22
1E927-99 0.268 1E927-99 3.09
1E832-98 27.38 1E832-98 7.44
1E889-42 5.11 1E889-42 0.159
Table 5- hPIV-3 and hPIV-1 IC50 values for tested compounds
Date recue/ date received 2022-02-18
